0001628280-23-015990.txt : 20230505 0001628280-23-015990.hdr.sgml : 20230505 20230505073941 ACCESSION NUMBER: 0001628280-23-015990 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 23891254 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20230331.htm 10-Q mrk-20230331
FALSE2023Q1000031015812/31http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent00003101582023-01-012023-03-310000310158us-gaap:CommonStockMember2023-01-012023-03-310000310158mrk:A0.500Notesdue2024Member2023-01-012023-03-310000310158mrk:A1.875Notesdue2026Member2023-01-012023-03-310000310158mrk:A2.500Notesdue2034Member2023-01-012023-03-310000310158mrk:A1.375Notesdue2036Member2023-01-012023-03-3100003101582023-04-30xbrli:sharesiso4217:USD00003101582022-01-012022-03-31iso4217:USDxbrli:shares00003101582023-03-3100003101582022-12-3100003101582021-12-3100003101582022-03-310000310158mrk:PrometheusBiosciencesIncMemberus-gaap:SubsequentEventMember2023-04-300000310158mrk:PrometheusBiosciencesIncMemberus-gaap:SubsequentEventMember2023-04-012023-04-300000310158mrk:PrometheusBiosciencesIncMemberus-gaap:SubsequentEventMember2023-07-012023-09-300000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-02-012023-02-280000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-02-280000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-310000310158mrk:ImagoBioSciencesIncMember2023-01-012023-01-310000310158mrk:ImagoBioSciencesIncMember2023-01-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2022-01-012022-03-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2022-03-310000310158mrk:LynparzaMember2022-01-012022-03-310000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-03-310000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-12-310000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:LynparzaMemberus-gaap:OtherNoncurrentAssetsMember2023-03-310000310158mrk:AlliancerevenueLynparzaMemberus-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:AlliancerevenueLynparzaMemberus-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:AllianceRevenueKoselugoMemberus-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:AllianceRevenueKoselugoMemberus-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2022-01-012022-03-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158us-gaap:OtherCurrentAssetsMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158us-gaap:OtherCurrentAssetsMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158mrk:EisaiMembermrk:LenvimaMembermrk:SalesBasedMilestonesMember2023-01-012023-03-310000310158mrk:EisaiMembermrk:LenvimaMembermrk:SalesBasedMilestonesMember2023-03-310000310158mrk:LenvimaMember2023-01-012023-03-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-03-310000310158mrk:LenvimaMemberus-gaap:OtherNoncurrentAssetsMember2023-03-310000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2022-01-012022-03-310000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:EisaiMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310000310158us-gaap:OtherIntangibleAssetsMembermrk:AdempasMember2023-03-310000310158mrk:VerquvoMemberus-gaap:OtherIntangibleAssetsMember2023-03-310000310158mrk:BayerAGMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:BayerAGMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:BayerAGMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2023-01-012023-03-310000310158mrk:BayerAGMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2022-01-012022-03-310000310158mrk:BayerAGMembermrk:VerquvoMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:BayerAGMembermrk:VerquvoMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2022-01-012022-03-310000310158mrk:BayerAGMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:BayerAGMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158mrk:BayerAGMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158mrk:BayerAGMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:LagevrioMember2023-01-012023-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMembermrk:LagevrioMember2022-01-012022-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMemberus-gaap:CostOfSalesMember2022-01-012022-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2023-01-012023-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2022-01-012022-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2023-03-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158mrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMembersrt:MinimumMember2023-01-012023-03-31xbrli:pure0000310158mrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMembersrt:MaximumMember2023-01-012023-03-310000310158mrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMember2023-01-012023-03-310000310158mrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMember2023-01-012023-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AllianceRevenueReblozylMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMember2022-01-012022-03-310000310158mrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMember2022-01-012022-03-310000310158mrk:TransitionServicesAgreementMembersrt:MinimumMember2021-06-022021-06-020000310158mrk:TransitionServicesAgreementMembersrt:MaximumMember2021-06-022021-06-020000310158mrk:ManufacturingAndSupplyAgreementsMembersrt:MinimumMember2021-06-022021-06-020000310158mrk:ManufacturingAndSupplyAgreementsMembersrt:MaximumMember2021-06-022021-06-020000310158mrk:OrganonCoMember2023-01-012023-03-310000310158mrk:OrganonCoMember2022-01-012022-03-310000310158mrk:OrganonCoMember2023-03-310000310158mrk:OrganonCoMember2022-12-310000310158srt:ScenarioForecastMember2023-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2023-01-012023-03-310000310158us-gaap:CostOfSalesMember2023-01-012023-03-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310000310158us-gaap:RestructuringChargesMemberus-gaap:OneTimeTerminationBenefitsMember2023-01-012023-03-310000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2023-01-012023-03-310000310158us-gaap:RestructuringChargesMemberus-gaap:OtherRestructuringMember2023-01-012023-03-310000310158us-gaap:RestructuringChargesMember2023-01-012023-03-310000310158us-gaap:OneTimeTerminationBenefitsMember2023-01-012023-03-310000310158mrk:AcceleratedDepreciationMember2023-01-012023-03-310000310158us-gaap:OtherRestructuringMember2023-01-012023-03-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2022-01-012022-03-310000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2022-01-012022-03-310000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2022-01-012022-03-310000310158us-gaap:CostOfSalesMember2022-01-012022-03-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2022-01-012022-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2022-01-012022-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OtherRestructuringMember2022-01-012022-03-310000310158us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310000310158us-gaap:RestructuringChargesMemberus-gaap:OneTimeTerminationBenefitsMember2022-01-012022-03-310000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2022-01-012022-03-310000310158us-gaap:RestructuringChargesMemberus-gaap:OtherRestructuringMember2022-01-012022-03-310000310158us-gaap:RestructuringChargesMember2022-01-012022-03-310000310158us-gaap:OneTimeTerminationBenefitsMember2022-01-012022-03-310000310158mrk:AcceleratedDepreciationMember2022-01-012022-03-310000310158us-gaap:OtherRestructuringMember2022-01-012022-03-310000310158us-gaap:OneTimeTerminationBenefitsMember2022-12-310000310158mrk:AcceleratedDepreciationMember2022-12-310000310158us-gaap:OtherRestructuringMember2022-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2023-03-310000310158mrk:AcceleratedDepreciationMember2023-03-310000310158us-gaap:OtherRestructuringMember2023-03-310000310158srt:MaximumMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-03-310000310158us-gaap:NondesignatedMembersrt:MaximumMember2023-01-012023-03-310000310158us-gaap:ForeignExchangeContractMember2023-01-012023-03-310000310158us-gaap:ForeignExchangeContractMember2022-01-012022-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2023-01-012023-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2022-01-012022-03-310000310158mrk:EurodominatedNotesMember2023-01-012023-03-310000310158mrk:EurodominatedNotesMember2022-01-012022-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2023-01-012023-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2022-01-012022-03-31mrk:interest_rate_swap0000310158us-gaap:SubsequentEventMember2023-04-300000310158us-gaap:InterestRateSwapMember2023-03-310000310158us-gaap:InterestRateSwapMemberus-gaap:SubsequentEventMember2023-04-300000310158us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000310158us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000310158us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2023-03-310000310158us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2022-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2023-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2023-03-310000310158us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2023-03-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2022-12-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2022-12-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2023-03-310000310158us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:NondesignatedMember2023-03-310000310158us-gaap:NondesignatedMember2022-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-03-310000310158us-gaap:InterestRateSwapMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-03-310000310158us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000310158us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000310158us-gaap:InterestRateSwapMember2023-01-012023-03-310000310158us-gaap:InterestRateSwapMember2022-01-012022-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2023-01-012023-03-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2022-01-012022-03-310000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2023-01-012023-03-310000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2022-01-012022-03-310000310158us-gaap:CommercialPaperMember2023-03-310000310158us-gaap:CommercialPaperMember2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000310158us-gaap:CorporateDebtSecuritiesMember2023-03-310000310158us-gaap:CorporateDebtSecuritiesMember2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2023-03-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2022-12-310000310158us-gaap:EquityFundsMember2023-01-012023-03-310000310158us-gaap:EquityFundsMember2022-01-012022-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-03-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-03-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2023-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2022-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-03-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeOptionMember2023-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Member2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeOptionMember2022-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-03-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-03-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:FairValueInputsLevel2Member2023-03-310000310158us-gaap:FairValueInputsLevel2Member2022-12-310000310158mrk:SanofiPasteurMember2023-03-3100003101582022-01-012022-06-300000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2023-03-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2022-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2023-03-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2022-12-310000310158country:USmrk:GardasilGardasil9Member2023-03-31mrk:case0000310158us-gaap:NonUsMembermrk:GardasilGardasil9Member2023-03-310000310158country:COmrk:GardasilGardasil9Member2023-03-310000310158mrk:ZetiaantitrustlitigationMember2020-08-31mrk:direct_purchaser0000310158mrk:ZetiaantitrustlitigationMemberus-gaap:PendingLitigationMember2022-06-302022-06-30mrk:claim0000310158mrk:ZetiaantitrustlitigationMember2023-01-012023-03-310000310158us-gaap:PendingLitigationMembermrk:RotaTeqAntitrustLitigationMember2023-03-03mrk:state0000310158mrk:BridionMemberus-gaap:PendingLitigationMemberus-gaap:PatentsMember2022-12-192022-12-190000310158mrk:BridionMemberus-gaap:PatentsMember2023-01-012023-03-31mrk:company0000310158mrk:BridionMemberus-gaap:PendingLitigationMemberus-gaap:PatentsMember2023-03-310000310158mrk:JanuviaAndJanumetMemberus-gaap:PatentsMember2023-01-012023-03-310000310158mrk:ComplaintAgainstTheJohnsHopkinsUniversityMemberus-gaap:PendingLitigationMemberus-gaap:SubsequentEventMember2023-04-132023-04-13mrk:patent0000310158mrk:LegalDefenseCostsMember2023-03-310000310158mrk:LegalDefenseCostsMember2022-12-310000310158us-gaap:CommonStockMember2021-12-310000310158us-gaap:AdditionalPaidInCapitalMember2021-12-310000310158us-gaap:RetainedEarningsMember2021-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000310158us-gaap:TreasuryStockCommonMember2021-12-310000310158us-gaap:NoncontrollingInterestMember2021-12-310000310158us-gaap:RetainedEarningsMember2022-01-012022-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000310158us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000310158us-gaap:TreasuryStockCommonMember2022-01-012022-03-310000310158us-gaap:NoncontrollingInterestMember2022-01-012022-03-310000310158us-gaap:CommonStockMember2022-03-310000310158us-gaap:AdditionalPaidInCapitalMember2022-03-310000310158us-gaap:RetainedEarningsMember2022-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000310158us-gaap:TreasuryStockCommonMember2022-03-310000310158us-gaap:NoncontrollingInterestMember2022-03-310000310158us-gaap:CommonStockMember2022-12-310000310158us-gaap:AdditionalPaidInCapitalMember2022-12-310000310158us-gaap:RetainedEarningsMember2022-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000310158us-gaap:TreasuryStockCommonMember2022-12-310000310158us-gaap:NoncontrollingInterestMember2022-12-310000310158us-gaap:RetainedEarningsMember2023-01-012023-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000310158us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000310158us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000310158us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000310158us-gaap:CommonStockMember2023-03-310000310158us-gaap:AdditionalPaidInCapitalMember2023-03-310000310158us-gaap:RetainedEarningsMember2023-03-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000310158us-gaap:TreasuryStockCommonMember2023-03-310000310158us-gaap:NoncontrollingInterestMember2023-03-310000310158us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-03-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-03-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-03-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-03-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-03-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-03-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2023-03-31mrk:segment0000310158country:USmrk:KeytrudaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:InternationalMembermrk:KeytrudaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:KeytrudaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:KeytrudaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:InternationalMembermrk:KeytrudaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:KeytrudaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AlliancerevenueLynparzaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AlliancerevenueLynparzaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:LenvimaMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:LenvimaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:LenvimaMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:LenvimaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:LenvimaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AllianceRevenueReblozylMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AllianceRevenueReblozylMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AllianceRevenueReblozylMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AllianceRevenueReblozylMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:WeliregMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:WeliregMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:WeliregMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:WeliregMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:WeliregMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:WeliregMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:ProQuadMMRIIVarivaxMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:ProQuadMMRIIVarivaxMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:ProQuadMMRIIVarivaxMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:ProQuadMMRIIVarivaxMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:ProQuadMMRIIVarivaxMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:InternationalMembermrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:InternationalMembermrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:RotateqMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2023-01-012023-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2023-01-012023-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2022-01-012022-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2022-01-012022-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaxneuvanceMember2022-01-012022-03-310000310158country:USmrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:InternationalMembermrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:InternationalMembermrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:Pneumovax23Memberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:VaqtaMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:VaqtaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:VaqtaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:VaqtaMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:VaqtaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:VaqtaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:BridionMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:BridionMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:BridionMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:BridionMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:BridionMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:BridionMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:PrevymisMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:PrevymisMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:PrevymisMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:PrevymisMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:PrevymisMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:PrevymisMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrimaxinMember2023-01-012023-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrimaxinMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrimaxinMember2023-01-012023-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrimaxinMember2022-01-012022-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrimaxinMember2022-01-012022-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrimaxinMember2022-01-012022-03-310000310158mrk:DificidMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:DificidMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:DificidMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:DificidMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:DificidMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:DificidMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:NoxafilMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:NoxafilMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:NoxafilMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:NoxafilMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:NoxafilMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:NoxafilMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:ZerbaxaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:ZerbaxaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:ZerbaxaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:ZerbaxaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:ZerbaxaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:ZerbaxaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AllianceRevenueAdempasVerquvoMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:AdempasMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:InternationalMembermrk:AdempasMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:AdempasMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:AdempasMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:InternationalMembermrk:AdempasMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:AdempasMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2023-01-012023-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2023-01-012023-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2022-01-012022-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2022-01-012022-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2022-01-012022-03-310000310158mrk:IsentressIsentressHDMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:IsentressIsentressHDMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:IsentressIsentressHDMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:IsentressIsentressHDMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:IsentressIsentressHDMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:IsentressIsentressHDMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:BelsomraMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:BelsomraMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:BelsomraMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:BelsomraMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:BelsomraMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:BelsomraMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:SimponiMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:SimponiMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:SimponiMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:SimponiMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:SimponiMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:SimponiMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:RemicadeMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:RemicadeMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:RemicadeMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:RemicadeMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:RemicadeMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:JanuviaMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:JanuviaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:JanuviaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:JanuviaMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:JanuviaMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:JanuviaMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:JanumetMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:JanumetMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:JanumetMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USmrk:JanumetMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:JanumetMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:JanumetMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:OtherPharmaceuticalMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:OtherPharmaceuticalMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:OtherPharmaceuticalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:OtherPharmaceuticalMembercountry:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:OtherPharmaceuticalMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:OtherPharmaceuticalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-03-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-03-310000310158country:USmrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:LivestockMembermrk:InternationalMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158country:USmrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:LivestockMembermrk:InternationalMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:CompanionAnimalsMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:CompanionAnimalsMembermrk:InternationalMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:CompanionAnimalsMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:CompanionAnimalsMembermrk:InternationalMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:InternationalMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:InternationalMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158country:USus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158us-gaap:OperatingSegmentsMember2023-01-012023-03-310000310158country:USus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158us-gaap:OperatingSegmentsMember2022-01-012022-03-310000310158country:USus-gaap:CorporateNonSegmentMember2023-01-012023-03-310000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2023-01-012023-03-310000310158us-gaap:CorporateNonSegmentMember2023-01-012023-03-310000310158country:USus-gaap:CorporateNonSegmentMember2022-01-012022-03-310000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2022-01-012022-03-310000310158us-gaap:CorporateNonSegmentMember2022-01-012022-03-310000310158country:US2023-01-012023-03-310000310158mrk:InternationalMember2023-01-012023-03-310000310158country:US2022-01-012022-03-310000310158mrk:InternationalMember2022-01-012022-03-310000310158us-gaap:EMEAMember2023-01-012023-03-310000310158us-gaap:EMEAMember2022-01-012022-03-310000310158country:CN2023-01-012023-03-310000310158country:CN2022-01-012022-03-310000310158srt:AsiaPacificMember2023-01-012023-03-310000310158srt:AsiaPacificMember2022-01-012022-03-310000310158country:JP2023-01-012023-03-310000310158country:JP2022-01-012022-03-310000310158srt:LatinAmericaMember2023-01-012023-03-310000310158srt:LatinAmericaMember2022-01-012022-03-310000310158mrk:OtherCountriesMember2023-01-012023-03-310000310158mrk:OtherCountriesMember2022-01-012022-03-310000310158us-gaap:MaterialReconcilingItemsMember2023-01-012023-03-310000310158us-gaap:MaterialReconcilingItemsMember2022-01-012022-03-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
126 East Lincoln Avenue
RahwayNew Jersey07065
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
0.500% Notes due 2024MRK 24New York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒   No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐ Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒
The number of shares of common stock outstanding as of the close of business on April 30, 2023: 2,537,435,954




Table of Contents




Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 Three Months Ended
March 31,
 20232022
Sales$14,487 $15,901 
Costs, Expenses and Other
Cost of sales3,926 5,380 
Selling, general and administrative2,479 2,323 
Research and development4,276 2,576 
Restructuring costs67 53 
Other (income) expense, net89 708 
 10,837 11,040 
Income Before Taxes3,650 4,861 
Taxes on Income825 554 
Net Income2,825 4,307 
Less: Net Income (Loss) Attributable to Noncontrolling Interests4 (3)
Net Income Attributable to Merck & Co., Inc.$2,821 $4,310 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 Three Months Ended
March 31,
 20232022
Net Income Attributable to Merck & Co., Inc.$2,821 $4,310 
Other Comprehensive (Loss) Income Net of Taxes:
Net unrealized (loss) gain on derivatives, net of reclassifications(133)63 
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization(50)32 
Cumulative translation adjustment68 (35)
 (115)60 
Comprehensive Income Attributable to Merck & Co., Inc.$2,706 $4,370 
 The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
March 31, 2023December 31, 2022
Assets
Current Assets
Cash and cash equivalents$9,707 $12,694 
Short-term investments680 498 
Accounts receivable (net of allowance for doubtful accounts of $76 in 2023
 and $72 in 2022)
10,415 9,450 
Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022
classified in Other assets - see Note 7)
5,863 5,911 
Other current assets6,737 7,169 
Total current assets33,402 35,722 
Investments1,290 1,015 
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256
in 2023 and $17,985 in 2022
21,758 21,422 
Goodwill21,209 21,204 
Other Intangibles, Net19,857 20,269 
Other Assets10,280 9,528 
 $107,796 $109,160 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt$2,672 $1,946 
Trade accounts payable3,680 4,264 
Accrued and other current liabilities13,000 14,159 
Income taxes payable1,872 1,986 
Dividends payable1,907 1,884 
Total current liabilities23,131 24,239 
Long-Term Debt28,074 28,745 
Deferred Income Taxes1,442 1,795 
Other Noncurrent Liabilities8,244 8,323 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2023 and 2022
1,788 1,788 
Other paid-in capital44,467 44,379 
Retained earnings62,039 61,081 
Accumulated other comprehensive loss(4,883)(4,768)
103,411 102,480 
Less treasury stock, at cost:
1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022
56,577 56,489 
Total Merck & Co., Inc. stockholders’ equity46,834 45,991 
Noncontrolling Interests71 67 
Total equity46,905 46,058 
 $107,796 $109,160 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
 
 Three Months Ended
March 31,
 20232022
Cash Flows from Operating Activities
Net income$2,825 $4,307 
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization543 699 
Depreciation448 421 
(Income) loss from investments in equity securities, net(450)708 
Charge for the acquisition of Imago BioSciences, Inc.1,192 — 
Deferred income taxes(277)(338)
Share-based compensation145 120 
Other(197)143 
Net changes in assets and liabilities(2,890)(1,299)
Net Cash Provided by Operating Activities 1,339 4,761 
Cash Flows from Investing Activities
Capital expenditures(1,007)(984)
Purchases of securities and other investments(562)(372)
Proceeds from sales of securities and other investments500 1 
Acquisition of Imago BioSciences, Inc., net of cash acquired(1,327)— 
Other37 182 
Net Cash Used in Investing Activities (2,359)(1,173)
Cash Flows from Financing Activities
Payments on debt(1)(1,250)
Purchases of treasury stock(149)— 
Dividends paid to stockholders(1,853)(1,745)
Proceeds from exercise of stock options30 12 
Other(81)(103)
Net Cash Used in Financing Activities(2,054)(3,086)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash87 (55)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash(2,987)447 
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of
$79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)
12,773 8,167 
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79
and $58 at March 31, 2023 and 2022, respectively, included in Other current assets)
$9,786 $8,614 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -
Notes to Condensed Consolidated Financial Statements (unaudited)

1. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 24, 2023.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Adopted Accounting Standard
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
Recently Issued Accounting Standard Not Yet Adopted
In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption.
2.    Acquisitions, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus’ lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3 billion in Research and development expenses.
In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in Research and development expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion
- 6 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
(including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as Research and development expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
3.    Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at March 31, 2023) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. Also in the first quarter of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400 million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca (which had been previously accrued for) of $105 million. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at March 31, 2023 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.

- 7 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lynparza$275 $266 
Alliance revenue - Koselugo23 9 
Total alliance revenue$298 $275 
Cost of sales (1)
70 299 
Selling, general and administrative47 44 
Research and development21 26 
($ in millions)March 31, 2023December 31, 2022
Receivables from AstraZeneca included in Other current assets
$303 $303 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
21 123 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 600 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Eisai
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125 million sales-based milestone payment from Merck to Eisai. Accordingly, Merck recorded a $125 million liability and a corresponding increase to the intangible asset related to Lenvima. Merck also recognized $72 million of cumulative amortization catch-up expense related to the recognition of this milestone. In 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million (of which $300 million was paid in the first quarter of 2022). Potential future sales-based milestone payments of $2.4 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai (of which $25 million was paid in the first quarter of 2022). There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $812 million at March 31, 2023 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.

- 8 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lenvima$232 $227 
Cost of sales (1)
126 53 
Selling, general and administrative51 31 
Research and development39 57 
($ in millions)March 31, 2023December 31, 2022
Receivables from Eisai included in Other current assets
$244 $214 
Payables to Eisai included in Accrued and other current liabilities (2)
125 — 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021, and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In the first quarter of 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $613 million and $56 million, respectively, at March 31, 2023 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Adempas/Verquvo$99 $72 
Net sales of Adempas recorded by Merck59 61 
Net sales of Verquvo recorded by Merck7 3 
Total sales$165 $136 
Cost of sales (1)
57 50 
Selling, general and administrative33 23 
Research and development25 17 
($ in millions)March 31, 2023December 31, 2022
Receivables from Bayer included in Other current assets
$142 $143 
Payables to Bayer included in Accrued and other current liabilities
68 80 
(1)    Includes amortization of intangible assets.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and
- 9 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations worldwide.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Net sales of Lagevrio recorded by Merck
$392 $3,247 
Cost of sales (1)(2)
221 1,726 
Selling, general and administrative (2)
27 35 
Research and development (2)
16 25 
($ in millions)March 31, 2023December 31, 2022
Payables to Ridgeback included in Accrued and other current liabilities (3)
$191 $348 
(1)    Includes royalty expense and amortization of capitalized milestone payments.
(2)    Expenses include an allocation for overhead charges.
(3)    Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment.
Bristol Myers Squibb
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue related to this collaboration within Sales of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32 million and the receipt of a regulatory approval milestone payment of $20 million).
4. Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $94 million and $99 million and related cost of sales of $107 million and $105 million for the first quarter of 2023 and 2022,
- 10 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for both the first quarter of 2023 and 2022.
The amounts due from Organon under all of the above agreements were $473 million and $511 million at March 31, 2023 and December 31, 2022, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $229 million and $345 million at March 31, 2023 and December 31, 2022, respectively, and are included in Accrued and other current liabilities.
5.    Restructuring
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
The Company recorded total pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March 31, 2023, Merck has recorded total pretax accumulated costs of approximately $3.4 billion. For the full year of 2023, the Company expects to record charges of approximately $400 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended March 31, 2023
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $21 $8 $29 
Selling, general and administrative— — 1 1 
Restructuring costs41 — 26 67 
$41 $21 $35 $97 
 Three Months Ended March 31, 2022
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $18 $28 $46 
Selling, general and administrative— 4 17 21 
Research and development— 7 — 7 
Restructuring costs26 — 27 53 
$26 $29 $72 $127 
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2023 and 2022 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.

- 11 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2023:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2023
$479 $— $34 $513 
Expenses41 21 35 97 
(Payments) receipts, net(47)— (27)(74)
Non-cash activity— (21)(9)(30)
Restructuring reserves March 31, 2023 (1)
$473 $— $33 $506 
(1)The remaining cash outlays are expected to be largely completed by the end of 2025.
6.    Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI
- 12 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended March 31,Three Months Ended March 31,
($ in millions)2023202220232022
Net Investment Hedging Relationships
Foreign exchange contracts$1 $(16)$1 $(1)
Euro-denominated notes52 (53)— — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. In March 2023, the Company entered into five forward starting swaps and in April 2023 entered into two additional forward starting swaps, each with a notional amount of $100 million.
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  March 31, 2023December 31, 2022
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contractsOther Assets$1 $— $300 $— $— $— 
Interest rate swap contractsOther Noncurrent Liabilities— 1 200 — — — 
Foreign exchange contractsOther current assets104 — 4,253 220 — 4,824 
Foreign exchange contractsOther Assets32 — 1,756 27 — 1,609 
Foreign exchange contractsAccrued and other current liabilities— 116 3,444 — 101 2,691 
Foreign exchange contractsOther Noncurrent Liabilities— 2 120 — 1 91 
  $137 $119 $10,073 $247 $102 $9,215 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$121 $— $9,507 $186 $— $8,540 
Foreign exchange contractsOther Assets1 — 65 — — — 
Foreign exchange contractsAccrued and other current liabilities— 164 10,592 — 307 10,926 
Foreign exchange contractsOther Noncurrent Liabilities— 1 124 — — — 
  $122 $165 $20,288 $186 $307 $19,466 
  $259 $284 $30,361 $433 $409 $28,681 

- 13 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 March 31, 2023December 31, 2022
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$259 $284 $433 $409 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(148)(148)(220)(220)
Cash collateral received/posted(13)— (66)(19)
Net amounts$98 $136 $147 $170 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended March 31,
($ in millions)202320222023202220232022
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$14,487 $15,901 $89 $708 $(115)$60 
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — — (10)— — 
Derivatives designated as hedging instruments— — — 4 — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (66)148 
Increase in Sales as a result of AOCL reclassifications
101 67 — — (101)(67)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)(1)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)(1)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended March 31,
($ in millions)20232022
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$13 $28 
Foreign exchange contracts (2)
Sales2 (2)
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
At March 31, 2023, the Company estimates $71 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.

- 14 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 March 31, 2023December 31, 2022
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Commercial paper$663 $— $— $663 $498 $— $— $498 
U.S. government and agency securities92 — — 92 68 — — 68 
Corporate notes and bonds4 — — 4 3 — — 3 
Foreign government bonds1 — — 1 — — — — 
Total debt securities$760 $— $— $760 $569 $— $— $569 
Publicly traded equity securities (1)
1,585 1,284 
Total debt and publicly traded equity securities$2,345 $1,853 
(1)    Unrealized net gains of $338 million were recorded in Other (income) expense, net in the first quarter of 2023 on equity securities still held at March 31, 2023. Unrealized net losses of $225 million were recorded in Other (income) expense, net in the first quarter of 2022 on equity securities still held at March 31, 2022.
At March 31, 2023 and March 31, 2022, the Company also had $942 million and $643 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first quarter of 2023, the Company recorded unrealized gains of $1 million and unrealized losses of $21 million related to certain of these equity investments still held at March 31, 2023. During the first quarter of 2022, the Company recorded unrealized gains of $14 million related to certain of these investments still held at March 31, 2022. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March 31, 2023 were $287 million and $40 million, respectively.
At March 31, 2023 and March 31, 2022, the Company also had $725 million and $1.2 billion, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. (Gains) losses recorded in Other (income) expense, net relating to these investment funds were $(132) million and $509 million for the first quarter of 2023 and 2022, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

- 15 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)March 31, 2023December 31, 2022
Assets
Investments
Commercial paper$— $663 $— $663 $— $498 $— $498 
U.S. government and agency securities— 22 — 22 — — — — 
Foreign government bonds— 1 — 1 — — — — 
Publicly traded equity securities1,284 — — 1,284 1,015 — — 1,015 
 1,284 686 — 1,970 1,015 498 — 1,513 
Other assets (1)
U.S. government and agency securities70 — — 70 68 — — 68 
Corporate notes and bonds4 — — 4 3 — — 3 
Publicly traded equity securities301 — — 301 269 — — 269 
375 — — 375 340 — — 340 
Derivative assets (2)
Purchased currency options— 139 — 139 — 215 — 215 
Forward exchange contracts— 119 — 119 — 218 — 218 
Interest rate swap contracts— 1 — 1 — — — — 
 — 259 — 259 — 433 — 433 
Total assets$1,659 $945 $— $2,604 $1,355 $931 $— $2,286 
Liabilities
Other liabilities
Contingent consideration$— $— $353 $353 $— $— $456 $456 
Derivative liabilities (2)
Forward exchange contracts— 276 — 276 — 402 — 402 
Written currency options— 7 — 7 — 7 — 7 
Interest rate swap contracts— 1 — 1 — — — — 
— 284 — 284 — 409 — 409 
Total liabilities$— $284 $353 $637 $— $409 $456 $865 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of March 31, 2023 and December 31, 2022, Cash and cash equivalents included $8.8 billion and $11.3 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20232022
Fair value January 1$456 $777 
Changes in estimated fair value (1)
14 (84)
Payments(117)(119)
Other— (2)
Fair value March 31 (2)
$353 $572 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    At March 31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March 31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.
The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.

- 16 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2023, was $28.2 billion compared with a carrying value of $30.7 billion and at December 31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable as of March 31, 2023 and December 31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March 31, 2023 and December 31, 2022, the Company had collected $31 million and $67 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The Company remitted the cash to the financial institutions in April 2023 and January 2023, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $13 million and $66 million at March 31, 2023 and December 31, 2022, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities. Cash collateral advanced by the Company to various counterparties was $19 million at December 31, 2022.
7.    Inventories
Inventories consisted of:
($ in millions)March 31, 2023December 31, 2022
Finished goods$1,883 $1,841 
Raw materials and work in process7,348 7,063 
Supplies266 238 
Total (approximates current cost)9,497 9,142 
Decrease to LIFO cost(350)(293)
 $9,147 $8,849 
Recognized as:
Inventories$5,863 $5,911 
Other Assets3,284 2,938 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At March 31, 2023 and December 31, 2022, these amounts included $2.7 billion and $2.4 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $590 million and $516 million at March 31, 2023 and December 31, 2022, respectively, of inventories produced in preparation for product launches.
- 17 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
8.    Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Gardasil/Gardasil 9
Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March 31, 2023, approximately 95 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.
Governmental Proceedings
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, Merck Sharp & Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. In April 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.
- 18 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending.
In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.
In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene.
On February 10, 2023, the district court denied the Merck Defendants’ and Glenmark Defendants’ motions for summary judgment. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck will pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs’ claims, which was recorded as an expense in the Company’s first quarter 2023 financial results.
RotaTeq Antitrust Litigation
On March 3, 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for RotaTeq. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of RotaTeq, trebled, and fees and costs.
Bravecto Litigation
As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend Bravecto causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave Bravecto Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal in February 2022 and issued a decision in April 2022 allowing both parties’ appeals in part. The Court of Appeal amended the class period to start on July 2, 2014, allowed a second plaintiff to serve as a class representative, and modified the list of conditions in the class definition by adding “death” and removing “lack of efficacy.” The Court of Appeal also added to the list of questions to be considered by the trial court the questions of whether the Consumer Protection Act of Quebec applies to the sale of a veterinary product and, if so, whether it was breached. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever
- 19 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered post-trial briefing on this defense and held closing arguments on February 3, 2023.
The Company has settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.
Januvia, Janumet, Janumet XR — As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCI), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the Janumet formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.
Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the District Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit. The parties have now settled the matter, and Mylan has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.
Additionally, in 2019, Mylan filed a petition for inter partes review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held in August 2022. In September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.
In total, the Company has settled with 25 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Januvia.
In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus has filed a NDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for Janumet will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Janumet.
As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in
- 20 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026.
Supplementary Protection Certificates (SPCs) for Janumet expired between April 7 and 10, 2023, for the majority of European countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the Janumet SPCs in Europe, for which an oral hearing was held on March 8, 2023, and an Advocate General Opinion is expected on July 13, 2023. If the CJEU renders a decision that negatively impacts the validity of the Janumet SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the Janumet SPC.
Keytruda — The Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract; declaratory judgment of noninfringement; and promissory estoppel. JHU answered the complaint on April 13, 2023, denying Merck’s claims, and counterclaiming for willful infringement of five issued U.S. patents, including a demand for damages.
Lynparza — In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2023 and December 31, 2022 of approximately $225 million and $230 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.

- 21 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
9.    Equity
Three Months Ended March 31,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20223,577 $1,788 $44,238 $53,696 $(4,429)1,049 $(57,109)$73 $38,257 
Net income attributable to Merck & Co., Inc.— — — 4,310 — — — — 4,310 
Other comprehensive income, net of taxes— — — — 60 — — — 60 
Cash dividends declared on common stock ($0.69 per share)
— — — (1,754)— — — — (1,754)
Share-based compensation plans and other— — 37 — — — 46 — 83 
Net loss attributable to noncontrolling interests— — — — — — — (3)(3)
Balance at March 31, 20223,577 $1,788 $44,275 $56,252 $(4,369)1,049 $(57,063)$70 $40,953 
Balance at January 1, 20233,577 $1,788 $44,379 $61,081 $(4,768)1,039 $(56,489)$67 $46,058 
Net income attributable to Merck & Co., Inc.— — — 2,821 — — — — 2,821 
Other comprehensive loss, net of taxes— — — — (115)— — — (115)
Cash dividends declared on common stock ($0.73 per share)
— — — (1,863)— — — — (1,863)
Treasury stock shares purchased— — — — — 1 (149)— (149)
Share-based compensation plans and other— — 88 — — — 61 — 149 
Net income attributable to noncontrolling interests— — — — — — — 4 4 
Balance at March 31, 20233,577 $1,788 $44,467 $62,039 $(4,883)1,040 $(56,577)$71 $46,905 
10.    Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
  Three Months Ended
March 31,
20232022
($ in millions)U.S.InternationalU.S.International
Service cost$76 $49 $99 $75 
Interest cost133 74 103 38 
Expected return on plan assets(187)(128)(196)(101)
Amortization of unrecognized prior service credit— (3)(8)(4)
Net (gain) loss amortization— (1)56 25 
Curtailments2 — 3 — 
Settlements21 — 1 — 
 $45 $(9)$58 $33 
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
March 31,
($ in millions)20232022
Service cost$8 $12 
Interest cost16 11 
Expected return on plan assets(16)(21)
Amortization of unrecognized prior service credit(12)(14)
Net gain amortization(11)(11)
 $(15)$(23)
- 22 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21 million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March 31, 2023, resulted in a net increase of $44 million to net pension liabilities and also resulted in a related adjustment to AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 11), with the exception of certain amounts for termination benefits and curtailments which are recorded in Restructuring costs if the event giving rise to the termination benefits or curtailment is related to restructuring actions.
11.    Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
March 31,
($ in millions)20232022
Interest income$(112)$(7)
Interest expense242 243 
Exchange losses61 39 
(Income) loss from investments in equity securities, net (1)
(450)708 
Net periodic defined benefit plan (credit) cost other than service cost(115)(121)
Other, net463 (154)
 $89 $708 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Other, net (as reflected in the table above) in the first quarter of 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 8).
Interest paid for the three months ended March 31, 2023 and 2022 was $208 million and $211 million, respectively.
12.    Taxes on Income
The effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company’s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate.
13.    Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
March 31,
($ and shares in millions except per share amounts)20232022
Net Income Attributable to Merck & Co., Inc.$2,821 $4,310 
Average common shares outstanding2,538 2,528 
Common shares issuable (1)
13 9 
Average common shares outstanding assuming dilution 2,551 2,537 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
(1)    Issuable primarily under share-based compensation plans.
For the first quarter of 2023 and 2022, 1 million and 7 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
- 23 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
14.    Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended March 31,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2022, net of taxes$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax148 1 (18)131 
Tax(31)(2)(17)(50)
Other comprehensive income (loss) before reclassification adjustments, net of taxes117 (1)(35)81 
Reclassification adjustments, pretax(68)
(1)
45 
(2)
— (23)
Tax14 (12)— 2 
Reclassification adjustments, net of taxes(54)

33 

— (21)
Other comprehensive income (loss), net of taxes63 32 (35)60 
Balance March 31, 2022, net of taxes$207 $(2,711)$(1,865)$(4,369)
Balance January 1, 2023, net of taxes$73 $(2,408)$(2,433)$(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax(66)(47)79 (34)
Tax14 2 (20)(4)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(52)(45)59 (38)
Reclassification adjustments, pretax(102)
(1)
(7)
(2)
9 (100)
Tax21 2 — 23 
Reclassification adjustments, net of taxes(81)

(5)

9 (77)
Other comprehensive income (loss), net of taxes(133)(50)68 (115)
Balance March 31, 2023, net of taxes$(60)$(2,458)$(2,365)$(4,883)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).

15.    Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.

- 24 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Sales of the Company’s products were as follows:
Three Months Ended March 31,
20232022
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$3,485 $2,310 $5,795 $2,779 $2,030 $4,809 
Alliance revenue-Lynparza (1)
142 133 275 141 125 266 
Alliance revenue-Lenvima (1)
153 79 232 156 71 227 
Alliance revenue-Reblozyl (2)
30 12 43 27 25 52 
Welireg41 1 42 18 — 18 
Vaccines
Gardasil/Gardasil 9
416 1,556 1,972 418 1,042 1,460 
ProQuad/M-M-R II/Varivax
421 107 528 371 99 470 
RotaTeq180 117 297 175 41 216 
Vaxneuvance94 13 106 5 — 5 
Pneumovax 23
40 56 96 118 55 173 
Vaqta30 10 40 29 7 36 
Hospital Acute Care
Bridion276 210 487 195 199 395 
Prevymis54 75 129 40 54 94 
Primaxin4 76 80 1 58 58 
Dificid62 3 65 49 3 52 
Noxafil14 46 60 10 48 57 
Zerbaxa27 23 50 18 12 30 
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
83 16 99 71 1 72 
Adempas— 59 59 — 61 61 
Virology
Lagevrio(2)394 392 1,523 1,723 3,247 
Isentress/Isentress HD
52 71 123 61 97 158 
Neuroscience
Belsomra16 40 56 20 48 69 
Immunology
Simponi— 180 180 — 186 186 
Remicade— 51 51 — 61 61 
Diabetes
Januvia271 280 551 325 454 779 
Janumet56 272 329 63 391 454 
Other pharmaceutical (4)
172 414 584 160 443 602 
Total Pharmaceutical segment sales6,117 6,604 12,721 6,773 7,334 14,107 
Animal Health:
Livestock174 676 849 171 661 832 
Companion Animals308 334 642 302 348 650 
Total Animal Health segment sales482 1,010 1,491 473 1,009 1,482 
Total segment sales6,599 7,614 14,212 7,246 8,343 15,589 
Other (5)
60 214 275 93 220 312 
 $6,659 $7,828 $14,487 $7,339 $8,563 $15,901 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99 million and $69 million for the three months ended March 31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2023 and 2022 also includes $51 million and $114 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
- 25 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.1 billion and $2.9 billion for the three months ended March 31, 2023 and 2022, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20232022
United States$6,659 $7,339 
Europe, Middle East and Africa3,303 4,359 
China1,715 1,143 
Asia Pacific (other than China and Japan)846 930 
Japan758 989 
Latin America661 607 
Other545 534 
 $14,487 $15,901 
A reconciliation of segment profits to Income Before Taxes is as follows:
 Three Months Ended
March 31,
($ in millions)20232022
Segment profits:
Pharmaceutical segment$9,140 $9,501 
Animal Health segment566 585 
Total segment profits9,706 10,086 
Other profits164 194 
Unallocated:
Interest income112 7 
Interest expense(242)(243)
Amortization(543)(699)
Depreciation(398)(378)
Research and development(4,147)(2,446)
Restructuring costs(67)(53)
Charge for Zetia antitrust litigation settlements(573)— 
Other unallocated, net(362)(1,607)
 $3,650 $4,861 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.



- 26 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Business Developments
Below is a summary of significant business development activity thus far in 2023. See Note 2 to the condensed consolidated financial statements for additional information.
In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus’ lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3 billion in Research and development expenses or approximately $4.00 per share. Additionally, Merck anticipates earnings per share (EPS) will be negatively affected by approximately $0.25 in the first 12 months following the closing of the transaction resulting from investments to advance the related pipeline assets, as well as the cost of financing.
In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in Research and development expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $219 million, as well as Research and development expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first three months of 2023 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In 2022, the U.S. Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.
Supply Chain
As a result of global macroeconomic conditions, the Company is experiencing some minor disruption and volatility in its global supply chain network. These disruptions could increase in the future and cause delays in shipments of raw materials and packaging, as well as related cost inflation.

- 27 -

Operating Results
Sales
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
United States$6,659 $7,339 (9)%(9)%
International7,828 8,563 (9)%(2)%
Total$14,487 $15,901 (9)%(5)%
U.S. plus international may not equal total due to rounding.
Worldwide sales declined 9% to $14.5 billion in the first quarter of 2023 primarily due to lower sales in the virology franchise, largely attributable to Lagevrio (molnupiravir), which had sales of $392 million in the first quarter of 2023 compared with $3.2 billion in the first quarter of 2022. Also contributing to the revenue decline in the first quarter of 2023 were lower sales in the diabetes franchise due to Januvia (sitagliptin) and Janumet (sitagliptin and metformin HCl), as well as lower sales of Pneumovax 23 (pneumococcal vaccine polyvalent). The sales decline in the first quarter of 2023 was partially offset by higher sales in the oncology franchise, largely driven by strong growth of Keytruda (pembrolizumab), higher sales in the vaccines franchise, primarily attributable to growth of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and the ongoing launch of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for pediatric use, as well as higher sales of hospital acute care products, including Bridion (sugammadex) Injection.
See Note 15 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.
Pharmaceutical Segment
Oncology
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
Keytruda$5,795 $4,809 20 %24 %
Alliance Revenue - Lynparza (1)
275 266 3 %8 %
Alliance Revenue - Lenvima (1)
232 227 2 %5 %
Alliance Revenue - Reblozyl (2)
43 52 (19)%(19)%
Welireg42 18 **
* > 100%
(1)    Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
(2)    Alliance revenue represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 3 to the consolidated financial statements).
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, MSI-H/dMMR advanced endometrial carcinoma, primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma including non-muscle invasive bladder cancer. Additionally, Keytruda is approved as monotherapy for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence and for certain patients with completely resected stage IIB, IIC or III melanoma, and for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage 1B (T2a ≥4 cm), II, or IIIA NSCLC. Keytruda is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, Keytruda is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy with or without bevacizumab for advanced cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for locally recurrent unresectable or metastatic TNBC, in combination with axitinib for advanced RCC, in combination with Lenvima for certain patients with advanced endometrial carcinoma or advanced RCC, and in combination with enfortumab vedotin for certain patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. The Keytruda clinical development program includes studies across a broad range of cancer types. See “Research and Development Update” below.
Global sales of Keytruda grew 20% in the first quarter of 2023. Sales growth was primarily driven by higher demand as the Company continues to launch Keytruda with multiple new indications globally. Sales growth in the U.S. reflects increased
- 28 -

uptake across earlier-stage indications including in high-risk early stage TNBC, as well as certain types of RCC and melanoma, and higher demand across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, NSCLC, TNBC, and HNSCC cancers. Keytruda sales growth in international markets reflects higher demand for the HNSCC and RCC metastatic indications, as well as uptake in earlier-stage indications, particularly in Europe and Latin America.
Keytruda received the following regulatory approvals thus far in 2023.
DateApproval
January 2023FDA approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.
March 2023FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on results from the Phase 2 KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.
April 2023FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on data from the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.
Lynparza (olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza increased 3% in the first quarter of 2023 largely driven by higher demand, particularly in Europe in certain patients with ovarian cancer.
Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with Keytruda for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to Lenvima grew 2% in the first quarter of 2023 reflecting uptake in the advanced RCC indication in Europe, partially offset by lower volumes in China.
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (see Note 3 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Merck recorded alliance revenue related to this collaboration of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32 million and the receipt of a regulatory approval milestone payment of $20 million).
Sales of Welireg (belzutifan), for the treatment of adult patients with certain von Hippel-Lindau disease-associated tumors, were $42 million in the first quarter of 2023 compared with $18 million in the first quarter of 2022 due to continued uptake in the U.S. following launch in 2021.
Vaccines
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
Gardasil/Gardasil 9
$1,972 $1,460 35 %43 %
ProQuad190 162 17 %18 %
M-M-R II
102 103 (1)%— %
Varivax236 204 15 %17 %
RotaTeq297 216 38 %42 %
Vaxneuvance106 5 **
Pneumovax 2396 173 (44)%(40)%
* > 100%
Combined worldwide sales of Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 35% in the first quarter of 2023 driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from the timing of shipments and increased supply. Sales of Gardasil 9 in the U.S. were essentially flat in the first quarter of 2023 as lower sales due to public sector buying patterns were offset by higher pricing.
Global sales of ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, increased 17% in the first quarter of 2023 primarily reflecting higher demand and pricing in the U.S. and higher demand in Europe.
- 29 -

Worldwide sales of M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, declined 1% in the first quarter of 2023 primarily due to lower tenders in Latin America, largely offset by higher pricing and demand in the U.S.
Global sales of Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), grew 15% in the first quarter of 2023 primarily attributable to higher demand and pricing in the U.S.
Global sales of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children, grew 38% in the first quarter of 2023 primarily due to inventory stocking in China.
Worldwide sales of Vaxneuvance, a vaccine to help prevent invasive pneumococcal disease, increased to $106 million in the first quarter of 2023 primarily due to continued uptake in the pediatric indication in the U.S. following launch in 2022.
Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, declined 44% in the first quarter of 2023 primarily reflecting lower demand in the U.S. as the market continues to shift toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices in 2021. The Company expects the decline in U.S. sales of Pneumovax 23 to continue.
Hospital Acute Care
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
Bridion$487 $395 23 %27 %
Prevymis129 94 38 %44 %
Worldwide sales of Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 23% in the first quarter of 2023 primarily due to higher demand, particularly in the U.S., reflecting Bridion’s growing share among neuromuscular blockade reversal agents. The patent that provides market exclusivity for Bridion in the European Union (EU) will expire in July 2023; the Company anticipates sales of Bridion in these markets will decline thereafter.
Worldwide sales of Prevymis (letermovir), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 38% in the first quarter of 2023 due to higher demand in the U.S. and Europe, as well as uptake from the 2022 launch in China. In February 2023, the FDA granted priority review for a supplemental New Drug Application (NDA) for Prevymis for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (D+/R-); the Prescription Drug User Fee Act (PDUFA), or target action, date is June 5, 2023.
Cardiovascular
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
Alliance Revenue - Adempas/Verquvo (1)
$99 $72 38 %38 %
Adempas59 61 (3)%5 %
(1) Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note 3 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension and chronic pulmonary hypertension. Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Alliance revenue from the collaboration grew 38% in the first quarter of 2023 primarily due to higher profit sharing reflecting increased demand in Bayer’s marketing territories. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories were nearly flat in the first quarter of 2023 compared with the prior year.
Virology
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
Lagevrio$392 $3,247 (88)%(87)%
Isentress/Isentress HD123 158 (23)%(20)%
- 30 -

Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note 3 to the condensed consolidated financial statements). Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations worldwide. Sales of Lagevrio declined 88% in the first quarter of 2023 largely attributable to sales in the U.S. and UK markets in the first quarter of 2022 that did not recur in the first quarter of 2023. The Lagevrio sales decline was also attributable to lower sales in Japan and Australia. The Company expects full-year 2023 Lagevrio sales to be approximately $1.0 billion. In April 2023, Japan’s Ministry of Health, Labor and Welfare granted full approval for Lagevrio. Lagevrio was previously granted Special Approval for Emergency in Japan in December 2021.
Global combined sales of Isentress/Isentress HD (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 23% in the first quarter of 2023 primarily due to lower global demand, reflecting in part competitive pressure particularly in Europe and the U.S. The Company expects competitive pressure for Isentress/Isentress HD to continue. The patent that provides market exclusivity for Isentress/Isentress HD in the EU will expire in July 2023; the Company anticipates sales declines of Isentress/Isentress HD in these markets will accelerate thereafter.
Diabetes
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
Januvia/Janumet$880 $1,233 (29)%(25)%
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 29% in the first quarter of 2023 primarily reflecting the loss of exclusivity in several markets in Europe and the Asia Pacific region, as well as in Canada, coupled with lower demand and pricing in the U.S. due to competitive pressures.
While the key U.S. patent for Januvia and Janumet claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note 8 to the condensed consolidated financial statements), the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026. As a result of competitive pressures, the Company anticipates pricing and volume declines for Januvia and Janumet in the U.S. for the remainder of 2023 and thereafter.
The Company lost market exclusivity for Januvia in all of the EU and for Janumet in some European countries in September 2022. Exclusivity for Janumet was lost in other European countries in April 2023. While the Company lost market exclusivity for Januvia in China in 2022 with the launch of a generic equivalent product, the impact on sales in 2023 is expected to be modest. Although several generic equivalents of Janumet have been approved in China, none have launched, and the Company expects it is unlikely that any will launch prior to December 2023.
Combined sales of Januvia and Janumet in Europe, China and the U.S. represented 11%, 13% and 37%, respectively, of total combined Januvia and Janumet sales for the first quarter of 2023.
In response to a request from a regulatory authority, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug’s manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities’ interim acceptable NTTP limits for continuing distribution of product to the market. The Company is making progress in its efforts to reduce the level of nitrosamines in its sitagliptin-containing medicines. However, difficulties in reducing those levels, or achieving timely regulatory approvals for required changes, could result in product shortages.
Animal Health Segment
Three Months Ended
March 31,		% Change
Excluding
Foreign
Exchange
($ in millions)20232022% Change
Livestock$849 $832 2 %8 %
Companion Animal642 650 (1)%2 %
Sales of livestock products grew 2% in the first quarter of 2023 primarily reflecting strong demand in the ruminant and poultry product portfolio, which includes technology solution products, as well as higher pricing. Sales of companion animal products declined 1% in the first quarter of 2023. Excluding the unfavorable effect of foreign exchange, companion animal sales performance primarily reflects higher pricing. Sales of the Bravecto (fluralaner) parasiticide line of products were $314 million in both the first quarter of 2023 and the first quarter of 2022.
- 31 -

Costs, Expenses and Other
Three Months Ended
March 31,
($ in millions)20232022% Change
Cost of sales$3,926 $5,380 (27)%
Selling, general and administrative2,479 2,323 7 %
Research and development4,276 2,576 66 %
Restructuring costs67 53 26 %
Other (income) expense, net89 708 (87)%
$10,837 $11,040 (2)%
Cost of Sales
Cost of sales decreased 27% in the first quarter of 2023. Cost of sales includes $221 million and $1.7 billion in the first quarter of 2023 and 2022, respectively, related to sales of Lagevrio, which is being developed in a collaboration with Ridgeback (see Note 3 to the condensed consolidated financial statements). Cost of sales also includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $532 million and $683 million in the first quarter of 2023 and 2022, respectively. Amortization expense in the first quarter of 2023 and 2022 includes $72 million and $250 million, respectively, of cumulative catch-up amortization related to Merck’s collaborations with Eisai and AstraZeneca, respectively, (see Note 3 to the condensed consolidated financial statements). Also included in cost of sales are expenses associated with restructuring activities, which amounted to $29 million and $46 million in the first quarter of 2023 and 2022, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
Gross margin was 72.9% in the first quarter of 2023 compared with 66.2% in the first quarter of 2022. The gross margin improvement primarily reflects the favorable impacts of lower Lagevrio sales (which have a low gross margin), product mix and lower amortization of intangible assets (noted above).
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses increased 7% in the first quarter of 2023 primarily due to higher administrative costs and increased promotional spending, partially offset by the favorable effect of foreign exchange.
Research and Development
Research and development (R&D) expenses increased 66% to $4.3 billion in the first quarter of 2023 primarily due to a $1.2 billion charge for the acquisition of Imago, as well as higher upfront charges related to collaborations and licensing arrangements. Also contributing to the increase in R&D expenses were higher compensation and benefit costs, reflecting in part increased headcount to support clinical development activity, higher investments in discovery research and early drug development, as well as increased clinical development spending. The increase in R&D expenses was partially offset by the favorable effect of foreign exchange.
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $2.1 billion and $1.8 billion for the first quarter of 2023 and 2022, respectively. Also included in R&D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $2.2 billion and $750 million for the first quarter of 2023 and 2022, respectively. The increase in these expenses in the first quarter of 2023 was largely attributable to a $1.2 billion charge for the acquisition of Imago (as noted above) and a $175 million charge for a license and collaboration agreement with Kelun-Biotech. See Note 2 for additional information related to business development activity.
Restructuring Costs
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. Merck expects to record charges of approximately $400 million for the full year of 2023 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in cumulative annual net cost savings of approximately $900 million by the end of 2023.
Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $67 million and $53 million for the first quarter of 2023 and 2022, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and
- 32 -

termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities (see Note 5 to the condensed consolidated financial statements).
Other (Income) Expense, Net
Other (income) expense, net, was $89 million of expense in the first quarter of 2023 compared with $708 million of expense in the first quarter of 2022. The change was primarily due to net unrealized gains from investments in equity securities recorded in the first quarter of 2023 compared with net unrealized losses recorded in the first quarter of 2022, as well as higher interest income in the first quarter of 2023. The favorability was partially offset by a $572.5 million charge in the first quarter of 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 8 to the consolidated financial statements).
For details on the components of Other (income) expense, net, see Note 11 to the condensed consolidated financial statements.
Segment Profits
 Three Months Ended
March 31,
($ in millions)20232022
Pharmaceutical segment profits$9,140 $9,501 
Animal Health segment profits566 585 
Other(6,056)(5,225)
Income Before Taxes$3,650 $4,861 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements.
Pharmaceutical segment profits declined 4% in the first quarter of 2023 reflecting lower sales, largely attributable to Lagevrio, as well as higher administrative and promotional costs, and the unfavorable effect of foreign exchange. Animal Health segment profits declined 3% in the first quarter of 2023 reflecting higher administrative and promotional costs, as well as increased research and development expenses.
Taxes on Income
The effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company’s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate.
Non-GAAP Income and Non-GAAP EPS
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance.
- 33 -

Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP).
A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
Three Months Ended
March 31,
($ in millions except per share amounts)20232022
Income before taxes as reported under GAAP$3,650 $4,861 
Increase (decrease) for excluded items:
Acquisition- and divestiture-related costs590 637 
Restructuring costs97 127 
(Income) loss from investments in equity securities, net(429)684 
Other items:
Charge for Zetia antitrust litigation settlements573 — 
Non-GAAP income before taxes4,481 6,309 
Taxes on income as reported under GAAP825 554 
Estimated tax benefit on excluded items (1)
88 329 
Non-GAAP taxes on income913 883 
Non-GAAP net income3,568 5,426 
Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP4 (3)
Non-GAAP net income attributable to Merck & Co., Inc.$3,564 $5,429 
EPS assuming dilution as reported under GAAP$1.11 $1.70 
EPS difference0.29 0.44 
Non-GAAP EPS assuming dilution$1.40 $2.14 
(1)    The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
Acquisition- and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 5 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2023 is a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 8 to the condensed consolidated financial statements).
- 34 -

Research and Development Update
The Company currently has several candidates under regulatory review in the U.S. and internationally.
MK-4482, Lagevrio, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing Lagevrio in collaboration with Ridgeback. The FDA granted Emergency Use Authorization for Lagevrio in December 2021; last issued in February 2023, to authorize Lagevrio for the treatment of adults with a current diagnosis of mild to moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. Lagevrio is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. In November 2021, the European Medicines Agency (EMA) issued a positive scientific opinion for Lagevrio, which is intended to support national decision-making on the possible use of Lagevrio prior to marketing authorization. In October 2021, the EMA initiated a rolling review for Lagevrio for the treatment of COVID-19 in adults. In February 2023, Merck and Ridgeback announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended the refusal of the marketing authorization application (MAA) for Lagevrio. Merck and Ridgeback have appealed the decision and requested a re-examination of the MAA. Applications to other regulatory bodies are underway.
MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA and the EMA. The marketing applications for gefapixant are based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck’s NDA for gefapixant. In the CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. The CRL was not related to the safety of gefapixant. The Company is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023 in response to the CRL. The review period in the EU was extended pending the receipt of additional information, which Merck submitted to the EMA in the first quarter of 2023.
MK-3475, Keytruda, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently encompasses more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
Keytruda is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. Keytruda is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.
Additionally, Keytruda is under review by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. This submission is based on data from the Phase 3 KEYNOTE-913 trial. Keytruda is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.
Keytruda is also under review by the FDA in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. The submission is based on data from the KEYNOTE-859 trial, in which Keytruda plus chemotherapy demonstrated a statistically significant improvement in overall survival versus chemotherapy alone, regardless of PD-L1 expression, in patients who were HER2 negative. The FDA set a PDUFA date of December 16, 2023. KEYNOTE-859 is also under review in the EU.
In addition, Keytruda is under review by the FDA as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB NSCLC based on the KEYNOTE-671 study. A perioperative treatment regimen includes treatment before surgery (neoadjuvant) and continued after surgery (adjuvant). The FDA set a PDUFA date of October 16, 2023. KEYNOTE-671 is also under review in the EU.
Keytruda is under review in the EU for the adjuvant treatment of patients with stage IB (≥4 cm), II or IIIA NSCLC following complete surgical resection. The submission is based on data from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS.
Keytruda is under review in Japan for the treatment of patients with relapsed or refractory PMBCL. This submission is based on data from the Phase 2 KEYNOTE-170 study and the Phase 1 KEYNOTE-A33 study.
In February 2023, Merck announced it was discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) based on the recommendation of an independent Data Monitoring Committee. At an interim analysis, Keytruda in combination with enzalutamide and ADT did not demonstrate an improvement in radiographic progression-
- 35 -

free survival or overall survival, the trial’s dual primary endpoints, compared to placebo plus enzalutamide and ADT, and crossed a pre-specified futility boundary for overall survival.
In March 2023, Merck provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe-002 is evaluating MK-7684A, a coformulation of vibostolimab, an anti-TIGIT therapy, and Keytruda, with or without docetaxel for the treatment of patients with metastatic NSCLC with progressive disease after treatment with immunotherapy and platinum-doublet chemotherapy. KeyVibe-002, a partially blinded study, was designed with two primary objectives: 1) to evaluate the efficacy of MK-7684A alone compared with docetaxel, a standard of care; and 2) in a blinded assessment, evaluate the efficacy of adding MK-7684A to docetaxel compared with docetaxel alone. Results from the open-label arm of the study evaluating MK-7684A alone showed that the coformulation did not reach statistical significance for the primary endpoint of progression-free survival and was numerically less effective compared with docetaxel. The blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel alone. Results will be presented at an upcoming medical meeting once further data from the blinded study arms are available.
MK-7339, Lynparza, is an oral PARP inhibitor currently approved for the treatment of several cancers being co-developed for additional cancer types as part of a collaboration with AstraZeneca (see Note 3 to the condensed consolidated financial statements).
In April 2023, the FDA convened its Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental NDA for use of Lynparza in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with mCRPC, based on the results of the Phase 3 PROpel trial. By a vote of 11 to 1 with one abstention, the OADC supported FDA approval of Lynparza plus abi/pred for the first-line treatment of adult patients with BRCA-mutated (BRCAm) mCRPC. The committee voted that the FDA should restrict use of Lynparza plus abi/pred to these BRCAm mCRPC patients, recommending against approval beyond this patient population. The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer. The FDA is not bound by the committee’s guidance but takes its advice into consideration. AstraZeneca and Merck will continue to work with the FDA as the agency completes its review of the application. Lynparza is also under review in Japan for the treatment of certain patients with mCRPC based on the PROpel trial.
MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor currently approved for the treatment of several cancers being developed as part of a collaboration with Eisai. Merck and Eisai are studying the Keytruda plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program.
In April 2023, Merck and Eisai announced the discontinuation of the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma based on the recommendation of an independent Data Monitoring Committee, which reviewed data from a planned interim analysis and determined Keytruda plus Lenvima did not demonstrate an improvement in overall survival, one of the study’s dual primary endpoints, versus Keytruda alone. Merck and Eisai also provided an update on the Phase 3 LEAP-017 trial evaluating Keytruda plus Lenvima for the treatment of patients with unresectable and metastatic colorectal cancer that is mismatch repair proficient or not MSI-H who experienced disease progression on, or became intolerant to, prior therapy. The trial did not meet statistical significance for its primary endpoint of overall survival in the final pre-specified analysis.
The charts below reflect the Company’s research pipeline as of May 3, 2023. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
- 36 -

Phase 2
Cancer
MK-0482(2)
     Non-Small-Cell Lung
MK-1308 (quavonlimab)(2)
Non-Small-Cell Lung
MK-1308A (quavonlimab+pembrolizumab)
Colorectal
Hepatocellular
Melanoma
Small-Cell Lung
MK-2140 (zilovertamab vedotin)
Bladder
Breast
Gastric
Hematological Malignancies
Non-Small-Cell Lung
Ovarian
Pancreatic
MK-2870(1)(3)
Neoplasm Malignant
MK-3475 Keytruda
Advanced Solid Tumors
Prostate
MK-3543 (bomedemstat)
Myeloproliferative Disorders
MK-4280 (favezelimab)(2)
    Non-Small-Cell Lung
MK-4280A (favezelimab+pembrolizumab)
Baldder
Esophageal
Melanoma
Renal Cell
Small-Cell Lung
MK-4830(2)
        Colorectal
     Esophageal
     Melanoma
Non-Small-Cell Lung
Ovarian
Renal Cell
    Small-Cell Lung
MK-5684(1)
Prostate
MK-5890 (boserolimab)(2)
     Non-Small-Cell Lung
     Small-Cell Lung



Cancer
MK-6440 (ladiratuzumab vedotin)(1)(3)
Breast
Esophageal
Gastric
Head and Neck
Melanoma
Non-Small-Cell Lung
Prostate
Small-Cell Lung
MK-6482 Welireg(3)
Biliary
Colorectal
Endometrial
Esophageal
Hepatocellular
Pancreatic
Rare cancers
Von Hippel-Lindau Disease-Associated Tumors (EU)
MK-7119 Tukysa(1)
Advanced Solid Tumors
Biliary
Bladder
Cervical
Endometrial
Gastric
Non-Small-Cell Lung
MK-7339 Lynparza(1)(3)
Advanced Solid Tumors
MK-7684A (vibostolimab+pembrolizumab)
Biliary
Bladder
Breast
Cervical
Colorectal
Endometrial
Esophageal
Gastric
Head and Neck
Hematological Malignancies
Hepatocellular
Ovarian
Prostate

Cancer
MK-7902 Lenvima(1)(2)
Biliary
Melanoma
Pancreatic
Prostate
Small-Cell Lung
V940(1)(2)
Melanoma
Dengue Fever Virus Vaccine
V181
HIV-1 Infection
MK-8591B (islatravir+MK-8507)(4)
MK-8591D (islatravir+lenacapavir)(1)(5)
Hypercholesterolemia
MK-0616
Nonalcoholic Steatohepatitis (NASH)
MK-6024 (efinopegdutide)
Pulmonary Arterial Hypertension
MK-5475
Pulmonary Hypertension Due To Left Heart Disease
MK-7962 (sotatercept)
Schizophrenia
MK-8189(6)
Thrombosis
MK-2060
Treatment Resistant Depression
MK-1942

- 37 -

Phase 3 (Phase 3 entry date)Under Review
Antiviral COVID-19
     MK-4482 Lagevrio (U.S.) (May 2021)(1)(7)
Cancer
MK-1026 (nemtabrutinib)
     Hematological Malignancies (March 2023)
MK-1308A (quavonlimab+pembrolizumab)
Renal Cell (April 2021)
MK-3475 Keytruda
Biliary (September 2019)
Cutaneous Squamous Cell (August 2019) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Ovarian (December 2018)
Small-Cell Lung (May 2017)
MK-3475 (pembrolizumab subcutaneous)
Non-Small-Cell Lung (August 2021)
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Non-Small-Cell Lung (February 2023)
MK-4280A (favezelimab+pembrolizumab)
Colorectal (November 2021)
Hematological Malignancies (October 2022)
MK-6482 Welireg(3)
Renal Cell (February 2020)
MK-7119 Tukysa(1)
Breast (October 2019)
Colorectal (August 2022)
MK-7339 Lynparza(1)(2)
Non-Small-Cell Lung (June 2019)
Small-Cell Lung (December 2020)
MK-7684A (vibostolimab+pembrolizumab)
Melanoma (January 2023)
Non-Small-Cell Lung (April 2021)
Small-Cell Lung (March 2022)
MK-7902 Lenvima(1)(2)
Esophageal (July 2021)
Gastric (December 2020)
Head and Neck (February 2020)
Non-Small-Cell Lung (March 2019)
HIV-1 Infection
     MK-8591A (doravirine+islatravir) (February 2020)(5)
Pneumococcal Vaccine Adult
V116 (July 2022)
Pulmonary Arterial Hypertension
MK-7962 (sotatercept) (January 2021)
Respiratory Syncytial Virus
MK-1654 (clesrovimab) (November 2021)
New Molecular Entities
Antiviral COVID-19
MK-4482 Lagevrio (EU)(1)(8)
Cough
MK-7264 (gefapixant) (U.S.)(9) (EU)






Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• Second-Line Hepatocellular Carcinoma
(KEYNOTE-394) (U.S.)
• Locally Advanced or Metastatic Merkel Cell Carcinoma
(KEYNOTE-913) (U.S.)
• First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer
(KEYNOTE-859) (U.S.) (EU)
• Resectable Stage II, IIIA or IIIB NSCLC
(KEYNOTE-671) (U.S.) (EU)
• Adjuvant Non-Small-Cell Lung Cancer
(KEYNOTE-091) (EU)
• Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma
(KEYNOTE-170/KEYNOTE-A33) (JPN)

MK-7339 Lynparza(1)
• First-Line Metastatic Prostate Cancer
(PROpel) (U.S.) (JPN)



Footnotes:
(1) Being developed in a collaboration.
(2) Being developed in combination with Keytruda.
(3) Being developed as monotherapy and/or in combination with Keytruda.
(4) On FDA clinical hold.
(5) On FDA partial clinical hold for higher doses than those used in current clinical trials.
(6) Phase 2b development costs are being co-funded.
(7) Available in the U.S. under Emergency Use Authorization.
(8) Requested re-examination of EU MAA following CHMP recommendation for the refusal of the marketing authorization.
(9) In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023.


Analysis of Liquidity and Capital Resources
($ in millions)March 31, 2023December 31, 2022
Cash and investments$11,677 $14,207 
Working capital10,271 11,483 
Total debt to total liabilities and equity28.5 %28.1 %
Cash provided by operating activities was $1.3 billion in the first three months of 2023 compared with $4.8 billion in the first three months of 2022 primarily reflecting the impact of lower Lagevrio sales. Cash provided by operating activities was reduced by milestone payments related to certain collaborations of $115 million and $1.2 billion in the first three months of 2023 and 2022, respectively. Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases.
Cash used in investing activities was $2.4 billion in the first three months of 2023 compared with $1.2 billion in the first three months of 2022. The higher use of cash in investing activities was primarily due to the acquisition of Imago and higher purchases of securities and other investments, partially offset by higher proceeds from sales of securities and other investments.
Cash used in financing activities was $2.1 billion in the first three months of 2023 compared with $3.1 billion in the first three months of 2022. The decrease in cash used in financing activities was primarily due to lower payments on long-term debt, partially offset by treasury stock purchases and higher dividends paid to shareholders.
Capital expenditures totaled $1.0 billion in the first three months of 2023 compared with $984 million in the first three months of 2022.
- 38 -

The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable at March 31, 2023 and December 31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows.
Dividends paid to stockholders were $1.9 billion and $1.7 billion for the first three months of 2023 and 2022, respectively. In January 2023, the Board of Directors declared a quarterly dividend of $0.73 per share on the Company’s outstanding common stock for the first quarter that was paid in April 2023.
As discussed above, in April 2023, Merck announced an agreement to acquire Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023.
In February 2022, the Company’s $1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In September 2022, the Company’s $1.0 billion, 2.40% notes matured in accordance with their terms and were repaid.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The Company anticipates making modest share repurchases under this program in 2023. During the first three months of 2023, the Company purchased $149 million (1 million shares) of its common stock for its treasury under this program. As of March 31, 2023, the Company’s remaining share repurchase authorization was $4.9 billion.
The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Estimates
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2022 included in Merck’s Form 10‑K filed on February 24, 2023. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2023. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K. There have been no significant changes in the Company’s critical accounting estimates since December 31, 2022.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Company’s 2022 Form 10-K filed on February 24, 2023.
Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2023, the Company’s disclosure controls and procedures are effective. During the quarter, the Company upgraded its financial consolidation system to the latest software version and moved it to an externally hosted cloud-based environment. The Company completed testing of this system prior to its launch, continues to monitor impacted financial and business processes and believes that an effective control environment has been maintained post-implementation.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and
- 39 -

other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December 31, 2022, filed on February 24, 2023, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.
PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 8 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended March 31, 2023 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period
Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
January 1 - January 31— — — $5,047
February 1 - February 28328,800 $108.43328,800 $5,012
March 1 - March 311,066,937 $106.551,066,937 $4,898
Total1,395,737 $107.001,395,737 
(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.
- 40 -


Item 6. Exhibits
Number  Description
3.1—
3.2—
31.1 —
31.2 —
32.1 —
32.2 —
101.INS—XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH—XBRL Taxonomy Extension Schema Document.
101.CAL—XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF—XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB—XBRL Taxonomy Extension Label Linkbase Document.
101.PRE—XBRL Taxonomy Extension Presentation Linkbase Document.
104 —Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
- 41 -




Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 MERCK & CO., INC.
Date: May 5, 2023 /s/ Jennifer Zachary
 JENNIFER ZACHARY
 Executive Vice President and General Counsel
Date: May 5, 2023 /s/ Rita A. Karachun
 RITA A. KARACHUN
 Senior Vice President Finance - Global Controller
- 42 -
 EX-31.1 2 exhibit311-rule13ax14a15dx.htm RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CHIEF EXECUTIVE OFFICER Document

Exhibit 31.1
CERTIFICATION
I, Robert M. Davis, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 5, 2023
 
By:     /s/ Robert M. Davis
ROBERT M. DAVIS
Chairman, Chief Executive Officer and President

 EX-31.2 3 exhibit312-rule13ax14a15dx.htm RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CHIEF FINANCIAL OFFICER Document

Exhibit 31.2
CERTIFICATION
I, Caroline Litchfield, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:   May 5, 2023
By:      /s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

 EX-32.1 4 exhibit321-section1350cert.htm SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER Document

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
 
 
 
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 5, 2023
/s/ Robert M. Davis
Name:
Title:		ROBERT M. DAVIS
Chairman, Chief Executive Officer and President



 EX-32.2 5 exhibit322-section1350cert.htm SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER Document

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer



Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 5, 2023
/s/ Caroline Litchfield
Name:
Title:		CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer




 EX-101.SCH 6 mrk-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Spin-Off of Organon & Co. link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Taxes on Income link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Spin-Off of Organon & Co. (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Collaborative Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Collaborative Arrangements - Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Restructuring - Activities by Program (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Other (Income) Expense, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Segment Reporting - Sales from Products (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mrk-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mrk-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mrk-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Inventory [Axis] Inventory [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Net Income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Loss contingency, pending claims Loss Contingency, Pending Claims, Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Investments Debt Securities, Trading, and Equity Securities, FV-NI Schedule of Equity Schedule of Stockholders Equity [Table Text Block] Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Dividends paid to stockholders Payments of Ordinary Dividends, Common Stock Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fair value of loans payable and long-term debt, including current portion Debt Instrument, Fair Value Disclosure Restructuring reserve, beginning balance Restructuring reserve, ending balance Restructuring Reserve Foreign exchange contracts Foreign Exchange Contract [Member] Revenue related to the sale of the marketing rights Proceeds from Sale of Intangible Assets Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Lagevrio Lagevrio [Member] Lagevrio Other (Income) Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Financial Instruments Financial Instruments [Domain] Other Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Depreciation Location and Amount of Pretax Gains and Losses of Derivatives Derivative Instruments, Gain (Loss) [Table Text Block] Other current assets Other Current Assets [Member] Other paid-in capital Additional Paid in Capital, Common Stock Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Other Other Noncash Income (Expense) Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Bayer AG Bayer AG [Member] Bayer AG [Member] Treasury stock shares purchased Treasury Stock, Value, Acquired, Cost Method Net Income Attributable to Merck & Co., Inc. Net Income Attributable to Merck & Co., Inc. Net income attributable to Merck & Co., Inc. Net Income (Loss) Attributable to Parent Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Partial settlement charge Defined Benefit Plan, Plan Assets, Payment for Settlement Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Other Intangible Assets Other Intangible Assets [Member] Amortization of unrecognized prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Total assets Assets, Fair Value Disclosure Number of interest rate swaps held (in interest rate swaps) Number of Interest Rate Derivatives Held Legal Defense Costs Legal Defense Costs [Member] Legal Defense Costs [Member] Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022 Treasury Stock, Common, Value Debt securities, fair value Investments Debt Securities, Available-for-Sale Hedging Designation [Domain] Hedging Designation [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Sales discounts Sales Discounts Sales Discounts Payables included in Other Noncurrent Liabilities Liabilities, Noncurrent AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Other Comprehensive (Loss) Income Net of Taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Fair Value of Derivative, Asset Gross amounts recognized in the consolidated balance sheet, asset Derivative assets Derivative Asset Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Related Party Transaction [Domain] Related Party Transaction [Domain] Costs, Expenses and Other Costs and Expenses [Abstract] Net periodic defined benefit plan (credit) cost other than service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Expected restructuring and related cost Restructuring and Related Cost, Expected Cost Animal Health Animal Health segment Animal Health segment [Member] Animal Health segment [Member] Raw materials and work in process Inventory, Work in Process and Raw Materials Long-Term Debt Long-Term Debt, Excluding Current Maturities Liabilities Liabilities Alliance revenue - Koselugo Alliance revenue - Koselugo [Member] Alliance revenue - Koselugo Geographical [Axis] Geographical [Axis] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Collaboration Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Cash collateral advanced to counterparties Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Factored accounts receivable Accounts Receivable, Sale Document Type Document Type Acquisition of Imago BioSciences, Inc., net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Assets Assets, Fair Value Disclosure [Abstract] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Restructuring Type [Axis] Restructuring Type [Axis] Segments [Axis] Segments [Axis] Product and Service [Domain] Product and Service [Domain] Asset Acquisition [Axis] Asset Acquisition [Axis] Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Entity Shell Company Entity Shell Company Deferred income taxes Deferred Income Tax Expense (Benefit) Financial Instrument Financial Instrument [Axis] Capitalized milestone payment Milestone Payments Made to Collaborative Partner Milestone Payments Made to Collaborative Partner Amount of gain (loss) recognized in OCI on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Complaint Against The Johns Hopkins University Complaint Against The Johns Hopkins University [Member] Complaint Against The Johns Hopkins University SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Financial Instruments Financial Instruments Disclosure [Text Block] Sanofi Pasteur Sanofi Pasteur [Member] Sanofi Pasteur [Member] Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Januvia Januvia [Member] Januvia [Member] . Regulatory milestone payments accrued Collaborative Arrangement, Regulatory Milestone Payments Accrued Collaborative Arrangement, Regulatory Milestone Payments Accrued Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Alliance revenue - profit sharing Collaborative Arrangement, Profit Sharing Collaborative Arrangement, Profit Sharing Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Changes in AOCI by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total Assets Assets Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Currency options Foreign Exchange Option [Member] Publicly traded equity securities, fair value Publicly traded equity securities Equity Securities, FV-NI, Current Other current assets Deferred Income Taxes and Other Assets, Current [Member] Deferred Income Taxes and Other Assets, Current Interest rate swap contracts Interest Rate Swap [Member] Eligible future contingent development-related payments (up to) Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Net Cash Used in Financing Activities Net Cash Provided by (Used in) Financing Activities Reclassification adjustments, net of taxes Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Merck & Co., Inc. Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Income Before Taxes Profits Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest RotaTeq Rotateq [Member] RotaTeq [Member] Maximum average period of maturities of contracts in years (less than) Derivative, Average Remaining Maturity Segments [Domain] Segments [Domain] Transition services agreement Transition services agreement [Member] Transition services agreement Earnings Per Share Earnings Per Share [Text Block] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Interest cost Defined Benefit Plan, Interest Cost Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Loss contingency, claims settled Loss Contingency, Claims Settled, Number Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Other pharmaceutical Other Pharmaceutical [Member] Other pharmaceutical. Finished goods Inventory, Finished Goods, Gross Derivative Contract [Domain] Derivative Contract [Domain] Entity Registrant Name Entity Registrant Name Tax benefit resulting from acquisition charge Tax Benefit Resulting From Acquisition Charge Tax Benefit Resulting From Acquisition Charge COLOMBIA COLOMBIA China CHINA Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Patents Patents [Member] Entity Address, City or Town Entity Address, City or Town Belsomra Belsomra [Member] Belsomra [Member] Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] Pneumovax 23 Pneumovax 23 [Member] Pneumovax 23[Member]. Europe, Middle East and Africa EMEA [Member] Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Total equity Equity, beginning balance Equity, ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 0.500% Notes due 2024 0.500% Notes due 2024 [Member] 0.500% Notes due 2024 [Member] Alliance revenue - Lenvima Lenvima Lenvima [Member] Lenvima [Member] Legal Costs Legal Costs, Policy [Policy Text Block] Minimum Minimum [Member] Noncontrolling Interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table]   Treasury Stock Treasury Stock, Common [Member] Pension Plans Pension Plan [Member] Asset acquisition, share price (in dollars per share) Asset Acquisition Share Price Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition. Trading Symbol Trading Symbol Entity File Number Entity File Number 1.875% Notes due 2026 1.875% Notes due 2026 [Member] 1.875% Notes due 2026 [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] [Line Items] for Stockholders Equity [Table] Treasury stock (in shares) Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Tax Reclassification from AOCI, Current Period, Tax Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Research and development Research and development Research and Development Expense Supplies Other Inventory, Supplies, Gross Probable contingent payments Probable Contingent Payments Collaborative Arrangement Probable Contingent Payments Collaborative Arrangement Restricted cash Restricted Cash and Cash Equivalents Entity Information [Line Items] Entity Information [Line Items] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Due from related parties, current Due from Related Parties, Current Isentress/Isentress HD Isentress/Isentress HD [Member] Isentress/Isentress HD [Member]. Sales Sales Revenues Inventory [Table] Inventory [Table] Inventory [Table] Cumulative costs since program inception Restructuring and Related Cost, Cost Incurred to Date Taxes on Income Income Tax Disclosure [Text Block] Revenue from related party Revenue from Related Parties Amortization of intangible assets Amortization of Intangible Assets Basic Earnings Per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Basic Debt, carrying amount Debt, Long-Term and Short-Term, Combined Amount Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Recognized as: Recognized As [Abstract] Recognized as. Imago Bio Sciences, Inc. Imago Bio Sciences, Inc. [Member] Imago Bio Sciences, Inc. Corporate, Non-Segment Corporate, Non-Segment Corporate, Non-Segment [Member] Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Primaxin Primaxin [Member] Primaxin [Member]. Counterparty Name [Domain] Counterparty Name [Domain] Total Merck & Co., Inc. stockholders’ equity Stockholders' Equity Attributable to Parent Asset acquisition costs Asset Acquisition, Consideration Transferred, Transaction Cost Estimate of cumulative pre tax costs that will result in cash outlays Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense). Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Vaqta Vaqta [Member] Vaqta [Member] Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other Information About the Changes in Liabilities for Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Cash dividends declared on common stock Dividends, Common Stock, Cash Loss related to litigation settlement Charge for Zetia antitrust litigation settlements Gain (Loss) Related to Litigation Settlement Other (income) expense, net Other Nonoperating Income (Expense) [Member] Potential future sales-based milestone payments Potential Future Milestone Payments Sales-Based Potential Future Milestone Payments Sales-Based Noxafil Noxafil [Member] Noxafil [Member]. Litigation Status [Domain] Litigation Status [Domain] Common Stock ($0.50 par value)    Common Stock Common Stock [Member] Other comprehensive income (loss), net of taxes Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) before reclassification adjustments, net of taxes OCI, before Reclassifications, Net of Tax, Attributable to Parent Purchases of treasury stock Payments for Repurchase of Common Stock Net changes in assets and liabilities Increase (Decrease) in Operating Capital Contingent consideration Fair value, beginning balance Fair value, ending balance Business Combination, Contingent Consideration, Liability Class of Stock [Axis] Class of Stock [Axis] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Receivables included in Other current assets Receivables, Net, Current Investments Marketable Securities, Noncurrent Document Quarterly Report Document Quarterly Report Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Current Assets Assets, Current [Abstract] Benefit plan net (loss) gain and prior service (cost) credit, net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Statistical Measurement [Axis] Statistical Measurement [Axis] Charge for the acquisition of Imago BioSciences, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off Treasury stock shares purchased (in shares) Treasury Stock, Shares, Acquired Asset Acquisition [Domain] Asset Acquisition [Domain] Januvia and Janumet Januvia and Janumet [Member] Januvia and Janumet Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Retained earnings Retained Earnings (Accumulated Deficit) ProQuad/M-M-R II/Varivax ProQuad MMR II Varivax [Member] ProQuad/M-M-R II/Varivax [Member]. Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Cash equivalents Cash Equivalents, at Carrying Value Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022) Accounts Receivable, after Allowance for Credit Loss, Current Purchases of securities and other investments Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis Offsetting Assets And Liabilities [Table Text Block] Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. Document Fiscal Year Focus Document Fiscal Year Focus International Foreign Plan [Member] Estimate of cumulative pre tax costs that will be noncash Estimate Of Cumulative Pre Tax Costs That Will Be Noncash Estimate of cumulative pre tax costs that will be noncash. Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Simponi Simponi [Member] Simponi [Member]. Total debt and publicly traded equity securities, fair value Debt Securities and Equity Securities, FV-NI Debt Securities and Equity Securities, FV-NI Current liability Business Combination, Contingent Consideration, Liability, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Changes in estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Debt securities, unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Reclassification adjustments, pretax Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Non-cash activity Restructuring Reserve, Increase (Decrease) Noncash Activity Noncash activity affecting the restructuring reserve, including accelerated depreciation. Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Cumulative unrealized losses on investments Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Capital expenditures Payments to Acquire Productive Assets Other, net Other Nonoperating Income Expense, Other Other nonoperating income and expense items not separately disclosed. Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Litigation Status [Axis] Litigation Status [Axis] Keytruda Keytruda [Member] Keytruda [Member] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Loss Contingency, number of states in which plaintiffs reside Loss Contingency, Number Of States In Which Plaintiffs Reside Loss Contingency, Number Of States In Which Plaintiffs Reside Loss contingency, trial period Loss Contingency, Trial Period Loss Contingency, Trial Period Total (approximates current cost) Inventory, Gross Goodwill Goodwill Accrued and other current liabilities Other Current Liabilities [Member] Total liabilities Liabilities, Fair Value Disclosure Equity Funds Equity Funds [Member] Alliance revenue - Adempas/Verquvo Alliance revenue - Adempas/Verquvo [Member] Alliance revenue - Adempas/Verquvo Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Taxes on Income Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Deferred Income Taxes Deferred Income Tax Liabilities, Net Income Statement [Abstract] Income Statement [Abstract] Other Paid-In Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Licensing Agreements Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones [Member] Cost of sales Cost of Goods and Services Sold Average common shares outstanding assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative [Line Items] Derivative [Line Items] Cash collateral received, liability Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Fair Value of Derivative, Liability Gross amounts recognized in the consolidated balance sheet, liability Derivative liabilities Derivative Liability Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Preferred stock investment in counterparty Collaborative Arrangement, Preferred Stock Investment In Counterparty Collaborative Arrangement, Preferred Stock Investment In Counterparty Inventories Schedule of Inventory, Current [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Equity securities, noncurrent Equity Securities, FV-NI, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Unrealized losses recognized on investments in equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Collaborative Arrangement Collaborative Arrangement [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Manufacturing and supply agreements Manufacturing and supply agreements [Member] Manufacturing and supply agreements Information on Investments in Debt and Equity Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022 Common Stock, Value, Issued Restructuring costs Restructuring Charges [Member] Related party amount in cost of sales Related Parties Amount in Cost of Sales Loss contingency, number of patents allegedly infringed Loss Contingency, Patents Allegedly Infringed, Number Lynparza Lynparza [Member] Lynparza [Member] Asia Pacific (other than China and Japan) Asia Pacific [Member] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Operating Segments Operating Segments Operating Segments [Member] Total current and noncurrent inventories Inventory Net And Inventory Noncurrent Total of current and noncurrent inventories. Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets) Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March 31, 2023 and 2022, respectively, included in Other current assets) Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Zetia antitrust litigation Zetia antitrust litigation [Member] Zetia antitrust litigation [Member] Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Acquisitions, Research Collaborations and License Agreements Acquisitions Research Collaborations And License Agreements [Text Block] Information related to acquisitions, divestitures, research collaborations and license agreements. Contingencies Commitments and Contingencies Disclosure [Text Block] Current Liabilities Liabilities, Current [Abstract] Net income attributable to Merck & Co., Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Proceeds from exercise of stock options Proceeds from Stock Options Exercised Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Common stock, issued (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Issued 1.375% Notes due 2036 1.375% Notes due 2036 [Member] 1.375% Notes due 2036 [Member] Exchange losses Foreign Currency Transaction Gain (Loss), before Tax Retirement Plan Type [Domain] Retirement Plan Type [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Alliance Revenue - Reblozyl Alliance Revenue - Reblozyl [Member] Alliance Revenue - Reblozyl Amendment Flag Amendment Flag Net Cash Used in Investing Activities Net Cash Provided by (Used in) Investing Activities Net amounts, asset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Other Assets Deferred Income Taxes and Other Assets, Noncurrent Investment Type [Axis] Investment Type [Axis] Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Loss contingency, new claims filed Loss Contingency, New Claims Filed, Number Comprehensive Income Attributable to Merck & Co., Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Potential future regulatory milestone payments Potential Future Milestone Payments Regulatory Potential Future Milestone Payments Regulatory Debt securities, unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Accrued and other current liabilities Other Liabilities, Current Other assets Other Assets, Noncurrent Ridgeback Biotherapeutics LP Ridgeback Biotherapeutics LP [Member] Ridgeback Biotherapeutics LP (Payments) receipts, net Payments for Restructuring Total Costs, Expenses and Other Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense. Bristol Myers Squibb Bristol Myers Squibb [Member] Bristol Myers Squibb Japan JAPAN Royalties Royalty Income, Nonoperating Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones [Member] Royalty rate Royalty Rate, Percentage Royalty Rate, Percentage Counterparty Name [Axis] Counterparty Name [Axis] Derivative [Table] Derivative [Table] Increase to pension liabilities due to remeasurement Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Contingent proceeds collaborative arrangement Contingent Proceeds Collaborative Arrangement Represents proceeds that may be received in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Share-based compensation plans and other Stockholders' Equity, Other Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022 Property, Plant and Equipment, Net Entities [Table] Entities [Table] Payments on debt Repayments of Long-Term Debt Domestic Plan Domestic Plan [Member] Other Other Countries [Member] Other Countries [Member] Other (Income) Expense, Net Other Income and Other Expense Disclosure [Text Block] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Restructuring Restructuring and Related Activities Disclosure [Text Block] Common stock, authorized (shares) Common Stock, Shares Authorized Amount of Derivative Pretax (Gain) Loss Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income taxes payable Accrued Income Taxes, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Sales from Products Revenue from External Customers by Products and Services [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Consolidated Sales by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Inventory [Domain] Inventory [Domain] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Income Statement Effects of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value (Income) loss from investments in equity securities, net Loss (income) from investments in equity securities, net Equity Securities, FV-NI, Gain (Loss) Total current assets Assets, Current Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Net unrealized (loss) gain on derivatives, net of reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Measurement Frequency [Domain] Measurement Frequency [Domain] Equity Stockholders' Equity Note Disclosure [Text Block] Cash dividends declared on common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Finite-lived intangible assets Finite-Lived Intangible Assets, Net Net income Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Prevymis Prevymis [Member] Prevymis [Member] Verquvo Verquvo [Member] Verquvo Sales milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Title of 12(b) Security Title of 12(b) Security 2.500% Notes due 2034 2.500% Notes due 2034 [Member] 2.500% Notes due 2034 [Member] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Proceeds from sales of securities and other investments Proceeds from Sale, Maturity and Collection of Investments Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Short-term investments Short-Term Investments Sales-based milestone payments Milestone Payments Sales-Based Milestone Payments Sales-Based Asset acquisition, price of acquisition, expected Asset Acquisition, Price of Acquisition, Expected Business Combination and Asset Acquisition [Abstract] Net assets acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Asset Acquisition, Assets Acquired And Liabilities Assumed, Net U.S. government and agency securities US Government Agencies Debt Securities [Member] Segment Reporting Segment Reporting Disclosure [Text Block] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Amount of gain recognized in Other (income) expense, net on derivatives Derivative, Gain (Loss) on Derivative, Net Liabilities and Equity Liabilities and Equity [Abstract] Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Regulatory milestones payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Cumulative unrealized gains on investments Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Other comprehensive income (loss) before reclassification adjustments, pretax OCI, before Reclassifications, before Tax, Attributable to Parent Euro-denominated notes Euro-dominated Notes [Member] Euro-dominated Notes [Member] Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7) Inventories Inventory, Net Trade accounts payable Accounts Payable, Current Restructuring costs Restructuring costs Restructuring Charges Period of continuing involvement after disposal Discontinued Operation, Period of Continuing Involvement after Disposal Royalty rate, deduction Royalty Rate, Deduction, Percentage Royalty Rate, Deduction, Percentage Hedging Designation [Axis] Hedging Designation [Axis] Entity Filer Category Entity Filer Category Average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Bridion Bridion [Member] Bridion [Member]. U.S. United States UNITED STATES Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Liabilities Liabilities, Fair Value Disclosure [Abstract] Consideration transferred, asset acquisition Asset Acquisition, Consideration Transferred Eisai Eisai [Member] Eisai [Member] Welireg Welireg [Member] Welireg Security Exchange Name Security Exchange Name Net amounts, liability Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Int’l International [Member] International [Member] Total swap notional amount U.S Dollar Notional Amount Derivative, Notional Amount Increase in Sales as a result of AOCL reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Restricted cash Restricted Cash, Current Segment Reconciling Items Segment Reconciling Items [Member] Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Stockholders' equity before deduction for treasury stock Stockholders' Equity before Treasury Stock Other current assets Deferred Income Taxes and Other Assets, Current Service cost Defined Benefit Plan, Service Cost Loans payable and current portion of long-term debt Debt, Current Cover [Abstract] Cover [Abstract] Pending Litigation Pending Litigation [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Pharmaceutical Pharmaceutical segment Pharmaceutical segment [Member] Pharmaceutical segment. Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Other Assets Deferred Income Taxes And Other Assets, Noncurrent [Member] Deferred Income Taxes And Other Assets, Noncurrent Segment Reporting [Abstract] Segment Reporting [Abstract] Non- controlling Interests Noncontrolling Interest [Member] Investments [Domain] Investments [Domain] Total pretax restructuring costs Expenses Restructuring and Related Cost, Incurred Cost Forecast Forecast [Member] RotaTeq Antitrust Litigation RotaTeq Antitrust Litigation [Member] RotaTeq Antitrust Litigation Net (gain) loss amortization Defined Benefit Plan, Amortization of Gain (Loss) Liabilities and Equity Liabilities and Equity Vaxneuvance Vaxneuvance [Member] Vaxneuvance Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Non-US Non-US [Member] Revenue Sales Sales [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Inventories Produced in Preparation for Product Launches Inventories Produced in Preparation for Product Launches [Member] Inventories Produced in Preparation for Product Launches [Member] Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Level 2 Fair Value, Inputs, Level 2 [Member] Reconciliation of Segment Profits to Income before Taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Net income attributable to Merck & Co., Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Other Intangibles, Net Intangible Assets, Net (Excluding Goodwill) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Diluted Inventory [Line Items] Inventory [Line Items] Gardasil/Gardasil 9 Gardasil/Gardasil 9 [Member] Gardasil/Gardasil 9 [Member]. Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Consolidation Items [Axis] Consolidation Items [Axis] Unrealized gains recognized on investments in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Total current liabilities Payables included in Accrued and other liabilities Liabilities, Current Other Other Restructuring [Member] Prometheus Biosciences, Inc. Prometheus Biosciences, Inc. [Member] Prometheus Biosciences, Inc. Remicade Remicade [Member] Remicade [Member]. Stockholders Equity [Table] Stockholders Equity [Table] Stockholders Equity [Table] Publicly traded equity securities Equity Securities [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Spin-Off of Organon & Co. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Janumet Janumet [Member] Janumet [Member]. Corporate notes and bonds Corporate Debt Securities [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Unrealized net (gains) losses Equity Securities, FV-NI, Unrealized Gain (Loss) Amortization Amortization Amortization Foreign government bonds Debt Security, Government, Non-US [Member] Entity Address, Address Line One Entity Address, Address Line One Other Proceeds from (Payments for) Other Financing Activities Zerbaxa Zerbaxa [Member] Zerbaxa [Member] Product and Service [Axis] Product and Service [Axis] Dificid Dificid [Member] Dificid Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Class of Stock [Domain] Class of Stock [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Cash collateral received from counterparties Cash collateral received, asset Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Interest expense Interest expense Interest Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Retirement Plan Type [Axis] Retirement Plan Type [Axis] Inventories classified in Other assets Other Assets Inventory, Noncurrent Increase (Decrease) In Hedge Revenue Increase (Decrease) In Hedge Revenue Increase (Decrease) In Hedge Revenue Inventories Inventory Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Adempas Adempas [Member] Adempas Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Decrease to LIFO cost Inventory, LIFO Reserve Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Other Noncurrent Assets Other Noncurrent Assets [Member] Alliance revenue - Lynparza Alliance revenue - Lynparza [Member] Alliance revenue - Lynparza [Member] Livestock Livestock [Member] Livestock [Member] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Other unallocated, net Segment Reporting Unallocated Other Expenses Net Other net expenses not allocated to segments. Dividends payable Dividends Payable, Current Inventories Not Expected to be Sold Within One Year Inventory Not Expected to be Sold Within One Year [Member] Inventory Not Expected to be Sold Within One Year [Member] Foreign Exchange Future Foreign Exchange Future [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Currency Swap Currency Swap [Member] Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Charges and Spending Relating to Restructuring Activities by Program Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Common shares issuable (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Charges Related to Restructuring Program Activities by Type of Cost Restructuring and Related Costs [Table Text Block] Contingent consideration, measurement input, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Interest income Interest income Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Latin America Latin America [Member] Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Separation Costs One-time Termination Benefits [Member] Legal defense costs reserve Estimated Litigation Liability City Area Code City Area Code Assets Assets [Abstract] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Companion Animals Companion Animals [Member] Companion Animals [Member] Due to related parties, current Due to Related Parties, Current Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Other Noncurrent Liabilities Other Liabilities, Noncurrent Interest Rate Contract Interest Rate Contract [Member] Research and development Research and Development Expense [Member] Proceeds from Collaborators Proceeds from Collaborators Calculations of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Organon & Co. Organon & Co. [Member] Organon & Co. Cost of sales Cost of sales Cost of Sales [Member] Net sales by Merck Collaborative Arrangement, Sales, Net Collaborative Arrangement, Sales, Net Other Postretirement Benefit Plans Other Postretirement Benefits Plan [Member] Less: Net Income (Loss) Attributable to Noncontrolling Interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest EX-101.PRE 10 mrk-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2023
Apr. 30, 2023
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 1-6571  
Entity Registrant Name Merck & Co., Inc.  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1918501  
Entity Address, Address Line One 126 East Lincoln Avenue  
Entity Address, City or Town Rahway  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07065  
City Area Code (908)  
Local Phone Number 740-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,537,435,954
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0000310158  
Current Fiscal Year End Date --12-31  
Common Stock ($0.50 par value)    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock ($0.50 par value)  
Trading Symbol MRK  
Security Exchange Name NYSE  
0.500% Notes due 2024    
Entity Information [Line Items]    
Title of 12(b) Security 0.500% Notes due 2024  
Trading Symbol MRK 24  
Security Exchange Name NYSE  
1.875% Notes due 2026    
Entity Information [Line Items]    
Title of 12(b) Security 1.875% Notes due 2026  
Trading Symbol MRK/26  
Security Exchange Name NYSE  
2.500% Notes due 2034    
Entity Information [Line Items]    
Title of 12(b) Security 2.500% Notes due 2034  
Trading Symbol MRK/34  
Security Exchange Name NYSE  
1.375% Notes due 2036    
Entity Information [Line Items]    
Title of 12(b) Security 1.375% Notes due 2036  
Trading Symbol MRK 36A  
Security Exchange Name NYSE  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Sales $ 14,487 $ 15,901
Costs, Expenses and Other    
Cost of sales 3,926 5,380
Selling, general and administrative 2,479 2,323
Research and development 4,276 2,576
Restructuring costs 67 53
Other (income) expense, net 89 708
Total Costs, Expenses and Other 10,837 11,040
Income Before Taxes 3,650 4,861
Taxes on Income 825 554
Net Income 2,825 4,307
Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 (3)
Net Income Attributable to Merck & Co., Inc. $ 2,821 $ 4,310
Basic Earnings Per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.11 $ 1.70
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.11 $ 1.70
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net Income Attributable to Merck & Co., Inc. $ 2,821 $ 4,310
Other Comprehensive (Loss) Income Net of Taxes:    
Net unrealized (loss) gain on derivatives, net of reclassifications (133) 63
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization (50) 32
Cumulative translation adjustment 68 (35)
Other comprehensive income (loss), net of taxes (115) 60
Comprehensive Income Attributable to Merck & Co., Inc. $ 2,706 $ 4,370
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 9,707 $ 12,694
Short-term investments 680 498
Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022) 10,415 9,450
Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7) 5,863 5,911
Other current assets 6,737 7,169
Total current assets 33,402 35,722
Investments 1,290 1,015
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022 21,758 21,422
Goodwill 21,209 21,204
Other Intangibles, Net 19,857 20,269
Other Assets 10,280 9,528
Total Assets 107,796 109,160
Current Liabilities    
Loans payable and current portion of long-term debt 2,672 1,946
Trade accounts payable 3,680 4,264
Accrued and other current liabilities 13,000 14,159
Income taxes payable 1,872 1,986
Dividends payable 1,907 1,884
Total current liabilities 23,131 24,239
Long-Term Debt 28,074 28,745
Deferred Income Taxes 1,442 1,795
Other Noncurrent Liabilities 8,244 8,323
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022 1,788 1,788
Other paid-in capital 44,467 44,379
Retained earnings 62,039 61,081
Accumulated other comprehensive loss (4,883) (4,768)
Stockholders' equity before deduction for treasury stock 103,411 102,480
Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022 56,577 56,489
Total Merck & Co., Inc. stockholders’ equity 46,834 45,991
Noncontrolling Interests 71 67
Total equity 46,905 46,058
Liabilities and Equity $ 107,796 $ 109,160
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 76 $ 72
Inventories classified in Other assets 3,284 2,938
Accumulated depreciation $ 18,256 $ 17,985
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, authorized (shares) 6,500,000,000 6,500,000,000
Common stock, issued (in shares) 3,577,103,522 3,577,103,522
Treasury stock (in shares) 1,039,651,210 1,039,269,638
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash Flows from Operating Activities    
Net income $ 2,825 $ 4,307
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization 543 699
Depreciation 448 421
(Income) loss from investments in equity securities, net (450) 708
Charge for the acquisition of Imago BioSciences, Inc. 1,192 0
Deferred income taxes (277) (338)
Share-based compensation 145 120
Other (197) 143
Net changes in assets and liabilities (2,890) (1,299)
Net Cash Provided by Operating Activities 1,339 4,761
Cash Flows from Investing Activities    
Capital expenditures (1,007) (984)
Purchases of securities and other investments (562) (372)
Proceeds from sales of securities and other investments 500 1
Acquisition of Imago BioSciences, Inc., net of cash acquired (1,327) 0
Other 37 182
Net Cash Used in Investing Activities (2,359) (1,173)
Cash Flows from Financing Activities    
Payments on debt (1) (1,250)
Purchases of treasury stock (149) 0
Dividends paid to stockholders (1,853) (1,745)
Proceeds from exercise of stock options 30 12
Other (81) (103)
Net Cash Used in Financing Activities (2,054) (3,086)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 87 (55)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash (2,987) 447
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets) 12,773 8,167
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March 31, 2023 and 2022, respectively, included in Other current assets) $ 9,786 $ 8,614
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Statement of Cash Flows [Abstract]        
Restricted cash $ 79 $ 79 $ 58 $ 71
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 24, 2023.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Adopted Accounting Standard
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
Recently Issued Accounting Standard Not Yet Adopted
In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Spin-Off of Organon & Co.
 3 Months Ended
Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Spin-Off of Organon & Co. Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $94 million and $99 million and related cost of sales of $107 million and $105 million for the first quarter of 2023 and 2022,
respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for both the first quarter of 2023 and 2022.
The amounts due from Organon under all of the above agreements were $473 million and $511 million at March 31, 2023 and December 31, 2022, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $229 million and $345 million at March 31, 2023 and December 31, 2022, respectively, and are included in Accrued and other current liabilities.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions, Research Collaborations and License Agreements
 3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions, Research Collaborations and License Agreements Acquisitions, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus’ lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3 billion in Research and development expenses.
In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in Research and development expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion
(including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as Research and development expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Arrangements
 3 Months Ended
Mar. 31, 2023
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at March 31, 2023) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. Also in the first quarter of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400 million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca (which had been previously accrued for) of $105 million. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at March 31, 2023 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lynparza$275 $266 
Alliance revenue - Koselugo23 9 
Total alliance revenue$298 $275 
Cost of sales (1)
70 299 
Selling, general and administrative47 44 
Research and development21 26 
($ in millions)March 31, 2023December 31, 2022
Receivables from AstraZeneca included in Other current assets
$303 $303 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
21 123 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 600 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Eisai
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125 million sales-based milestone payment from Merck to Eisai. Accordingly, Merck recorded a $125 million liability and a corresponding increase to the intangible asset related to Lenvima. Merck also recognized $72 million of cumulative amortization catch-up expense related to the recognition of this milestone. In 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million (of which $300 million was paid in the first quarter of 2022). Potential future sales-based milestone payments of $2.4 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai (of which $25 million was paid in the first quarter of 2022). There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $812 million at March 31, 2023 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lenvima$232 $227 
Cost of sales (1)
126 53 
Selling, general and administrative51 31 
Research and development39 57 
($ in millions)March 31, 2023December 31, 2022
Receivables from Eisai included in Other current assets
$244 $214 
Payables to Eisai included in Accrued and other current liabilities (2)
125 — 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021, and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In the first quarter of 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $613 million and $56 million, respectively, at March 31, 2023 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Adempas/Verquvo$99 $72 
Net sales of Adempas recorded by Merck59 61 
Net sales of Verquvo recorded by Merck7 3 
Total sales$165 $136 
Cost of sales (1)
57 50 
Selling, general and administrative33 23 
Research and development25 17 
($ in millions)March 31, 2023December 31, 2022
Receivables from Bayer included in Other current assets
$142 $143 
Payables to Bayer included in Accrued and other current liabilities
68 80 
(1)    Includes amortization of intangible assets.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and
related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations worldwide.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Net sales of Lagevrio recorded by Merck
$392 $3,247 
Cost of sales (1)(2)
221 1,726 
Selling, general and administrative (2)
27 35 
Research and development (2)
16 25 
($ in millions)March 31, 2023December 31, 2022
Payables to Ridgeback included in Accrued and other current liabilities (3)
$191 $348 
(1)    Includes royalty expense and amortization of capitalized milestone payments.
(2)    Expenses include an allocation for overhead charges.
(3)    Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment.
Bristol Myers Squibb
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue related to this collaboration within Sales of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32 million and the receipt of a regulatory approval milestone payment of $20 million).
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring
 3 Months Ended
Mar. 31, 2023
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
The Company recorded total pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March 31, 2023, Merck has recorded total pretax accumulated costs of approximately $3.4 billion. For the full year of 2023, the Company expects to record charges of approximately $400 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended March 31, 2023
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $21 $8 $29 
Selling, general and administrative— — 1 1 
Restructuring costs41 — 26 67 
$41 $21 $35 $97 
 Three Months Ended March 31, 2022
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $18 $28 $46 
Selling, general and administrative— 4 17 21 
Research and development— 7 — 7 
Restructuring costs26 — 27 53 
$26 $29 $72 $127 
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2023 and 2022 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2023:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2023
$479 $— $34 $513 
Expenses41 21 35 97 
(Payments) receipts, net(47)— (27)(74)
Non-cash activity— (21)(9)(30)
Restructuring reserves March 31, 2023 (1)
$473 $— $33 $506 
(1)The remaining cash outlays are expected to be largely completed by the end of 2025.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments
 3 Months Ended
Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI
and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended March 31,Three Months Ended March 31,
($ in millions)2023202220232022
Net Investment Hedging Relationships
Foreign exchange contracts$1 $(16)$1 $(1)
Euro-denominated notes52 (53)— — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. In March 2023, the Company entered into five forward starting swaps and in April 2023 entered into two additional forward starting swaps, each with a notional amount of $100 million.
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  March 31, 2023December 31, 2022
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contractsOther Assets$1 $— $300 $— $— $— 
Interest rate swap contractsOther Noncurrent Liabilities— 1 200 — — — 
Foreign exchange contractsOther current assets104 — 4,253 220 — 4,824 
Foreign exchange contractsOther Assets32 — 1,756 27 — 1,609 
Foreign exchange contractsAccrued and other current liabilities— 116 3,444 — 101 2,691 
Foreign exchange contractsOther Noncurrent Liabilities— 2 120 — 1 91 
  $137 $119 $10,073 $247 $102 $9,215 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$121 $— $9,507 $186 $— $8,540 
Foreign exchange contractsOther Assets1 — 65 — — — 
Foreign exchange contractsAccrued and other current liabilities— 164 10,592 — 307 10,926 
Foreign exchange contractsOther Noncurrent Liabilities— 1 124 — — — 
  $122 $165 $20,288 $186 $307 $19,466 
  $259 $284 $30,361 $433 $409 $28,681 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 March 31, 2023December 31, 2022
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$259 $284 $433 $409 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(148)(148)(220)(220)
Cash collateral received/posted(13)— (66)(19)
Net amounts$98 $136 $147 $170 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended March 31,
($ in millions)202320222023202220232022
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$14,487 $15,901 $89 $708 $(115)$60 
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — — (10)— — 
Derivatives designated as hedging instruments— — — 4 — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (66)148 
Increase in Sales as a result of AOCL reclassifications
101 67 — — (101)(67)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)(1)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)(1)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended March 31,
($ in millions)20232022
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$13 $28 
Foreign exchange contracts (2)
Sales2 (2)
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
At March 31, 2023, the Company estimates $71 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 March 31, 2023December 31, 2022
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Commercial paper$663 $— $— $663 $498 $— $— $498 
U.S. government and agency securities92 — — 92 68 — — 68 
Corporate notes and bonds4 — — 4 3 — — 3 
Foreign government bonds1 — — 1 — — — — 
Total debt securities$760 $— $— $760 $569 $— $— $569 
Publicly traded equity securities (1)
1,585 1,284 
Total debt and publicly traded equity securities$2,345 $1,853 
(1)    Unrealized net gains of $338 million were recorded in Other (income) expense, net in the first quarter of 2023 on equity securities still held at March 31, 2023. Unrealized net losses of $225 million were recorded in Other (income) expense, net in the first quarter of 2022 on equity securities still held at March 31, 2022.
At March 31, 2023 and March 31, 2022, the Company also had $942 million and $643 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first quarter of 2023, the Company recorded unrealized gains of $1 million and unrealized losses of $21 million related to certain of these equity investments still held at March 31, 2023. During the first quarter of 2022, the Company recorded unrealized gains of $14 million related to certain of these investments still held at March 31, 2022. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March 31, 2023 were $287 million and $40 million, respectively.
At March 31, 2023 and March 31, 2022, the Company also had $725 million and $1.2 billion, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. (Gains) losses recorded in Other (income) expense, net relating to these investment funds were $(132) million and $509 million for the first quarter of 2023 and 2022, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)March 31, 2023December 31, 2022
Assets
Investments
Commercial paper$— $663 $— $663 $— $498 $— $498 
U.S. government and agency securities— 22 — 22 — — — — 
Foreign government bonds— 1 — 1 — — — — 
Publicly traded equity securities1,284 — — 1,284 1,015 — — 1,015 
 1,284 686 — 1,970 1,015 498 — 1,513 
Other assets (1)
U.S. government and agency securities70 — — 70 68 — — 68 
Corporate notes and bonds4 — — 4 3 — — 3 
Publicly traded equity securities301 — — 301 269 — — 269 
375 — — 375 340 — — 340 
Derivative assets (2)
Purchased currency options— 139 — 139 — 215 — 215 
Forward exchange contracts— 119 — 119 — 218 — 218 
Interest rate swap contracts— 1 — 1 — — — — 
 — 259 — 259 — 433 — 433 
Total assets$1,659 $945 $— $2,604 $1,355 $931 $— $2,286 
Liabilities
Other liabilities
Contingent consideration$— $— $353 $353 $— $— $456 $456 
Derivative liabilities (2)
Forward exchange contracts— 276 — 276 — 402 — 402 
Written currency options— 7 — 7 — 7 — 7 
Interest rate swap contracts— 1 — 1 — — — — 
— 284 — 284 — 409 — 409 
Total liabilities$— $284 $353 $637 $— $409 $456 $865 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of March 31, 2023 and December 31, 2022, Cash and cash equivalents included $8.8 billion and $11.3 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20232022
Fair value January 1$456 $777 
Changes in estimated fair value (1)
14 (84)
Payments(117)(119)
Other— (2)
Fair value March 31 (2)
$353 $572 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    At March 31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March 31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.
The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2023, was $28.2 billion compared with a carrying value of $30.7 billion and at December 31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable as of March 31, 2023 and December 31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March 31, 2023 and December 31, 2022, the Company had collected $31 million and $67 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The Company remitted the cash to the financial institutions in April 2023 and January 2023, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $13 million and $66 million at March 31, 2023 and December 31, 2022, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities. Cash collateral advanced by the Company to various counterparties was $19 million at December 31, 2022.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of:
($ in millions)March 31, 2023December 31, 2022
Finished goods$1,883 $1,841 
Raw materials and work in process7,348 7,063 
Supplies266 238 
Total (approximates current cost)9,497 9,142 
Decrease to LIFO cost(350)(293)
 $9,147 $8,849 
Recognized as:
Inventories$5,863 $5,911 
Other Assets3,284 2,938 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At March 31, 2023 and December 31, 2022, these amounts included $2.7 billion and $2.4 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $590 million and $516 million at March 31, 2023 and December 31, 2022, respectively, of inventories produced in preparation for product launches.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Gardasil/Gardasil 9
Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March 31, 2023, approximately 95 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.
Governmental Proceedings
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, Merck Sharp & Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. In April 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.
In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending.
In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.
In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene.
On February 10, 2023, the district court denied the Merck Defendants’ and Glenmark Defendants’ motions for summary judgment. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck will pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs’ claims, which was recorded as an expense in the Company’s first quarter 2023 financial results.
RotaTeq Antitrust Litigation
On March 3, 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for RotaTeq. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of RotaTeq, trebled, and fees and costs.
Bravecto Litigation
As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend Bravecto causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave Bravecto Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal in February 2022 and issued a decision in April 2022 allowing both parties’ appeals in part. The Court of Appeal amended the class period to start on July 2, 2014, allowed a second plaintiff to serve as a class representative, and modified the list of conditions in the class definition by adding “death” and removing “lack of efficacy.” The Court of Appeal also added to the list of questions to be considered by the trial court the questions of whether the Consumer Protection Act of Quebec applies to the sale of a veterinary product and, if so, whether it was breached. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever
may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered post-trial briefing on this defense and held closing arguments on February 3, 2023.
The Company has settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.
Januvia, Janumet, Janumet XR — As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCI), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the Janumet formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.
Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the District Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit. The parties have now settled the matter, and Mylan has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.
Additionally, in 2019, Mylan filed a petition for inter partes review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held in August 2022. In September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.
In total, the Company has settled with 25 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Januvia.
In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus has filed a NDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for Janumet will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Janumet.
As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in
the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026.
Supplementary Protection Certificates (SPCs) for Janumet expired between April 7 and 10, 2023, for the majority of European countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the Janumet SPCs in Europe, for which an oral hearing was held on March 8, 2023, and an Advocate General Opinion is expected on July 13, 2023. If the CJEU renders a decision that negatively impacts the validity of the Janumet SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the Janumet SPC.
Keytruda — The Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract; declaratory judgment of noninfringement; and promissory estoppel. JHU answered the complaint on April 13, 2023, denying Merck’s claims, and counterclaiming for willful infringement of five issued U.S. patents, including a demand for damages.
Lynparza — In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2023 and December 31, 2022 of approximately $225 million and $230 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Equity
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Equity Equity
Three Months Ended March 31,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20223,577 $1,788 $44,238 $53,696 $(4,429)1,049 $(57,109)$73 $38,257 
Net income attributable to Merck & Co., Inc.— — — 4,310 — — — — 4,310 
Other comprehensive income, net of taxes— — — — 60 — — — 60 
Cash dividends declared on common stock ($0.69 per share)
— — — (1,754)— — — — (1,754)
Share-based compensation plans and other— — 37 — — — 46 — 83 
Net loss attributable to noncontrolling interests— — — — — — — (3)(3)
Balance at March 31, 20223,577 $1,788 $44,275 $56,252 $(4,369)1,049 $(57,063)$70 $40,953 
Balance at January 1, 20233,577 $1,788 $44,379 $61,081 $(4,768)1,039 $(56,489)$67 $46,058 
Net income attributable to Merck & Co., Inc.— — — 2,821 — — — — 2,821 
Other comprehensive loss, net of taxes— — — — (115)— — — (115)
Cash dividends declared on common stock ($0.73 per share)
— — — (1,863)— — — — (1,863)
Treasury stock shares purchased— — — — — 1 (149)— (149)
Share-based compensation plans and other— — 88 — — — 61 — 149 
Net income attributable to noncontrolling interests— — — — — — — 4 4 
Balance at March 31, 20233,577 $1,788 $44,467 $62,039 $(4,883)1,040 $(56,577)$71 $46,905 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Pension and Other Postretirement Benefit Plans
 3 Months Ended
Mar. 31, 2023
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
  Three Months Ended
March 31,
20232022
($ in millions)U.S.InternationalU.S.International
Service cost$76 $49 $99 $75 
Interest cost133 74 103 38 
Expected return on plan assets(187)(128)(196)(101)
Amortization of unrecognized prior service credit— (3)(8)(4)
Net (gain) loss amortization— (1)56 25 
Curtailments2 — 3 — 
Settlements21 — 1 — 
 $45 $(9)$58 $33 
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
March 31,
($ in millions)20232022
Service cost$8 $12 
Interest cost16 11 
Expected return on plan assets(16)(21)
Amortization of unrecognized prior service credit(12)(14)
Net gain amortization(11)(11)
 $(15)$(23)
In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21 million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March 31, 2023, resulted in a net increase of $44 million to net pension liabilities and also resulted in a related adjustment to AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 11), with the exception of certain amounts for termination benefits and curtailments which are recorded in Restructuring costs if the event giving rise to the termination benefits or curtailment is related to restructuring actions.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Other (Income) Expense, Net
 3 Months Ended
Mar. 31, 2023
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
March 31,
($ in millions)20232022
Interest income$(112)$(7)
Interest expense242 243 
Exchange losses61 39 
(Income) loss from investments in equity securities, net (1)
(450)708 
Net periodic defined benefit plan (credit) cost other than service cost(115)(121)
Other, net463 (154)
 $89 $708 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Other, net (as reflected in the table above) in the first quarter of 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 8).
Interest paid for the three months ended March 31, 2023 and 2022 was $208 million and $211 million, respectively.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Taxes on Income
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Taxes on Income Taxes on IncomeThe effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company’s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
March 31,
($ and shares in millions except per share amounts)20232022
Net Income Attributable to Merck & Co., Inc.$2,821 $4,310 
Average common shares outstanding2,538 2,528 
Common shares issuable (1)
13 9 
Average common shares outstanding assuming dilution 2,551 2,537 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
(1)    Issuable primarily under share-based compensation plans.
For the first quarter of 2023 and 2022, 1 million and 7 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended March 31,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2022, net of taxes$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax148 1 (18)131 
Tax(31)(2)(17)(50)
Other comprehensive income (loss) before reclassification adjustments, net of taxes117 (1)(35)81 
Reclassification adjustments, pretax(68)
(1)
45 
(2)
— (23)
Tax14 (12)— 2 
Reclassification adjustments, net of taxes(54)

33 

— (21)
Other comprehensive income (loss), net of taxes63 32 (35)60 
Balance March 31, 2022, net of taxes$207 $(2,711)$(1,865)$(4,369)
Balance January 1, 2023, net of taxes$73 $(2,408)$(2,433)$(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax(66)(47)79 (34)
Tax14 2 (20)(4)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(52)(45)59 (38)
Reclassification adjustments, pretax(102)
(1)
(7)
(2)
9 (100)
Tax21 2 — 23 
Reclassification adjustments, net of taxes(81)

(5)

9 (77)
Other comprehensive income (loss), net of taxes(133)(50)68 (115)
Balance March 31, 2023, net of taxes$(60)$(2,458)$(2,365)$(4,883)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Sales of the Company’s products were as follows:
Three Months Ended March 31,
20232022
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$3,485 $2,310 $5,795 $2,779 $2,030 $4,809 
Alliance revenue-Lynparza (1)
142 133 275 141 125 266 
Alliance revenue-Lenvima (1)
153 79 232 156 71 227 
Alliance revenue-Reblozyl (2)
30 12 43 27 25 52 
Welireg41 1 42 18 — 18 
Vaccines
Gardasil/Gardasil 9
416 1,556 1,972 418 1,042 1,460 
ProQuad/M-M-R II/Varivax
421 107 528 371 99 470 
RotaTeq180 117 297 175 41 216 
Vaxneuvance94 13 106 5 — 5 
Pneumovax 23
40 56 96 118 55 173 
Vaqta30 10 40 29 7 36 
Hospital Acute Care
Bridion276 210 487 195 199 395 
Prevymis54 75 129 40 54 94 
Primaxin4 76 80 1 58 58 
Dificid62 3 65 49 3 52 
Noxafil14 46 60 10 48 57 
Zerbaxa27 23 50 18 12 30 
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
83 16 99 71 1 72 
Adempas— 59 59 — 61 61 
Virology
Lagevrio(2)394 392 1,523 1,723 3,247 
Isentress/Isentress HD
52 71 123 61 97 158 
Neuroscience
Belsomra16 40 56 20 48 69 
Immunology
Simponi— 180 180 — 186 186 
Remicade— 51 51 — 61 61 
Diabetes
Januvia271 280 551 325 454 779 
Janumet56 272 329 63 391 454 
Other pharmaceutical (4)
172 414 584 160 443 602 
Total Pharmaceutical segment sales6,117 6,604 12,721 6,773 7,334 14,107 
Animal Health:
Livestock174 676 849 171 661 832 
Companion Animals308 334 642 302 348 650 
Total Animal Health segment sales482 1,010 1,491 473 1,009 1,482 
Total segment sales6,599 7,614 14,212 7,246 8,343 15,589 
Other (5)
60 214 275 93 220 312 
 $6,659 $7,828 $14,487 $7,339 $8,563 $15,901 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99 million and $69 million for the three months ended March 31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2023 and 2022 also includes $51 million and $114 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.1 billion and $2.9 billion for the three months ended March 31, 2023 and 2022, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20232022
United States$6,659 $7,339 
Europe, Middle East and Africa3,303 4,359 
China1,715 1,143 
Asia Pacific (other than China and Japan)846 930 
Japan758 989 
Latin America661 607 
Other545 534 
 $14,487 $15,901 
A reconciliation of segment profits to Income Before Taxes is as follows:
 Three Months Ended
March 31,
($ in millions)20232022
Segment profits:
Pharmaceutical segment$9,140 $9,501 
Animal Health segment566 585 
Total segment profits9,706 10,086 
Other profits164 194 
Unallocated:
Interest income112 7 
Interest expense(242)(243)
Amortization(543)(699)
Depreciation(398)(378)
Research and development(4,147)(2,446)
Restructuring costs(67)(53)
Charge for Zetia antitrust litigation settlements(573)— 
Other unallocated, net(362)(1,607)
 $3,650 $4,861 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation (Policies)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 24, 2023. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted
Recently Adopted Accounting Standard
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
Recently Issued Accounting Standard Not Yet Adopted
In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption
Legal Costs Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2023
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lynparza$275 $266 
Alliance revenue - Koselugo23 9 
Total alliance revenue$298 $275 
Cost of sales (1)
70 299 
Selling, general and administrative47 44 
Research and development21 26 
($ in millions)March 31, 2023December 31, 2022
Receivables from AstraZeneca included in Other current assets
$303 $303 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
21 123 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 600 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Lenvima$232 $227 
Cost of sales (1)
126 53 
Selling, general and administrative51 31 
Research and development39 57 
($ in millions)March 31, 2023December 31, 2022
Receivables from Eisai included in Other current assets
$244 $214 
Payables to Eisai included in Accrued and other current liabilities (2)
125 — 
(1)    Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.
(2)    Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Alliance revenue - Adempas/Verquvo$99 $72 
Net sales of Adempas recorded by Merck59 61 
Net sales of Verquvo recorded by Merck7 3 
Total sales$165 $136 
Cost of sales (1)
57 50 
Selling, general and administrative33 23 
Research and development25 17 
($ in millions)March 31, 2023December 31, 2022
Receivables from Bayer included in Other current assets
$142 $143 
Payables to Bayer included in Accrued and other current liabilities
68 80 
(1)    Includes amortization of intangible assets.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
March 31,
($ in millions)20232022
Net sales of Lagevrio recorded by Merck
$392 $3,247 
Cost of sales (1)(2)
221 1,726 
Selling, general and administrative (2)
27 35 
Research and development (2)
16 25 
($ in millions)March 31, 2023December 31, 2022
Payables to Ridgeback included in Accrued and other current liabilities (3)
$191 $348 
(1)    Includes royalty expense and amortization of capitalized milestone payments.
(2)    Expenses include an allocation for overhead charges.
(3)    Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring (Tables)
 3 Months Ended
Mar. 31, 2023
Restructuring and Related Activities [Abstract]  
Charges Related to Restructuring Program Activities by Type of Cost
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended March 31, 2023
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $21 $8 $29 
Selling, general and administrative— — 1 1 
Restructuring costs41 — 26 67 
$41 $21 $35 $97 
 Three Months Ended March 31, 2022
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $18 $28 $46 
Selling, general and administrative— 4 17 21 
Research and development— 7 — 7 
Restructuring costs26 — 27 53 
$26 $29 $72 $127 
Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2023:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2023
$479 $— $34 $513 
Expenses41 21 35 97 
(Payments) receipts, net(47)— (27)(74)
Non-cash activity— (21)(9)(30)
Restructuring reserves March 31, 2023 (1)
$473 $— $33 $506 
(1)The remaining cash outlays are expected to be largely completed by the end of 2025.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments (Tables)
 3 Months Ended
Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended March 31,Three Months Ended March 31,
($ in millions)2023202220232022
Net Investment Hedging Relationships
Foreign exchange contracts$1 $(16)$1 $(1)
Euro-denominated notes52 (53)— — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  March 31, 2023December 31, 2022
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contractsOther Assets$1 $— $300 $— $— $— 
Interest rate swap contractsOther Noncurrent Liabilities— 1 200 — — — 
Foreign exchange contractsOther current assets104 — 4,253 220 — 4,824 
Foreign exchange contractsOther Assets32 — 1,756 27 — 1,609 
Foreign exchange contractsAccrued and other current liabilities— 116 3,444 — 101 2,691 
Foreign exchange contractsOther Noncurrent Liabilities— 2 120 — 1 91 
  $137 $119 $10,073 $247 $102 $9,215 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$121 $— $9,507 $186 $— $8,540 
Foreign exchange contractsOther Assets1 — 65 — — — 
Foreign exchange contractsAccrued and other current liabilities— 164 10,592 — 307 10,926 
Foreign exchange contractsOther Noncurrent Liabilities— 1 124 — — — 
  $122 $165 $20,288 $186 $307 $19,466 
  $259 $284 $30,361 $433 $409 $28,681 
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 March 31, 2023December 31, 2022
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$259 $284 $433 $409 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(148)(148)(220)(220)
Cash collateral received/posted(13)— (66)(19)
Net amounts$98 $136 $147 $170 
Location and Amount of Pretax Gains and Losses of Derivatives
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended March 31,
($ in millions)202320222023202220232022
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$14,487 $15,901 $89 $708 $(115)$60 
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — — (10)— — 
Derivatives designated as hedging instruments— — — 4 — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (66)148 
Increase in Sales as a result of AOCL reclassifications
101 67 — — (101)(67)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)(1)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)(1)
(1)    Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended March 31,
($ in millions)20232022
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$13 $28 
Foreign exchange contracts (2)
Sales2 (2)
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 March 31, 2023December 31, 2022
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Commercial paper$663 $— $— $663 $498 $— $— $498 
U.S. government and agency securities92 — — 92 68 — — 68 
Corporate notes and bonds4 — — 4 3 — — 3 
Foreign government bonds1 — — 1 — — — — 
Total debt securities$760 $— $— $760 $569 $— $— $569 
Publicly traded equity securities (1)
1,585 1,284 
Total debt and publicly traded equity securities$2,345 $1,853 
(1)    Unrealized net gains of $338 million were recorded in Other (income) expense, net in the first quarter of 2023 on equity securities still held at March 31, 2023. Unrealized net losses of $225 million were recorded in Other (income) expense, net in the first quarter of 2022 on equity securities still held at March 31, 2022.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)March 31, 2023December 31, 2022
Assets
Investments
Commercial paper$— $663 $— $663 $— $498 $— $498 
U.S. government and agency securities— 22 — 22 — — — — 
Foreign government bonds— 1 — 1 — — — — 
Publicly traded equity securities1,284 — — 1,284 1,015 — — 1,015 
 1,284 686 — 1,970 1,015 498 — 1,513 
Other assets (1)
U.S. government and agency securities70 — — 70 68 — — 68 
Corporate notes and bonds4 — — 4 3 — — 3 
Publicly traded equity securities301 — — 301 269 — — 269 
375 — — 375 340 — — 340 
Derivative assets (2)
Purchased currency options— 139 — 139 — 215 — 215 
Forward exchange contracts— 119 — 119 — 218 — 218 
Interest rate swap contracts— 1 — 1 — — — — 
 — 259 — 259 — 433 — 433 
Total assets$1,659 $945 $— $2,604 $1,355 $931 $— $2,286 
Liabilities
Other liabilities
Contingent consideration$— $— $353 $353 $— $— $456 $456 
Derivative liabilities (2)
Forward exchange contracts— 276 — 276 — 402 — 402 
Written currency options— 7 — 7 — 7 — 7 
Interest rate swap contracts— 1 — 1 — — — — 
— 284 — 284 — 409 — 409 
Total liabilities$— $284 $353 $637 $— $409 $456 $865 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Information About the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20232022
Fair value January 1$456 $777 
Changes in estimated fair value (1)
14 (84)
Payments(117)(119)
Other— (2)
Fair value March 31 (2)
$353 $572 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    At March 31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March 31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Inventories
Inventories consisted of:
($ in millions)March 31, 2023December 31, 2022
Finished goods$1,883 $1,841 
Raw materials and work in process7,348 7,063 
Supplies266 238 
Total (approximates current cost)9,497 9,142 
Decrease to LIFO cost(350)(293)
 $9,147 $8,849 
Recognized as:
Inventories$5,863 $5,911 
Other Assets3,284 2,938 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Equity (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of Equity
Three Months Ended March 31,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20223,577 $1,788 $44,238 $53,696 $(4,429)1,049 $(57,109)$73 $38,257 
Net income attributable to Merck & Co., Inc.— — — 4,310 — — — — 4,310 
Other comprehensive income, net of taxes— — — — 60 — — — 60 
Cash dividends declared on common stock ($0.69 per share)
— — — (1,754)— — — — (1,754)
Share-based compensation plans and other— — 37 — — — 46 — 83 
Net loss attributable to noncontrolling interests— — — — — — — (3)(3)
Balance at March 31, 20223,577 $1,788 $44,275 $56,252 $(4,369)1,049 $(57,063)$70 $40,953 
Balance at January 1, 20233,577 $1,788 $44,379 $61,081 $(4,768)1,039 $(56,489)$67 $46,058 
Net income attributable to Merck & Co., Inc.— — — 2,821 — — — — 2,821 
Other comprehensive loss, net of taxes— — — — (115)— — — (115)
Cash dividends declared on common stock ($0.73 per share)
— — — (1,863)— — — — (1,863)
Treasury stock shares purchased— — — — — 1 (149)— (149)
Share-based compensation plans and other— — 88 — — — 61 — 149 
Net income attributable to noncontrolling interests— — — — — — — 4 4 
Balance at March 31, 20233,577 $1,788 $44,467 $62,039 $(4,883)1,040 $(56,577)$71 $46,905 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Pension and Other Postretirement Benefit Plans (Tables)
 3 Months Ended
Mar. 31, 2023
Pension Plans  
Defined Benefit Plan Disclosure [Line Items]  
Net Benefit Costs
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
  Three Months Ended
March 31,
20232022
($ in millions)U.S.InternationalU.S.International
Service cost$76 $49 $99 $75 
Interest cost133 74 103 38 
Expected return on plan assets(187)(128)(196)(101)
Amortization of unrecognized prior service credit— (3)(8)(4)
Net (gain) loss amortization— (1)56 25 
Curtailments2 — 3 — 
Settlements21 — 1 — 
 $45 $(9)$58 $33 
Other Postretirement Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Net Benefit Costs
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
March 31,
($ in millions)20232022
Service cost$8 $12 
Interest cost16 11 
Expected return on plan assets(16)(21)
Amortization of unrecognized prior service credit(12)(14)
Net gain amortization(11)(11)
 $(15)$(23)
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Other (Income) Expense, Net (Tables)
 3 Months Ended
Mar. 31, 2023
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
March 31,
($ in millions)20232022
Interest income$(112)$(7)
Interest expense242 243 
Exchange losses61 39 
(Income) loss from investments in equity securities, net (1)
(450)708 
Net periodic defined benefit plan (credit) cost other than service cost(115)(121)
Other, net463 (154)
 $89 $708 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Calculations of Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
March 31,
($ and shares in millions except per share amounts)20232022
Net Income Attributable to Merck & Co., Inc.$2,821 $4,310 
Average common shares outstanding2,538 2,528 
Common shares issuable (1)
13 9 
Average common shares outstanding assuming dilution 2,551 2,537 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$1.11 $1.70 
(1)    Issuable primarily under share-based compensation plans.
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Changes in AOCI by Component
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended March 31,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2022, net of taxes$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax148 1 (18)131 
Tax(31)(2)(17)(50)
Other comprehensive income (loss) before reclassification adjustments, net of taxes117 (1)(35)81 
Reclassification adjustments, pretax(68)
(1)
45 
(2)
— (23)
Tax14 (12)— 2 
Reclassification adjustments, net of taxes(54)

33 

— (21)
Other comprehensive income (loss), net of taxes63 32 (35)60 
Balance March 31, 2022, net of taxes$207 $(2,711)$(1,865)$(4,369)
Balance January 1, 2023, net of taxes$73 $(2,408)$(2,433)$(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax(66)(47)79 (34)
Tax14 2 (20)(4)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(52)(45)59 (38)
Reclassification adjustments, pretax(102)
(1)
(7)
(2)
9 (100)
Tax21 2 — 23 
Reclassification adjustments, net of taxes(81)

(5)

9 (77)
Other comprehensive income (loss), net of taxes(133)(50)68 (115)
Balance March 31, 2023, net of taxes$(60)$(2,458)$(2,365)$(4,883)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Sales from Products
Sales of the Company’s products were as follows:
Three Months Ended March 31,
20232022
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$3,485 $2,310 $5,795 $2,779 $2,030 $4,809 
Alliance revenue-Lynparza (1)
142 133 275 141 125 266 
Alliance revenue-Lenvima (1)
153 79 232 156 71 227 
Alliance revenue-Reblozyl (2)
30 12 43 27 25 52 
Welireg41 1 42 18 — 18 
Vaccines
Gardasil/Gardasil 9
416 1,556 1,972 418 1,042 1,460 
ProQuad/M-M-R II/Varivax
421 107 528 371 99 470 
RotaTeq180 117 297 175 41 216 
Vaxneuvance94 13 106 5 — 5 
Pneumovax 23
40 56 96 118 55 173 
Vaqta30 10 40 29 7 36 
Hospital Acute Care
Bridion276 210 487 195 199 395 
Prevymis54 75 129 40 54 94 
Primaxin4 76 80 1 58 58 
Dificid62 3 65 49 3 52 
Noxafil14 46 60 10 48 57 
Zerbaxa27 23 50 18 12 30 
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
83 16 99 71 1 72 
Adempas— 59 59 — 61 61 
Virology
Lagevrio(2)394 392 1,523 1,723 3,247 
Isentress/Isentress HD
52 71 123 61 97 158 
Neuroscience
Belsomra16 40 56 20 48 69 
Immunology
Simponi— 180 180 — 186 186 
Remicade— 51 51 — 61 61 
Diabetes
Januvia271 280 551 325 454 779 
Janumet56 272 329 63 391 454 
Other pharmaceutical (4)
172 414 584 160 443 602 
Total Pharmaceutical segment sales6,117 6,604 12,721 6,773 7,334 14,107 
Animal Health:
Livestock174 676 849 171 661 832 
Companion Animals308 334 642 302 348 650 
Total Animal Health segment sales482 1,010 1,491 473 1,009 1,482 
Total segment sales6,599 7,614 14,212 7,246 8,343 15,589 
Other (5)
60 214 275 93 220 312 
 $6,659 $7,828 $14,487 $7,339 $8,563 $15,901 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99 million and $69 million for the three months ended March 31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2023 and 2022 also includes $51 million and $114 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated Sales by Geographic Area
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20232022
United States$6,659 $7,339 
Europe, Middle East and Africa3,303 4,359 
China1,715 1,143 
Asia Pacific (other than China and Japan)846 930 
Japan758 989 
Latin America661 607 
Other545 534 
 $14,487 $15,901 
Reconciliation of Segment Profits to Income before Taxes
A reconciliation of segment profits to Income Before Taxes is as follows:
 Three Months Ended
March 31,
($ in millions)20232022
Segment profits:
Pharmaceutical segment$9,140 $9,501 
Animal Health segment566 585 
Total segment profits9,706 10,086 
Other profits164 194 
Unallocated:
Interest income112 7 
Interest expense(242)(243)
Amortization(543)(699)
Depreciation(398)(378)
Research and development(4,147)(2,446)
Restructuring costs(67)(53)
Charge for Zetia antitrust litigation settlements(573)— 
Other unallocated, net(362)(1,607)
 $3,650 $4,861 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Spin-Off of Organon & Co. (Details) - USD ($)
$ in Millions
 3 Months Ended
Jun. 02, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Organon & Co.        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenue from related party   $ 94 $ 99  
Related party amount in cost of sales   107 $ 105  
Due from related parties, current   473   $ 511
Due to related parties, current   $ 229   $ 345
Minimum | Transition services agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 25 months      
Minimum | Manufacturing and supply agreements        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 4 years      
Maximum | Transition services agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 35 months      
Maximum | Manufacturing and supply agreements        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 10 years      
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions, Research Collaborations and License Agreements (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2023
Feb. 28, 2023
Jan. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Business Acquisition [Line Items]              
Research and development         $ 4,276 $ 2,576  
Prometheus Biosciences, Inc. | Subsequent Event              
Business Acquisition [Line Items]              
Asset acquisition, share price (in dollars per share) $ 200            
Asset acquisition, price of acquisition, expected $ 10,800            
Research and development       $ 10,300      
Imago Bio Sciences, Inc.              
Business Acquisition [Line Items]              
Research and development     $ 1,200        
Asset acquisition costs     60        
Net assets acquired     219        
Consideration transferred, asset acquisition     1,350        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement              
Business Acquisition [Line Items]              
Research and development   $ 175          
Eligible future contingent development-related payments (up to)   1,000          
Regulatory milestones payments   2,800          
Sales milestone payments   $ 5,500          
Preferred stock investment in counterparty     $ 100        
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Lenvima              
Business Acquisition [Line Items]              
Capitalized milestone payment           $ 25 $ 50
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization $ 543 $ 699  
Sales 14,487 15,901  
Operating Segments      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 14,212 15,589  
Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 12,721 14,107  
Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization   250  
Lynparza | Other Noncurrent Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 1,500    
Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization 72    
Lenvima | Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 232 227  
Lenvima | Other Noncurrent Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 812    
Verquvo | Other Intangible Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 56    
Adempas | Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 59 61  
Adempas | Other Intangible Assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Finite-lived intangible assets 613    
Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 43 52  
AstraZeneca | Sales-Based Milestones | Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Probable contingent payments   600  
Liabilities   600  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales-based milestone payments   400  
Potential future sales-based milestone payments 2,100    
Regulatory milestone payments accrued     $ 105
Capitalized milestone payment     250
Potential future regulatory milestone payments 1,100    
Eisai | Sales-Based Milestones | Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Probable contingent payments 125    
Liabilities 125    
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales-based milestone payments   300 600
Potential future sales-based milestone payments $ 2,400    
Capitalized milestone payment   25 $ 50
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales-based milestone payments   400  
Bristol Myers Squibb | Licensing Agreements      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate, deduction 0.50    
Royalties   32  
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Contingent proceeds collaborative arrangement $ 80    
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Proceeds from Collaborators   $ 20  
Bristol Myers Squibb | Licensing Agreements | Minimum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate 20.00%    
Bristol Myers Squibb | Licensing Agreements | Maximum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate 24.00%    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Arrangements - Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 14,487 $ 15,901  
Cost of sales 3,926 5,380  
Selling, general and administrative 2,479 2,323  
Research and development 4,276 2,576  
Payables included in Accrued and other liabilities 23,131   $ 24,239
Amortization 543 699  
Alliance revenue - Lenvima      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization 72    
Other current assets | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 303   303
Other current assets | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 244   214
Other current assets | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 142   143
Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 21   123
Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 125   0
Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 68   80
Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other liabilities 191   348
Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Other Noncurrent Liabilities 600   $ 600
Revenue | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 298 275  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 275 266  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 23 9  
Revenue | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 232 227  
Revenue | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 99 72  
Sales 165 136  
Revenue | Bayer AG | Collaborative Arrangement | Adempas      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 59 61  
Revenue | Bayer AG | Collaborative Arrangement | Verquvo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 7 3  
Revenue | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 392 3,247  
Cost of sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 70 299  
Amortization of intangible assets 250    
Cost of sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 126 53  
Cost of sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 57 50  
Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 221 1,726  
Selling, general and administrative | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 47 44  
Selling, general and administrative | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 51 31  
Selling, general and administrative | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 33 23  
Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 27 35  
Research and development | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 21 26  
Research and development | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 39 57  
Research and development | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 25 17  
Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development $ 16 $ 25  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]      
Expected restructuring and related cost $ 3,700    
Estimate of cumulative pre tax costs that will result in cash outlays 70.00%    
Estimate of cumulative pre tax costs that will be noncash 30.00%    
Total pretax restructuring costs $ 97 $ 127  
Cumulative costs since program inception $ 3,400    
Forecast      
Restructuring Cost and Reserve [Line Items]      
Expected restructuring and related cost     $ 400
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring - Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs $ 97 $ 127
Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 41 26
Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 21 29
Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 35 72
Cost of sales    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 29 46
Cost of sales | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0 0
Cost of sales | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 21 18
Cost of sales | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 8 28
Selling, general and administrative    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 1 21
Selling, general and administrative | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0 0
Selling, general and administrative | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0 4
Selling, general and administrative | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 1 17
Research and development    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   7
Research and development | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   0
Research and development | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   7
Research and development | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs   0
Restructuring costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 67 53
Restructuring costs | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 41 26
Restructuring costs | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0 0
Restructuring costs | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs $ 26 $ 27
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Restructuring - Activities by Program (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance $ 513  
Expenses 97 $ 127
(Payments) receipts, net (74)  
Non-cash activity (30)  
Restructuring reserve, ending balance 506  
Separation Costs    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 479  
Expenses 41 26
(Payments) receipts, net (47)  
Non-cash activity 0  
Restructuring reserve, ending balance 473  
Accelerated Depreciation    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 0  
Expenses 21 29
(Payments) receipts, net 0  
Non-cash activity (21)  
Restructuring reserve, ending balance 0  
Other    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 34  
Expenses 35 $ 72
(Payments) receipts, net (27)  
Non-cash activity (9)  
Restructuring reserve, ending balance $ 33  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Narrative (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 31, 2023
USD ($)
interest_rate_swap
Mar. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Apr. 30, 2023
USD ($)
interest_rate_swap
Dec. 31, 2022
USD ($)
Derivative [Line Items]          
Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap 5        
Total swap notional amount $ 30,361       $ 28,681
Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales 71        
Equity investments without readily determinable fair values 942 $ 643      
Unrealized gains recognized on investments in equity securities without readily determinable fair value 1 14      
Unrealized losses recognized on investments in equity securities without readily determinable fair values 21        
Cumulative unrealized gains on investments 287        
Cumulative unrealized losses on investments 40        
Equity securities, noncurrent 725 1,200      
(Income) loss from investments in equity securities, net (450) 708      
Fair value of loans payable and long-term debt, including current portion 28,200       26,700
Debt, carrying amount 30,700       30,700
Factored accounts receivable 2,400   $ 2,500    
Restricted cash 31       67
Cash collateral received from counterparties 13       66
Cash collateral advanced to counterparties         19
Subsequent Event          
Derivative [Line Items]          
Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap       2  
Equity Funds          
Derivative [Line Items]          
(Income) loss from investments in equity securities, net (132) $ 509      
Level 2          
Derivative [Line Items]          
Cash equivalents 8,800       11,300
Interest rate swap contracts          
Derivative [Line Items]          
Total swap notional amount 100        
Interest rate swap contracts | Subsequent Event          
Derivative [Line Items]          
Total swap notional amount       $ 100  
Derivatives Designated as Hedging Instruments          
Derivative [Line Items]          
Total swap notional amount 10,073       9,215
Derivatives Not Designated as Hedging Instruments          
Derivative [Line Items]          
Total swap notional amount $ 20,288       $ 19,466
Maximum | Derivatives Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum average period of maturities of contracts in years (less than) 2 years        
Maximum | Derivatives Not Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum average period of maturities of contracts in years (less than) 6 months        
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ 1 $ (16)
Foreign exchange contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing 1 (1)
Euro-denominated notes    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income 52 (53)
Euro-denominated notes | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 259 $ 433
Fair Value of Derivative, Liability 284 409
U.S Dollar Notional Amount 30,361 28,681
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 137 247
Fair Value of Derivative, Liability 119 102
U.S Dollar Notional Amount 10,073 9,215
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 122 186
Fair Value of Derivative, Liability 165 307
U.S Dollar Notional Amount 20,288 19,466
Interest Rate Contract | Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 1 $ 0
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair Value of Derivative, Liability $ 1 $ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Interest Rate Contract | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
U.S Dollar Notional Amount $ 300 $ 0
Interest Rate Contract | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
U.S Dollar Notional Amount 200 0
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 32 $ 27
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
U.S Dollar Notional Amount $ 1,756 $ 1,609
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability $ 2 $ 1
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
U.S Dollar Notional Amount $ 120 $ 91
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 104 $ 220
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
U.S Dollar Notional Amount $ 4,253 $ 4,824
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability $ 116 $ 101
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
U.S Dollar Notional Amount $ 3,444 $ 2,691
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 1 $ 0
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
U.S Dollar Notional Amount $ 65 $ 0
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability $ 1 $ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
U.S Dollar Notional Amount $ 124 $ 0
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 121 $ 186
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
U.S Dollar Notional Amount $ 9,507 $ 8,540
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability $ 164 $ 307
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
U.S Dollar Notional Amount $ 10,592 $ 10,926
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 259 $ 433
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset (148) (220)
Cash collateral received, asset (13) (66)
Net amounts, asset 98 147
Gross amounts recognized in the consolidated balance sheet, liability 284 409
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability (148) (220)
Cash collateral received, liability 0 (19)
Net amounts, liability $ 136 $ 170
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]    
Sales $ 14,487 $ 15,901
Other (income) expense, net 89 708
Other comprehensive income (loss) (115) 60
Interest rate swap contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in OCI on derivatives (1) (1)
Amount of gain recognized in Other (income) expense, net on derivatives (1) (1)
Interest rate swap contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Hedged items 0 (10)
Derivatives designated as hedging instruments 0 4
Foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in OCI on derivatives (66) 148
Increase in Sales as a result of AOCL reclassifications (101) (67)
Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest    
Derivative Instruments, Gain (Loss) [Line Items]    
Sales $ 101 $ 67
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Currency Swap | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ 13 $ 28
Foreign Exchange Future | Sales    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ 2 $ (2)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost $ 760   $ 569
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 760   569
Publicly traded equity securities, fair value 1,585   1,284
Total debt and publicly traded equity securities, fair value 2,345   1,853
Unrealized net (gains) losses (338) $ 225  
Commercial paper      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 663   498
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 663   498
U.S. government and agency securities      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 92   68
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 92   68
Corporate notes and bonds      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 4   3
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 4   3
Foreign government bonds      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 1   0
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value $ 1   $ 0
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Assets        
Investments $ 760 $ 569    
Publicly traded equity securities 1,585 1,284    
Derivative assets 259 433    
Liabilities        
Contingent consideration 353 456 $ 572 $ 777
Derivative liabilities 284 409    
Commercial paper        
Assets        
Investments 663 498    
U.S. government and agency securities        
Assets        
Investments 92 68    
Foreign government bonds        
Assets        
Investments 1 0    
Corporate notes and bonds        
Assets        
Investments 4 3    
Fair Value, Measurements, Recurring        
Assets        
Investments 1,970 1,513    
Other assets 375 340    
Derivative assets 259 433    
Total assets 2,604 2,286    
Liabilities        
Contingent consideration 353 456    
Derivative liabilities 284 409    
Total liabilities 637 865    
Fair Value, Measurements, Recurring | Currency options        
Assets        
Derivative assets 139 215    
Liabilities        
Derivative liabilities 7 7    
Fair Value, Measurements, Recurring | Foreign exchange contracts        
Assets        
Derivative assets 119 218    
Liabilities        
Derivative liabilities 276 402    
Fair Value, Measurements, Recurring | Interest rate swap contracts        
Assets        
Derivative assets 1 0    
Liabilities        
Derivative liabilities 1 0    
Fair Value, Measurements, Recurring | Level 1        
Assets        
Investments 1,284 1,015    
Other assets 375 340    
Derivative assets 0 0    
Total assets 1,659 1,355    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 0 0    
Total liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 2        
Assets        
Investments 686 498    
Other assets 0 0    
Derivative assets 259 433    
Total assets 945 931    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 284 409    
Total liabilities 284 409    
Fair Value, Measurements, Recurring | Level 2 | Currency options        
Assets        
Derivative assets 139 215    
Liabilities        
Derivative liabilities 7 7    
Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts        
Assets        
Derivative assets 119 218    
Liabilities        
Derivative liabilities 276 402    
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts        
Assets        
Derivative assets 1 0    
Liabilities        
Derivative liabilities 1 0    
Fair Value, Measurements, Recurring | Level 3        
Assets        
Investments 0 0    
Other assets 0 0    
Derivative assets 0 0    
Total assets 0 0    
Liabilities        
Contingent consideration 353 456    
Derivative liabilities 0 0    
Total liabilities 353 456    
Fair Value, Measurements, Recurring | Level 3 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Commercial paper        
Assets        
Investments 663 498    
Fair Value, Measurements, Recurring | Commercial paper | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Commercial paper | Level 2        
Assets        
Investments 663 498    
Fair Value, Measurements, Recurring | Commercial paper | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities        
Assets        
Investments 22 0    
Other assets 70 68    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1        
Assets        
Investments 0 0    
Other assets 70 68    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2        
Assets        
Investments 22 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3        
Assets        
Investments 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds        
Assets        
Investments 1 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 2        
Assets        
Investments 1 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities        
Assets        
Publicly traded equity securities 1,284 1,015    
Other assets 301 269    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1        
Assets        
Publicly traded equity securities 1,284 1,015    
Other assets 301 269    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2        
Assets        
Publicly traded equity securities 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3        
Assets        
Publicly traded equity securities 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds        
Assets        
Other assets 4 3    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1        
Assets        
Other assets 4 3    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2        
Assets        
Other assets 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3        
Assets        
Other assets $ 0 $ 0    
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value, beginning balance $ 456 $ 777
Changes in estimated fair value 14 (84)
Payments (117) (119)
Other 0 (2)
Fair value, ending balance 353 572
Contingent consideration 353 $ 572
Current liability 127  
Sanofi Pasteur    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value, ending balance 263  
Contingent consideration $ 263  
Contingent consideration, measurement input, discount rate 0.115  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Finished goods $ 1,883 $ 1,841
Raw materials and work in process 7,348 7,063
Supplies 266 238
Total (approximates current cost) 9,497 9,142
Decrease to LIFO cost (350) (293)
Total current and noncurrent inventories 9,147 8,849
Recognized as:    
Inventories 5,863 5,911
Other Assets $ 3,284 $ 2,938
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Inventory [Line Items]    
Inventories classified in Other assets $ 3,284 $ 2,938
Inventories Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventories classified in Other assets 2,700 2,400
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventories classified in Other assets $ 590 $ 516
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Contingencies (Details)
$ in Millions
 3 Months Ended
Apr. 13, 2023
patent
Dec. 19, 2022
Jun. 30, 2022
claim
Mar. 31, 2023
USD ($)
case
company
Mar. 03, 2023
state
Dec. 31, 2022
USD ($)
Aug. 31, 2020
direct_purchaser
Legal Defense Costs              
Loss Contingencies [Line Items]              
Legal defense costs reserve | $       $ 225.0   $ 230.0  
Zetia antitrust litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims | direct_purchaser             35
Loss related to litigation settlement | $       $ 572.5      
Zetia antitrust litigation | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, new claims filed | claim     23        
RotaTeq Antitrust Litigation | Pending Litigation              
Loss Contingencies [Line Items]              
Loss Contingency, number of states in which plaintiffs reside | state         35    
Complaint Against The Johns Hopkins University | Pending Litigation | Subsequent Event              
Loss Contingencies [Line Items]              
Loss contingency, number of patents allegedly infringed | patent 5            
Gardasil/Gardasil 9 | U.S.              
Loss Contingencies [Line Items]              
Loss contingency, pending claims | case       95      
Gardasil/Gardasil 9 | Non-US              
Loss Contingencies [Line Items]              
Loss contingency, pending claims | case       15      
Gardasil/Gardasil 9 | COLOMBIA              
Loss Contingencies [Line Items]              
Loss contingency, pending claims | case       1      
Bridion | Patents              
Loss Contingencies [Line Items]              
Loss contingency, claims settled | company       5      
Bridion | Patents | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims | company       2      
Loss contingency, trial period   1 day          
Januvia and Janumet | Patents              
Loss Contingencies [Line Items]              
Loss contingency, claims settled | company       25      
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Common stock, beginning balance (in shares) 3,577,103,522  
Treasury stock, beginning balance (in shares) 1,039,269,638  
Equity, beginning balance $ 46,058 $ 38,257
Net income attributable to Merck & Co., Inc. 2,821 4,310
Other comprehensive income (loss), net of taxes (115) 60
Cash dividends declared on common stock (1,863) (1,754)
Treasury stock shares purchased (149)  
Share-based compensation plans and other 149 83
Net income (loss) attributable to noncontrolling interests $ 4 (3)
Common stock, ending balance (in shares) 3,577,103,522  
Treasury stock, ending balance (in shares) 1,039,651,210  
Equity, ending balance $ 46,905 $ 40,953
Cash dividends declared on common stock (in dollars per share) $ 0.73 $ 0.69
   Common Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Common stock, beginning balance (in shares) 3,577,000,000 3,577,000,000
Equity, beginning balance $ 1,788 $ 1,788
Common stock, ending balance (in shares) 3,577,000,000 3,577,000,000
Equity, ending balance $ 1,788 $ 1,788
Other Paid-In Capital    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 44,379 44,238
Share-based compensation plans and other 88 37
Equity, ending balance 44,467 44,275
Retained Earnings    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 61,081 53,696
Net income attributable to Merck & Co., Inc. 2,821 4,310
Cash dividends declared on common stock (1,863) (1,754)
Equity, ending balance 62,039 56,252
Accumulated Other Comprehensive Loss    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance (4,768) (4,429)
Other comprehensive income (loss), net of taxes (115) 60
Equity, ending balance $ (4,883) $ (4,369)
  Treasury Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Treasury stock, beginning balance (in shares) 1,039,000,000 1,049,000,000
Equity, beginning balance $ (56,489) $ (57,109)
Treasury stock shares purchased (in shares) 1,000,000  
Treasury stock shares purchased $ (149)  
Share-based compensation plans and other $ 61 $ 46
Treasury stock, ending balance (in shares) 1,040,000,000 1,049,000,000
Equity, ending balance $ (56,577) $ (57,063)
Non- controlling Interests    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 67 73
Net income (loss) attributable to noncontrolling interests 4 (3)
Equity, ending balance $ 71 $ 70
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Other Postretirement Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 8 $ 12
Interest cost 16 11
Expected return on plan assets (16) (21)
Amortization of unrecognized prior service credit (12) (14)
Net (gain) loss amortization (11) (11)
Net periodic benefit cost (15) (23)
U.S. | Pension Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 76 99
Interest cost 133 103
Expected return on plan assets (187) (196)
Amortization of unrecognized prior service credit 0 (8)
Net (gain) loss amortization 0 56
Curtailments 2 3
Settlements 21 1
Net periodic benefit cost 45 58
International | Pension Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 49 75
Interest cost 74 38
Expected return on plan assets (128) (101)
Amortization of unrecognized prior service credit (3) (4)
Net (gain) loss amortization (1) 25
Curtailments 0 0
Settlements 0 0
Net periodic benefit cost $ (9) $ 33
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Pension and Other Postretirement Benefit Plans - Narrative (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2023
USD ($)
Retirement Benefits [Abstract]  
Partial settlement charge $ 21
Increase to pension liabilities due to remeasurement $ 44
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Other Income and Expenses [Abstract]    
Interest income $ (112) $ (7)
Interest expense 242 243
Exchange losses 61 39
Loss (income) from investments in equity securities, net (450) 708
Net periodic defined benefit plan (credit) cost other than service cost (115) (121)
Other, net 463 (154)
Other (income) expense, net $ 89 $ 708
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Loss Contingencies [Line Items]    
Interest paid $ 208.0 $ 211.0
Zetia antitrust litigation    
Loss Contingencies [Line Items]    
Loss related to litigation settlement $ 572.5  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Taxes on Income (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Effective income tax rate 22.60% 11.40%
Tax benefit resulting from acquisition charge $ 0  
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Earnings Per Share [Abstract]    
Net income attributable to Merck & Co., Inc., basic $ 2,821,000 $ 4,310,000
Net income attributable to Merck & Co., Inc., diluted $ 2,821,000 $ 4,310,000
Average common shares outstanding (in shares) 2,538 2,528
Common shares issuable (in shares) 13 9
Average common shares outstanding assuming dilution (in shares) 2,551 2,537
Basic Earnings Per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.11 $ 1.70
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.11 $ 1.70
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings Per Share - Narrative (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Earnings Per Share [Abstract]    
Antidilutive shares (in shares) 1 7
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance $ 46,058 $ 38,257
Other comprehensive income (loss) before reclassification adjustments, pretax (34) 131
Tax (4) (50)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (38) 81
Reclassification adjustments, pretax (100) (23)
Tax 23 2
Reclassification adjustments, net of taxes (77) (21)
Other comprehensive income (loss), net of taxes (115) 60
Equity, ending balance 46,905 40,953
Derivatives    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance 73 144
Other comprehensive income (loss) before reclassification adjustments, pretax (66) 148
Tax 14 (31)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (52) 117
Reclassification adjustments, pretax (102) (68)
Tax 21 14
Reclassification adjustments, net of taxes (81) (54)
Other comprehensive income (loss), net of taxes (133) 63
Equity, ending balance (60) 207
Employee Benefit Plans    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (2,408) (2,743)
Other comprehensive income (loss) before reclassification adjustments, pretax (47) 1
Tax 2 (2)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (45) (1)
Reclassification adjustments, pretax (7) 45
Tax 2 (12)
Reclassification adjustments, net of taxes (5) 33
Other comprehensive income (loss), net of taxes (50) 32
Equity, ending balance (2,458) (2,711)
Foreign Currency Translation Adjustment    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (2,433) (1,830)
Other comprehensive income (loss) before reclassification adjustments, pretax 79 (18)
Tax (20) (17)
Other comprehensive income (loss) before reclassification adjustments, net of taxes 59 (35)
Reclassification adjustments, pretax 9 0
Tax 0 0
Reclassification adjustments, net of taxes 9 0
Other comprehensive income (loss), net of taxes 68 (35)
Equity, ending balance (2,365) (1,865)
Accumulated Other Comprehensive Loss    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (4,768) (4,429)
Equity, ending balance $ (4,883) $ (4,369)
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting - Narrative (Details)
$ in Billions
 3 Months Ended
Mar. 31, 2023
USD ($)
segment
Mar. 31, 2022
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 2  
Sales discounts | $ $ 3.1 $ 2.9
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting - Sales from Products (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Segment Reporting Information [Line Items]    
Sales $ 14,487 $ 15,901
Revenue related to the sale of the marketing rights 51 114
Increase (Decrease) In Hedge Revenue 99 69
U.S.    
Segment Reporting Information [Line Items]    
Sales 6,659 7,339
Int’l    
Segment Reporting Information [Line Items]    
Sales 7,828 8,563
Operating Segments    
Segment Reporting Information [Line Items]    
Sales 14,212 15,589
Operating Segments | U.S.    
Segment Reporting Information [Line Items]    
Sales 6,599 7,246
Operating Segments | Int’l    
Segment Reporting Information [Line Items]    
Sales 7,614 8,343
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Sales 275 312
Corporate, Non-Segment | U.S.    
Segment Reporting Information [Line Items]    
Sales 60 93
Corporate, Non-Segment | Int’l    
Segment Reporting Information [Line Items]    
Sales 214 220
Pharmaceutical | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 12,721 14,107
Pharmaceutical | Operating Segments | U.S.    
Segment Reporting Information [Line Items]    
Sales 6,117 6,773
Pharmaceutical | Operating Segments | Int’l    
Segment Reporting Information [Line Items]    
Sales 6,604 7,334
Pharmaceutical | Operating Segments | Keytruda    
Segment Reporting Information [Line Items]    
Sales 5,795 4,809
Pharmaceutical | Operating Segments | Keytruda | U.S.    
Segment Reporting Information [Line Items]    
Sales 3,485 2,779
Pharmaceutical | Operating Segments | Keytruda | Int’l    
Segment Reporting Information [Line Items]    
Sales 2,310 2,030
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza    
Segment Reporting Information [Line Items]    
Sales 275 266
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S.    
Segment Reporting Information [Line Items]    
Sales 142 141
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l    
Segment Reporting Information [Line Items]    
Sales 133 125
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima    
Segment Reporting Information [Line Items]    
Sales 232 227
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S.    
Segment Reporting Information [Line Items]    
Sales 153 156
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l    
Segment Reporting Information [Line Items]    
Sales 79 71
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl    
Segment Reporting Information [Line Items]    
Sales 43 52
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S.    
Segment Reporting Information [Line Items]    
Sales 30 27
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l    
Segment Reporting Information [Line Items]    
Sales 12 25
Pharmaceutical | Operating Segments | Welireg    
Segment Reporting Information [Line Items]    
Sales 42 18
Pharmaceutical | Operating Segments | Welireg | U.S.    
Segment Reporting Information [Line Items]    
Sales 41 18
Pharmaceutical | Operating Segments | Welireg | Int’l    
Segment Reporting Information [Line Items]    
Sales 1 0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9    
Segment Reporting Information [Line Items]    
Sales 1,972 1,460
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S.    
Segment Reporting Information [Line Items]    
Sales 416 418
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l    
Segment Reporting Information [Line Items]    
Sales 1,556 1,042
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax    
Segment Reporting Information [Line Items]    
Sales 528 470
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S.    
Segment Reporting Information [Line Items]    
Sales 421 371
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l    
Segment Reporting Information [Line Items]    
Sales 107 99
Pharmaceutical | Operating Segments | RotaTeq    
Segment Reporting Information [Line Items]    
Sales 297 216
Pharmaceutical | Operating Segments | RotaTeq | U.S.    
Segment Reporting Information [Line Items]    
Sales 180 175
Pharmaceutical | Operating Segments | RotaTeq | Int’l    
Segment Reporting Information [Line Items]    
Sales 117 41
Pharmaceutical | Operating Segments | Vaxneuvance    
Segment Reporting Information [Line Items]    
Sales 106 5
Pharmaceutical | Operating Segments | Vaxneuvance | U.S.    
Segment Reporting Information [Line Items]    
Sales 94 5
Pharmaceutical | Operating Segments | Vaxneuvance | Int’l    
Segment Reporting Information [Line Items]    
Sales 13 0
Pharmaceutical | Operating Segments | Pneumovax 23    
Segment Reporting Information [Line Items]    
Sales 96 173
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S.    
Segment Reporting Information [Line Items]    
Sales 40 118
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l    
Segment Reporting Information [Line Items]    
Sales 56 55
Pharmaceutical | Operating Segments | Vaqta    
Segment Reporting Information [Line Items]    
Sales 40 36
Pharmaceutical | Operating Segments | Vaqta | U.S.    
Segment Reporting Information [Line Items]    
Sales 30 29
Pharmaceutical | Operating Segments | Vaqta | Int’l    
Segment Reporting Information [Line Items]    
Sales 10 7
Pharmaceutical | Operating Segments | Bridion    
Segment Reporting Information [Line Items]    
Sales 487 395
Pharmaceutical | Operating Segments | Bridion | U.S.    
Segment Reporting Information [Line Items]    
Sales 276 195
Pharmaceutical | Operating Segments | Bridion | Int’l    
Segment Reporting Information [Line Items]    
Sales 210 199
Pharmaceutical | Operating Segments | Prevymis    
Segment Reporting Information [Line Items]    
Sales 129 94
Pharmaceutical | Operating Segments | Prevymis | U.S.    
Segment Reporting Information [Line Items]    
Sales 54 40
Pharmaceutical | Operating Segments | Prevymis | Int’l    
Segment Reporting Information [Line Items]    
Sales 75 54
Pharmaceutical | Operating Segments | Primaxin    
Segment Reporting Information [Line Items]    
Sales 80 58
Pharmaceutical | Operating Segments | Primaxin | U.S.    
Segment Reporting Information [Line Items]    
Sales 4 1
Pharmaceutical | Operating Segments | Primaxin | Int’l    
Segment Reporting Information [Line Items]    
Sales 76 58
Pharmaceutical | Operating Segments | Dificid    
Segment Reporting Information [Line Items]    
Sales 65 52
Pharmaceutical | Operating Segments | Dificid | U.S.    
Segment Reporting Information [Line Items]    
Sales 62 49
Pharmaceutical | Operating Segments | Dificid | Int’l    
Segment Reporting Information [Line Items]    
Sales 3 3
Pharmaceutical | Operating Segments | Noxafil    
Segment Reporting Information [Line Items]    
Sales 60 57
Pharmaceutical | Operating Segments | Noxafil | U.S.    
Segment Reporting Information [Line Items]    
Sales 14 10
Pharmaceutical | Operating Segments | Noxafil | Int’l    
Segment Reporting Information [Line Items]    
Sales 46 48
Pharmaceutical | Operating Segments | Zerbaxa    
Segment Reporting Information [Line Items]    
Sales 50 30
Pharmaceutical | Operating Segments | Zerbaxa | U.S.    
Segment Reporting Information [Line Items]    
Sales 27 18
Pharmaceutical | Operating Segments | Zerbaxa | Int’l    
Segment Reporting Information [Line Items]    
Sales 23 12
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo    
Segment Reporting Information [Line Items]    
Sales 99 72
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S.    
Segment Reporting Information [Line Items]    
Sales 83 71
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l    
Segment Reporting Information [Line Items]    
Sales 16 1
Pharmaceutical | Operating Segments | Adempas    
Segment Reporting Information [Line Items]    
Sales 59 61
Pharmaceutical | Operating Segments | Adempas | U.S.    
Segment Reporting Information [Line Items]    
Sales 0 0
Pharmaceutical | Operating Segments | Adempas | Int’l    
Segment Reporting Information [Line Items]    
Sales 59 61
Pharmaceutical | Operating Segments | Lagevrio    
Segment Reporting Information [Line Items]    
Sales 392 3,247
Pharmaceutical | Operating Segments | Lagevrio | U.S.    
Segment Reporting Information [Line Items]    
Sales (2) 1,523
Pharmaceutical | Operating Segments | Lagevrio | Int’l    
Segment Reporting Information [Line Items]    
Sales 394 1,723
Pharmaceutical | Operating Segments | Isentress/Isentress HD    
Segment Reporting Information [Line Items]    
Sales 123 158
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S.    
Segment Reporting Information [Line Items]    
Sales 52 61
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l    
Segment Reporting Information [Line Items]    
Sales 71 97
Pharmaceutical | Operating Segments | Belsomra    
Segment Reporting Information [Line Items]    
Sales 56 69
Pharmaceutical | Operating Segments | Belsomra | U.S.    
Segment Reporting Information [Line Items]    
Sales 16 20
Pharmaceutical | Operating Segments | Belsomra | Int’l    
Segment Reporting Information [Line Items]    
Sales 40 48
Pharmaceutical | Operating Segments | Simponi    
Segment Reporting Information [Line Items]    
Sales 180 186
Pharmaceutical | Operating Segments | Simponi | U.S.    
Segment Reporting Information [Line Items]    
Sales 0 0
Pharmaceutical | Operating Segments | Simponi | Int’l    
Segment Reporting Information [Line Items]    
Sales 180 186
Pharmaceutical | Operating Segments | Remicade    
Segment Reporting Information [Line Items]    
Sales 51 61
Pharmaceutical | Operating Segments | Remicade | U.S.    
Segment Reporting Information [Line Items]    
Sales 0 0
Pharmaceutical | Operating Segments | Remicade | Int’l    
Segment Reporting Information [Line Items]    
Sales 51 61
Pharmaceutical | Operating Segments | Januvia    
Segment Reporting Information [Line Items]    
Sales 551 779
Pharmaceutical | Operating Segments | Januvia | U.S.    
Segment Reporting Information [Line Items]    
Sales 271 325
Pharmaceutical | Operating Segments | Januvia | Int’l    
Segment Reporting Information [Line Items]    
Sales 280 454
Pharmaceutical | Operating Segments | Janumet    
Segment Reporting Information [Line Items]    
Sales 329 454
Pharmaceutical | Operating Segments | Janumet | U.S.    
Segment Reporting Information [Line Items]    
Sales 56 63
Pharmaceutical | Operating Segments | Janumet | Int’l    
Segment Reporting Information [Line Items]    
Sales 272 391
Pharmaceutical | Operating Segments | Other pharmaceutical    
Segment Reporting Information [Line Items]    
Sales 584 602
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S.    
Segment Reporting Information [Line Items]    
Sales 172 160
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l    
Segment Reporting Information [Line Items]    
Sales 414 443
Animal Health | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 1,491 1,482
Animal Health | Operating Segments | U.S.    
Segment Reporting Information [Line Items]    
Sales 482 473
Animal Health | Operating Segments | Int’l    
Segment Reporting Information [Line Items]    
Sales 1,010 1,009
Animal Health | Operating Segments | Livestock    
Segment Reporting Information [Line Items]    
Sales 849 832
Animal Health | Operating Segments | Livestock | U.S.    
Segment Reporting Information [Line Items]    
Sales 174 171
Animal Health | Operating Segments | Livestock | Int’l    
Segment Reporting Information [Line Items]    
Sales 676 661
Animal Health | Operating Segments | Companion Animals    
Segment Reporting Information [Line Items]    
Sales 642 650
Animal Health | Operating Segments | Companion Animals | U.S.    
Segment Reporting Information [Line Items]    
Sales 308 302
Animal Health | Operating Segments | Companion Animals | Int’l    
Segment Reporting Information [Line Items]    
Sales $ 334 $ 348
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting - Consolidated Sales by Geographic Area (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue from External Customer [Line Items]    
Sales $ 14,487 $ 15,901
United States    
Revenue from External Customer [Line Items]    
Sales 6,659 7,339
Europe, Middle East and Africa    
Revenue from External Customer [Line Items]    
Sales 3,303 4,359
China    
Revenue from External Customer [Line Items]    
Sales 1,715 1,143
Asia Pacific (other than China and Japan)    
Revenue from External Customer [Line Items]    
Sales 846 930
Japan    
Revenue from External Customer [Line Items]    
Sales 758 989
Latin America    
Revenue from External Customer [Line Items]    
Sales 661 607
Other    
Revenue from External Customer [Line Items]    
Sales $ 545 $ 534
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Segment Reporting Information [Line Items]    
Profits $ 3,650,000 $ 4,861,000
Interest income 112,000 7,000
Interest expense (242,000) (243,000)
Amortization (543,000) (699,000)
Depreciation (448,000) (421,000)
Research and development (4,276,000) (2,576,000)
Restructuring costs (67,000) (53,000)
Operating Segments    
Segment Reporting Information [Line Items]    
Profits 9,706,000 10,086,000
Operating Segments | Pharmaceutical segment    
Segment Reporting Information [Line Items]    
Profits 9,140,000 9,501,000
Operating Segments | Animal Health segment    
Segment Reporting Information [Line Items]    
Profits 566,000 585,000
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Profits 164,000 194,000
Segment Reconciling Items    
Segment Reporting Information [Line Items]    
Interest income 112,000 7,000
Interest expense (242,000) (243,000)
Amortization (543,000) (699,000)
Depreciation (398,000) (378,000)
Research and development (4,147,000) (2,446,000)
Restructuring costs (67,000) (53,000)
Charge for Zetia antitrust litigation settlements (573,000) 0
Other unallocated, net $ (362,000) $ (1,607,000)
XML 76 mrk-20230331_htm.xml IDEA: XBRL DOCUMENT 0000310158 2023-01-01 2023-03-31 0000310158 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000310158 mrk:A0.500Notesdue2024Member 2023-01-01 2023-03-31 0000310158 mrk:A1.875Notesdue2026Member 2023-01-01 2023-03-31 0000310158 mrk:A2.500Notesdue2034Member 2023-01-01 2023-03-31 0000310158 mrk:A1.375Notesdue2036Member 2023-01-01 2023-03-31 0000310158 2023-04-30 0000310158 2022-01-01 2022-03-31 0000310158 2023-03-31 0000310158 2022-12-31 0000310158 2021-12-31 0000310158 2022-03-31 0000310158 mrk:PrometheusBiosciencesIncMember us-gaap:SubsequentEventMember 2023-04-30 0000310158 mrk:PrometheusBiosciencesIncMember us-gaap:SubsequentEventMember 2023-04-01 2023-04-30 0000310158 mrk:PrometheusBiosciencesIncMember us-gaap:SubsequentEventMember 2023-07-01 2023-09-30 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-02-01 2023-02-28 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-02-28 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-01 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2022-03-31 0000310158 mrk:LynparzaMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:LynparzaMember us-gaap:OtherNoncurrentAssetsMember 2023-03-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2023-03-31 0000310158 mrk:LenvimaMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-03-31 0000310158 mrk:LenvimaMember us-gaap:OtherNoncurrentAssetsMember 2023-03-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000310158 mrk:VerquvoMember us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:BayerAGMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2023-03-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:BristolMyersSquibbMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0000310158 mrk:BristolMyersSquibbMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0000310158 mrk:BristolMyersSquibbMember us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0000310158 mrk:BristolMyersSquibbMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 mrk:BristolMyersSquibbMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0000310158 mrk:BristolMyersSquibbMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-03-31 0000310158 srt:MinimumMember mrk:TransitionServicesAgreementMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:TransitionServicesAgreementMember 2021-06-02 2021-06-02 0000310158 srt:MinimumMember mrk:ManufacturingAndSupplyAgreementsMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:ManufacturingAndSupplyAgreementsMember 2021-06-02 2021-06-02 0000310158 mrk:OrganonCoMember 2023-01-01 2023-03-31 0000310158 mrk:OrganonCoMember 2022-01-01 2022-03-31 0000310158 mrk:OrganonCoMember 2023-03-31 0000310158 mrk:OrganonCoMember 2022-12-31 0000310158 srt:ScenarioForecastMember 2023-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2023-01-01 2023-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2023-01-01 2023-03-31 0000310158 us-gaap:RestructuringChargesMember 2023-01-01 2023-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2023-01-01 2023-03-31 0000310158 mrk:AcceleratedDepreciationMember 2023-01-01 2023-03-31 0000310158 us-gaap:OtherRestructuringMember 2023-01-01 2023-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-03-31 0000310158 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2022-01-01 2022-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-03-31 0000310158 us-gaap:RestructuringChargesMember 2022-01-01 2022-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-03-31 0000310158 mrk:AcceleratedDepreciationMember 2022-01-01 2022-03-31 0000310158 us-gaap:OtherRestructuringMember 2022-01-01 2022-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2022-12-31 0000310158 mrk:AcceleratedDepreciationMember 2022-12-31 0000310158 us-gaap:OtherRestructuringMember 2022-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2023-03-31 0000310158 mrk:AcceleratedDepreciationMember 2023-03-31 0000310158 us-gaap:OtherRestructuringMember 2023-03-31 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 2023-03-31 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember 2022-01-01 2022-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-03-31 0000310158 mrk:EurodominatedNotesMember 2023-01-01 2023-03-31 0000310158 mrk:EurodominatedNotesMember 2022-01-01 2022-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-03-31 0000310158 us-gaap:SubsequentEventMember 2023-04-30 0000310158 us-gaap:InterestRateSwapMember 2023-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:SubsequentEventMember 2023-04-30 0000310158 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-03-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-03-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-03-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-03-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000310158 us-gaap:NondesignatedMember 2023-03-31 0000310158 us-gaap:NondesignatedMember 2022-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-01 2022-03-31 0000310158 us-gaap:InterestRateSwapMember 2023-01-01 2023-03-31 0000310158 us-gaap:InterestRateSwapMember 2022-01-01 2022-03-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-03-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2022-01-01 2022-03-31 0000310158 us-gaap:CommercialPaperMember 2023-03-31 0000310158 us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:EquityFundsMember 2023-01-01 2023-03-31 0000310158 us-gaap:EquityFundsMember 2022-01-01 2022-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member 2023-03-31 0000310158 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000310158 mrk:SanofiPasteurMember 2023-03-31 0000310158 2022-01-01 2022-06-30 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2023-03-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2022-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2023-03-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2022-12-31 0000310158 mrk:GardasilGardasil9Member country:US 2023-03-31 0000310158 mrk:GardasilGardasil9Member us-gaap:NonUsMember 2023-03-31 0000310158 mrk:GardasilGardasil9Member country:CO 2023-03-31 0000310158 mrk:ZetiaantitrustlitigationMember 2020-08-31 0000310158 mrk:ZetiaantitrustlitigationMember us-gaap:PendingLitigationMember 2022-06-30 2022-06-30 0000310158 mrk:ZetiaantitrustlitigationMember 2023-01-01 2023-03-31 0000310158 mrk:RotaTeqAntitrustLitigationMember us-gaap:PendingLitigationMember 2023-03-03 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2022-12-19 2022-12-19 0000310158 us-gaap:PatentsMember mrk:BridionMember 2023-01-01 2023-03-31 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2023-03-31 0000310158 us-gaap:PatentsMember mrk:JanuviaAndJanumetMember 2023-01-01 2023-03-31 0000310158 mrk:ComplaintAgainstTheJohnsHopkinsUniversityMember us-gaap:PendingLitigationMember us-gaap:SubsequentEventMember 2023-04-13 2023-04-13 0000310158 mrk:LegalDefenseCostsMember 2023-03-31 0000310158 mrk:LegalDefenseCostsMember 2022-12-31 0000310158 us-gaap:CommonStockMember 2021-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2021-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2021-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000310158 us-gaap:CommonStockMember 2022-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000310158 us-gaap:RetainedEarningsMember 2022-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-03-31 0000310158 us-gaap:CommonStockMember 2022-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-12-31 0000310158 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000310158 us-gaap:CommonStockMember 2023-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000310158 us-gaap:RetainedEarningsMember 2023-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000310158 us-gaap:TreasuryStockCommonMember 2023-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2023-03-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember 2023-01-01 2023-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2022-01-01 2022-03-31 0000310158 us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2023-01-01 2023-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2023-01-01 2023-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2022-01-01 2022-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000310158 country:US 2023-01-01 2023-03-31 0000310158 mrk:InternationalMember 2023-01-01 2023-03-31 0000310158 country:US 2022-01-01 2022-03-31 0000310158 mrk:InternationalMember 2022-01-01 2022-03-31 0000310158 us-gaap:EMEAMember 2023-01-01 2023-03-31 0000310158 us-gaap:EMEAMember 2022-01-01 2022-03-31 0000310158 country:CN 2023-01-01 2023-03-31 0000310158 country:CN 2022-01-01 2022-03-31 0000310158 srt:AsiaPacificMember 2023-01-01 2023-03-31 0000310158 srt:AsiaPacificMember 2022-01-01 2022-03-31 0000310158 country:JP 2023-01-01 2023-03-31 0000310158 country:JP 2022-01-01 2022-03-31 0000310158 srt:LatinAmericaMember 2023-01-01 2023-03-31 0000310158 srt:LatinAmericaMember 2022-01-01 2022-03-31 0000310158 mrk:OtherCountriesMember 2023-01-01 2023-03-31 0000310158 mrk:OtherCountriesMember 2022-01-01 2022-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-03-31 shares iso4217:USD iso4217:USD shares pure mrk:interest_rate_swap mrk:case mrk:direct_purchaser mrk:claim mrk:state mrk:company mrk:patent mrk:segment false 2023 Q1 0000310158 --12-31 http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent 10-Q true 2023-03-31 false 1-6571 Merck & Co., Inc. NJ 22-1918501 126 East Lincoln Avenue Rahway NJ 07065 (908) 740-4000 Common Stock ($0.50 par value) MRK NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE Yes Yes Large Accelerated Filer false false false 2537435954 14487000000 15901000000 3926000000 5380000000 2479000000 2323000000 4276000000 2576000000 67000000 53000000 -89000000 -708000000 10837000000 11040000000 3650000000 4861000000 825000000 554000000 2825000000 4307000000 4000000 -3000000 2821000000 4310000000 1.11 1.70 1.11 1.70 2821000000 4310000000 -133000000 63000000 50000000 -32000000 68000000 -35000000 -115000000 60000000 2706000000 4370000000 9707000000 12694000000 680000000 498000000 76000000 72000000 10415000000 9450000000 3284000000 2938000000 5863000000 5911000000 6737000000 7169000000 33402000000 35722000000 1290000000 1015000000 18256000000 17985000000 21758000000 21422000000 21209000000 21204000000 19857000000 20269000000 10280000000 9528000000 107796000000 109160000000 2672000000 1946000000 3680000000 4264000000 13000000000 14159000000 1872000000 1986000000 1907000000 1884000000 23131000000 24239000000 28074000000 28745000000 1442000000 1795000000 8244000000 8323000000 0.50 0.50 6500000000 6500000000 3577103522 3577103522 1788000000 1788000000 44467000000 44379000000 62039000000 61081000000 -4883000000 -4768000000 103411000000 102480000000 1039651210 1039269638 56577000000 56489000000 46834000000 45991000000 71000000 67000000 46905000000 46058000000 107796000000 109160000000 2825000000 4307000000 543000000 699000000 448000000 421000000 450000000 -708000000 1192000000 0 -277000000 -338000000 145000000 120000000 197000000 -143000000 2890000000 1299000000 1339000000 4761000000 1007000000 984000000 562000000 372000000 500000000 1000000 1327000000 0 -37000000 -182000000 -2359000000 -1173000000 1000000 1250000000 149000000 0 1853000000 1745000000 30000000 12000000 -81000000 -103000000 -2054000000 -3086000000 87000000 -55000000 -2987000000 447000000 79000000 71000000 12773000000 8167000000 79000000 58000000 9786000000 8614000000 Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 24, 2023. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 24, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption Certain reclassifications have been made to prior year amounts to conform to the current year presentation. <div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption Acquisitions, Research Collaborations and Licensing Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus’ lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3 billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span> 200 10800000000 10300000000 175000000 1000000000 2800000000 5500000000 100000000 1350000000 60000000 219000000 1200000000 Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at March 31, 2023) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. Also in the first quarter of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400 million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca (which had been previously accrued for) of $105 million. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at March 31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125 million sales-based milestone payment from Merck to Eisai. Accordingly, Merck recorded a $125 million liability and a corresponding increase to the intangible asset related to Lenvima. Merck also recognized $72 million of cumulative amortization catch-up expense related to the recognition of this milestone. In 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million (of which $300 million was paid in the first quarter of 2022). Potential future sales-based milestone payments of $2.4 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai (of which $25 million was paid in the first quarter of 2022). There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $812 million at March 31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021, and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In the first quarter of 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $613 million and $56 million, respectively, at March 31, 2023 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue related to this collaboration within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32 million and the receipt of a regulatory approval milestone payment of $20 million).</span></div> 600000000 600000000 250000000 400000000 2100000000 105000000 250000000 1100000000 1500000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> 275000000 266000000 23000000 9000000 298000000 275000000 70000000 299000000 47000000 44000000 21000000 26000000 303000000 303000000 21000000 123000000 600000000 600000000 250000000 125000000 125000000 72000000 600000000 300000000 2400000000 50000000 25000000 812000000 232000000 227000000 126000000 53000000 51000000 31000000 39000000 57000000 244000000 214000000 125000000 0 72000000 400000000 613000000 56000000 99000000 72000000 59000000 61000000 7000000 3000000 165000000 136000000 57000000 50000000 33000000 23000000 25000000 17000000 142000000 143000000 68000000 80000000 392000000 3247000000 221000000 1726000000 27000000 35000000 16000000 25000000 191000000 348000000 0.20 0.24 0.50 80000000 43000000 52000000 32000000 20000000 Spin-Off of Organon &amp; Co. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $94 million and $99 million and related cost of sales of $107 million and $105 million for the first quarter of 2023 and 2022, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for both the first quarter of 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $473 million and $511 million at March 31, 2023 and December 31, 2022, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $229 million and $345 million at March 31, 2023 and December 31, 2022, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> P25M P35M P4Y P10Y 94000000 99000000 107000000 105000000 473000000 511000000 229000000 345000000 Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March 31, 2023, Merck has recorded total pretax accumulated costs of approximately $3.4 billion. For the full year of 2023, the Company expects to record charges of approximately $400 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other activity in 2023 and 2022 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March 31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be largely completed by the end of 2025. 3700000000 0.70 0.30 97000000 127000000 3400000000 400000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0 21000000 8000000 29000000 0 0 1000000 1000000 41000000 0 26000000 67000000 41000000 21000000 35000000 97000000 0 18000000 28000000 46000000 0 4000000 17000000 21000000 0 7000000 0 7000000 26000000 0 27000000 53000000 26000000 29000000 72000000 127000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March 31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be largely completed by the end of 2025. 479000000 0 34000000 513000000 41000000 21000000 35000000 97000000 47000000 0 27000000 74000000 0 -21000000 -9000000 -30000000 473000000 0 33000000 506000000 Financial Instruments<div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. In March 2023, the Company entered into five forward starting swaps and in April 2023 entered into two additional forward starting swaps, each with a notional amount of $100 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">Other Assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">Other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,215 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,507 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,466 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,361 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,681 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.359%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2023, the Company estimates $71 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,345 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,853 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains of $338 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March 31, 2023. Unrealized net losses of $225 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2022 on equity securities still held at March 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2023 and March 31, 2022, the Company also had $942 million and $643 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $1 million and unrealized losses of $21 million related to certain of these equity investments still held at March 31, 2023. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $14 million related to certain of these investments still held at March 31, 2022. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March 31, 2023 were $287 million and $40 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March 31, 2023 and March 31, 2022, the Company also had $725 million and $1.2 billion, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. (Gains) losses recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $(132) million and $509 million for the first quarter of 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,659 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,604 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,286 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $8.8 billion and $11.3 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At March 31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March 31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2023, was $28.2 billion compared with a carrying value of $30.7 billion and at December 31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable as of March 31, 2023 and December 31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March 31, 2023 and December 31, 2022, the Company had collected $31 million and $67 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in April 2023 and January 2023, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $13 million and $66 million at March 31, 2023 and December 31, 2022, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>. Cash collateral advanced by the Company to various counterparties was $19 million at December 31, 2022. P2Y P6M <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div> -1000000 16000000 -1000000 1000000 -52000000 53000000 0 0 5 2 100000000 100000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">Other Assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">Other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,824 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,691 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,215 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,507 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,466 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,361 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,681 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1000000 300000000 0 0 1000000 200000000 0 0 104000000 4253000000 220000000 4824000000 32000000 1756000000 27000000 1609000000 116000000 3444000000 101000000 2691000000 2000000 120000000 1000000 91000000 137000000 119000000 10073000000 247000000 102000000 9215000000 121000000 9507000000 186000000 8540000000 1000000 65000000 0 0 164000000 10592000000 307000000 10926000000 1000000 124000000 0 0 122000000 165000000 20288000000 186000000 307000000 19466000000 259000000 284000000 30361000000 433000000 409000000 28681000000 The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 259000000 284000000 433000000 409000000 148000000 148000000 220000000 220000000 13000000 0 66000000 19000000 98000000 136000000 147000000 170000000 <div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div> 14487000000 15901000000 -89000000 -708000000 -115000000 60000000 0 10000000 0 -4000000 -66000000 148000000 101000000 67000000 -101000000 -67000000 1000000 1000000 -1000000 -1000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.359%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> -13000000 -28000000 -2000000 2000000 -71000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,345 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,853 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains of $338 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March 31, 2023. Unrealized net losses of $225 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2022 on equity securities still held at March 31, 2022.</span></div> 663000000 0 0 663000000 498000000 0 0 498000000 92000000 0 0 92000000 68000000 0 0 68000000 4000000 0 0 4000000 3000000 0 0 3000000 1000000 0 0 1000000 0 0 0 0 760000000 0 0 760000000 569000000 0 0 569000000 1585000000 1284000000 2345000000 1853000000 338000000 -225000000 942000000 643000000 1000000 21000000 14000000 287000000 40000000 725000000 1200000000 132000000 -509000000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,659 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,604 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,286 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div> 0 663000000 0 663000000 0 498000000 0 498000000 0 22000000 0 22000000 0 0 0 0 0 1000000 0 1000000 0 0 0 0 1284000000 0 0 1284000000 1015000000 0 0 1015000000 1284000000 686000000 0 1970000000 1015000000 498000000 0 1513000000 70000000 0 0 70000000 68000000 0 0 68000000 4000000 0 0 4000000 3000000 0 0 3000000 301000000 0 0 301000000 269000000 0 0 269000000 375000000 0 0 375000000 340000000 0 0 340000000 0 139000000 0 139000000 0 215000000 0 215000000 0 119000000 0 119000000 0 218000000 0 218000000 0 1000000 0 1000000 0 0 0 0 0 259000000 0 259000000 0 433000000 0 433000000 1659000000 945000000 0 2604000000 1355000000 931000000 0 2286000000 0 0 353000000 353000000 0 0 456000000 456000000 0 276000000 0 276000000 0 402000000 0 402000000 0 7000000 0 7000000 0 7000000 0 7000000 0 1000000 0 1000000 0 0 0 0 0 284000000 0 284000000 0 409000000 0 409000000 0 284000000 353000000 637000000 0 409000000 456000000 865000000 8800000000 11300000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At March 31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March 31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div> 456000000 777000000 14000000 -84000000 117000000 119000000 0 2000000 353000000 572000000 263000000 0.115 127000000 28200000000 30700000000 26700000000 30700000000 2400000000 2500000000 31000000 67000000 13000000 66000000 19000000 Inventories<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,284 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At March 31, 2023 and December 31, 2022, these amounts included $2.7 billion and $2.4 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $590 million and $516 million at March 31, 2023 and December 31, 2022, respectively, of inventories produced in preparation for product launches.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,142 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,284 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1883000000 1841000000 7348000000 7063000000 266000000 238000000 9497000000 9142000000 350000000 293000000 9147000000 8849000000 5863000000 5911000000 3284000000 2938000000 2700000000 2400000000 590000000 516000000 Contingencies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March 31, 2023, approximately 95 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, Merck Sharp &amp; Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. In April 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 10, 2023, the district court denied the Merck Defendants’ and Glenmark Defendants’ motions for summary judgment. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck will pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs’ claims, which was recorded as an expense in the Company’s first quarter 2023 financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 3, 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, trebled, and fees and costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal in February 2022 and issued a decision in April 2022 allowing both parties’ appeals in part. The Court of Appeal amended the class period to start on July 2, 2014, allowed a second plaintiff to serve as a class representative, and modified the list of conditions in the class definition by adding “death” and removing “lack of efficacy.” The Court of Appeal also added to the list of questions to be considered by the trial court the questions of whether the Consumer Protection Act of Quebec applies to the sale of a veterinary product and, if so, whether it was breached. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered post-trial briefing on this defense and held closing arguments on February 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCI), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the District Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit. The parties have now settled the matter, and Mylan has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held in August 2022. In September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In total, the Company has settled with 25 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus has filed a NDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary Protection Certificates (SPCs) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expired between April 7 and 10, 2023, for the majority of European countries. Prior to expiration, generic companies sought revocation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs in Europe, for which an oral hearing was held on March 8, 2023, and an Advocate General Opinion is expected on July 13, 2023. If the CJEU renders a decision that negatively impacts the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and JHU partnered to design and conduct a clinical study administering </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract; declaratory judgment of noninfringement; and promissory estoppel. JHU answered the complaint on April 13, 2023, denying Merck’s claims, and counterclaiming for willful infringement of five issued U.S. patents, including a demand for damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2023 and December 31, 2022 of approximately $225 million and $230 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div> Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. 95 15 1 35 23 -572500000 35 P1D 5 2 25 5 225000000 230000000 Equity<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,379 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,081 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,489)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,058 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.73 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,467 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,039 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,577)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,905 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,379 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,081 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,489)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,058 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.73 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,467 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,039 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,577)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,905 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3577000000 1788000000 44238000000 53696000000 -4429000000 1049000000 -57109000000 73000000 38257000000 4310000000 4310000000 60000000 60000000 0.69 1754000000 1754000000 -37000000 -46000000 -83000000 3000000 3000000 3577000000 1788000000 44275000000 56252000000 -4369000000 1049000000 -57063000000 70000000 40953000000 3577000000 1788000000 44379000000 61081000000 -4768000000 1039000000 -56489000000 67000000 46058000000 2821000000 2821000000 -115000000 -115000000 0.73 1863000000 1863000000 1000000 149000000 149000000 -88000000 -61000000 -149000000 -4000000 -4000000 3577000000 1788000000 44467000000 62039000000 -4883000000 1040000000 -56577000000 71000000 46905000000 Pension and Other Postretirement Benefit Plans<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gain) loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21 million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company’s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March 31, 2023, resulted in a net increase of $44 million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note 11), with the exception of certain amounts for termination benefits and curtailments which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits or curtailment is related to restructuring actions.</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gain) loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 76000000 49000000 99000000 75000000 133000000 74000000 103000000 38000000 187000000 128000000 196000000 101000000 0 -3000000 -8000000 -4000000 0 1000000 -56000000 -25000000 -2000000 0 -3000000 0 -21000000 0 -1000000 0 45000000 -9000000 58000000 33000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 8000000 12000000 16000000 11000000 16000000 21000000 -12000000 -14000000 11000000 11000000 -15000000 -23000000 21000000 -44000000 Other (Income) Expense, Net<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first quarter of 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 8).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid for the three months ended March 31, 2023 and 2022 was $208 million and $211 million, respectively.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. 112000000 7000000 242000000 243000000 -61000000 -39000000 450000000 -708000000 -115000000 -121000000 -463000000 154000000 -89000000 -708000000 -572500000 208000000 211000000 Taxes on IncomeThe effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&amp;D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company’s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate. 0.226 0.114 0 Earnings Per Share<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,528 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">    Issuable primarily under share-based compensation plans.</span></div>For the first quarter of 2023 and 2022, 1 million and 7 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,528 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,551 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">    Issuable primarily under share-based compensation plans.</span></div> 2821000000 2821000000 4310000000 4310000000 2538000000 2528000000 13000000 9000000 2551000000 2537000000 1.11 1.70 1.11 1.70 1000000 7000000 Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,458)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,365)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,458)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,365)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 144000000 -2743000000 -1830000000 -4429000000 148000000 1000000 -18000000 131000000 31000000 2000000 17000000 50000000 117000000 -1000000 -35000000 81000000 68000000 -45000000 0 23000000 14000000 -12000000 0 2000000 54000000 -33000000 0 21000000 63000000 32000000 -35000000 60000000 207000000 -2711000000 -1865000000 -4369000000 73000000 -2408000000 -2433000000 -4768000000 -66000000 -47000000 79000000 -34000000 -14000000 -2000000 20000000 4000000 -52000000 -45000000 59000000 -38000000 102000000 7000000 -9000000 100000000 21000000 2000000 0 23000000 81000000 5000000 -9000000 77000000 -133000000 -50000000 68000000 -115000000 -60000000 -2458000000 -2365000000 -4883000000 Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,599 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,212 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,246 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,339 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,563 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99 million and $69 million for the three months ended March 31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2023 and 2022 also includes $51 million and $114 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.1 billion and $2.9 billion for the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,901 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.528%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,086 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,607)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div> 2 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,972 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,482 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,599 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,212 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,246 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,828 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,339 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,563 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99 million and $69 million for the three months ended March 31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March 31, 2023 and 2022 also includes $51 million and $114 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div> 3485000000 2310000000 5795000000 2779000000 2030000000 4809000000 142000000 133000000 275000000 141000000 125000000 266000000 153000000 79000000 232000000 156000000 71000000 227000000 30000000 12000000 43000000 27000000 25000000 52000000 41000000 1000000 42000000 18000000 0 18000000 416000000 1556000000 1972000000 418000000 1042000000 1460000000 421000000 107000000 528000000 371000000 99000000 470000000 180000000 117000000 297000000 175000000 41000000 216000000 94000000 13000000 106000000 5000000 0 5000000 40000000 56000000 96000000 118000000 55000000 173000000 30000000 10000000 40000000 29000000 7000000 36000000 276000000 210000000 487000000 195000000 199000000 395000000 54000000 75000000 129000000 40000000 54000000 94000000 4000000 76000000 80000000 1000000 58000000 58000000 62000000 3000000 65000000 49000000 3000000 52000000 14000000 46000000 60000000 10000000 48000000 57000000 27000000 23000000 50000000 18000000 12000000 30000000 83000000 16000000 99000000 71000000 1000000 72000000 0 59000000 59000000 0 61000000 61000000 -2000000 394000000 392000000 1523000000 1723000000 3247000000 52000000 71000000 123000000 61000000 97000000 158000000 16000000 40000000 56000000 20000000 48000000 69000000 0 180000000 180000000 0 186000000 186000000 0 51000000 51000000 0 61000000 61000000 271000000 280000000 551000000 325000000 454000000 779000000 56000000 272000000 329000000 63000000 391000000 454000000 172000000 414000000 584000000 160000000 443000000 602000000 6117000000 6604000000 12721000000 6773000000 7334000000 14107000000 174000000 676000000 849000000 171000000 661000000 832000000 308000000 334000000 642000000 302000000 348000000 650000000 482000000 1010000000 1491000000 473000000 1009000000 1482000000 6599000000 7614000000 14212000000 7246000000 8343000000 15589000000 60000000 214000000 275000000 93000000 220000000 312000000 6659000000 7828000000 14487000000 7339000000 8563000000 15901000000 99000000 69000000 51000000 114000000 3100000000 2900000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,901 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 6659000000 7339000000 3303000000 4359000000 1715000000 1143000000 846000000 930000000 758000000 989000000 661000000 607000000 545000000 534000000 14487000000 15901000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.528%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,501 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,086 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,607)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 9140000000 9501000000 566000000 585000000 9706000000 10086000000 164000000 194000000 112000000 7000000 242000000 243000000 543000000 699000000 398000000 378000000 4147000000 2446000000 67000000 53000000 -573000000 0 362000000 1607000000 3650000000 4861000000 EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 577 298 1 false 134 0 false 12 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.merck.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME CONDENSED CONSOLIDATED STATEMENT OF INCOME Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET CONDENSED CONSOLIDATED BALANCE SHEET Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation Sheet http://www.merck.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 0000009 - Disclosure - Spin-Off of Organon & Co. Sheet http://www.merck.com/role/SpinOffofOrganonCo Spin-Off of Organon & Co. Notes 9 false false R10.htm 0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements Acquisitions, Research Collaborations and License Agreements Notes 10 false false R11.htm 0000011 - Disclosure - Collaborative Arrangements Sheet http://www.merck.com/role/CollaborativeArrangements Collaborative Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Restructuring Sheet http://www.merck.com/role/Restructuring Restructuring Notes 12 false false R13.htm 0000013 - Disclosure - Financial Instruments Sheet http://www.merck.com/role/FinancialInstruments Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Inventories Sheet http://www.merck.com/role/Inventories Inventories Notes 14 false false R15.htm 0000015 - Disclosure - Contingencies Sheet http://www.merck.com/role/Contingencies Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Equity Sheet http://www.merck.com/role/Equity Equity Notes 16 false false R17.htm 0000017 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 17 false false R18.htm 0000018 - Disclosure - Other (Income) Expense, Net Sheet http://www.merck.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 18 false false R19.htm 0000019 - Disclosure - Taxes on Income Sheet http://www.merck.com/role/TaxesonIncome Taxes on Income Notes 19 false false R20.htm 0000020 - Disclosure - Earnings Per Share Sheet http://www.merck.com/role/EarningsPerShare Earnings Per Share Notes 20 false false R21.htm 0000021 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 21 false false R22.htm 0000022 - Disclosure - Segment Reporting Sheet http://www.merck.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 0000023 - Disclosure - Basis of Presentation (Policies) Sheet http://www.merck.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 23 false false R24.htm 0000024 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.merck.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.merck.com/role/CollaborativeArrangements 24 false false R25.htm 0000025 - Disclosure - Restructuring (Tables) Sheet http://www.merck.com/role/RestructuringTables Restructuring (Tables) Tables http://www.merck.com/role/Restructuring 25 false false R26.htm 0000026 - Disclosure - Financial Instruments (Tables) Sheet http://www.merck.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.merck.com/role/FinancialInstruments 26 false false R27.htm 0000027 - Disclosure - Inventories (Tables) Sheet http://www.merck.com/role/InventoriesTables Inventories (Tables) Tables http://www.merck.com/role/Inventories 27 false false R28.htm 0000028 - Disclosure - Equity (Tables) Sheet http://www.merck.com/role/EquityTables Equity (Tables) Tables http://www.merck.com/role/Equity 28 false false R29.htm 0000029 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans 29 false false R30.htm 0000030 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.merck.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.merck.com/role/OtherIncomeExpenseNet 30 false false R31.htm 0000031 - Disclosure - Earnings Per Share (Tables) Sheet http://www.merck.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.merck.com/role/EarningsPerShare 31 false false R32.htm 0000032 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.merck.com/role/OtherComprehensiveIncomeLoss 32 false false R33.htm 0000033 - Disclosure - Segment Reporting (Tables) Sheet http://www.merck.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.merck.com/role/SegmentReporting 33 false false R34.htm 0000034 - Disclosure - Spin-Off of Organon & Co. (Details) Sheet http://www.merck.com/role/SpinOffofOrganonCoDetails Spin-Off of Organon & Co. (Details) Details http://www.merck.com/role/SpinOffofOrganonCo 34 false false R35.htm 0000035 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails Acquisitions, Research Collaborations and License Agreements (Details) Details http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements 35 false false R36.htm 0000036 - Disclosure - Collaborative Arrangements - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails Collaborative Arrangements - Narrative (Details) Details 36 false false R37.htm 0000037 - Disclosure - Collaborative Arrangements - Financial Information (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails Collaborative Arrangements - Financial Information (Details) Details 37 false false R38.htm 0000038 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.merck.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 38 false false R39.htm 0000039 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) Sheet http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails Restructuring - Charges Activities by Type of Cost (Details) Details 39 false false R40.htm 0000040 - Disclosure - Restructuring - Activities by Program (Details) Sheet http://www.merck.com/role/RestructuringActivitiesbyProgramDetails Restructuring - Activities by Program (Details) Details 40 false false R41.htm 0000041 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.merck.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 41 false false R42.htm 0000042 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails Financial Instruments - Effect of Net Investment Hedges (Details) Details 42 false false R43.htm 0000043 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Details 43 false false R44.htm 0000044 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Details 44 false false R45.htm 0000045 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Sheet http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Details 45 false false R46.htm 0000046 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Details 46 false false R47.htm 0000047 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails Financial Instruments - Information on Available-for-sale Investments (Details) Details 47 false false R48.htm 0000048 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 48 false false R49.htm 0000049 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Details 49 false false R50.htm 0000050 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.merck.com/role/InventoriesScheduleofInventoriesDetails Inventories - Schedule of Inventories (Details) Details 50 false false R51.htm 0000051 - Disclosure - Inventories - Narrative (Details) Sheet http://www.merck.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 51 false false R52.htm 0000052 - Disclosure - Contingencies (Details) Sheet http://www.merck.com/role/ContingenciesDetails Contingencies (Details) Details http://www.merck.com/role/Contingencies 52 false false R53.htm 0000053 - Disclosure - Equity (Details) Sheet http://www.merck.com/role/EquityDetails Equity (Details) Details http://www.merck.com/role/EquityTables 53 false false R54.htm 0000054 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) Details 54 false false R55.htm 0000055 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails Pension and Other Postretirement Benefit Plans - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 56 false false R57.htm 0000057 - Disclosure - Other (Income) Expense, Net - Narrative (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails Other (Income) Expense, Net - Narrative (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 57 false false R58.htm 0000058 - Disclosure - Taxes on Income (Details) Sheet http://www.merck.com/role/TaxesonIncomeDetails Taxes on Income (Details) Details http://www.merck.com/role/TaxesonIncome 58 false false R59.htm 0000059 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) Sheet http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails Earnings Per Share - Calculations of Earnings Per Share (Details) Details 59 false false R60.htm 0000060 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://www.merck.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 60 false false R61.htm 0000061 - Disclosure - Other Comprehensive Income (Loss) (Details) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossDetails Other Comprehensive Income (Loss) (Details) Details http://www.merck.com/role/OtherComprehensiveIncomeLossTables 61 false false R62.htm 0000062 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.merck.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 62 false false R63.htm 0000063 - Disclosure - Segment Reporting - Sales from Products (Details) Sheet http://www.merck.com/role/SegmentReportingSalesfromProductsDetails Segment Reporting - Sales from Products (Details) Details 63 false false R64.htm 0000064 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails Segment Reporting - Consolidated Sales by Geographic Area (Details) Details 64 false false R65.htm 0000065 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) Sheet http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) Details 65 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrk-20230331.htm 4 [dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrk-20230331.htm 4 [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrk-20230331.htm 4 mrk-20230331.htm exhibit311-rule13ax14a15dx.htm exhibit312-rule13ax14a15dx.htm exhibit321-section1350cert.htm exhibit322-section1350cert.htm mrk-20230331.xsd mrk-20230331_cal.xml mrk-20230331_def.xml mrk-20230331_lab.xml mrk-20230331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mrk-20230331.htm": { "axisCustom": 0, "axisStandard": 31, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 1204, "http://xbrl.sec.gov/dei/2022": 41 }, "contextCount": 577, "dts": { "calculationLink": { "local": [ "mrk-20230331_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20230331_def.xml" ] }, "inline": { "local": [ "mrk-20230331.htm" ] }, "labelLink": { "local": [ "mrk-20230331_lab.xml" ] }, "presentationLink": { "local": [ "mrk-20230331_pre.xml" ] }, "schema": { "local": [ "mrk-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 565, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 20, "http://xbrl.sec.gov/dei/2022": 5, "total": 25 }, "keyCustom": 33, "keyStandard": 265, "memberCustom": 65, "memberStandard": 66, "nsprefix": "mrk", "nsuri": "http://www.merck.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.merck.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements", "menuCat": "Notes", "order": "10", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements", "shortName": "Acquisitions, Research Collaborations and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Collaborative Arrangements", "menuCat": "Notes", "order": "11", "role": "http://www.merck.com/role/CollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Restructuring", "menuCat": "Notes", "order": "12", "role": "http://www.merck.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Financial Instruments", "menuCat": "Notes", "order": "13", "role": "http://www.merck.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Inventories", "menuCat": "Notes", "order": "14", "role": "http://www.merck.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Contingencies", "menuCat": "Notes", "order": "15", "role": "http://www.merck.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Equity", "menuCat": "Notes", "order": "16", "role": "http://www.merck.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Pension and Other Postretirement Benefit Plans", "menuCat": "Notes", "order": "17", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans", "shortName": "Pension and Other Postretirement Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Other (Income) Expense, Net", "menuCat": "Notes", "order": "18", "role": "http://www.merck.com/role/OtherIncomeExpenseNet", "shortName": "Other (Income) Expense, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Taxes on Income", "menuCat": "Notes", "order": "19", "role": "http://www.merck.com/role/TaxesonIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME", "menuCat": "Statements", "order": "2", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "mrk:CostsExpensesAndOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "20", "role": "http://www.merck.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Other Comprehensive Income (Loss)", "menuCat": "Notes", "order": "21", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss", "shortName": "Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "22", "role": "http://www.merck.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Basis of Presentation (Policies)", "menuCat": "Policies", "order": "23", "role": "http://www.merck.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Collaborative Arrangements (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.merck.com/role/CollaborativeArrangementsTables", "shortName": "Collaborative Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Restructuring (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.merck.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Financial Instruments (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.merck.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.merck.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Equity (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.merck.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "3", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Other (Income) Expense, Net (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables", "shortName": "Other (Income) Expense, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.merck.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables", "shortName": "Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.merck.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Spin-Off of Organon & Co. (Details)", "menuCat": "Details", "order": "34", "role": "http://www.merck.com/role/SpinOffofOrganonCoDetails", "shortName": "Spin-Off of Organon & Co. (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)", "menuCat": "Details", "order": "35", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "shortName": "Acquisitions, Research Collaborations and License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i1302ee97335a4b8a864d880d15a75ffd_I20230430", "decimals": "2", "lang": "en-US", "name": "mrk:AssetAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Collaborative Arrangements - Narrative (Details)", "menuCat": "Details", "order": "36", "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "shortName": "Collaborative Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Collaborative Arrangements - Financial Information (Details)", "menuCat": "Details", "order": "37", "role": "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "shortName": "Collaborative Arrangements - Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5973fb4a5d684bcca7a62270623ac406_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Restructuring - Narrative (Details)", "menuCat": "Details", "order": "38", "role": "http://www.merck.com/role/RestructuringNarrativeDetails", "shortName": "Restructuring - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)", "menuCat": "Details", "order": "39", "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "shortName": "Restructuring - Charges Activities by Type of Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET", "menuCat": "Statements", "order": "4", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Restructuring - Activities by Program (Details)", "menuCat": "Details", "order": "40", "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "shortName": "Restructuring - Activities by Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "interest_rate_swap", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Financial Instruments - Narrative (Details)", "menuCat": "Details", "order": "41", "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "reportCount": 1, "unique": true, "unitRef": "interest_rate_swap", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)", "menuCat": "Details", "order": "42", "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "menuCat": "Details", "order": "43", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i2a06f418da43474f9f2f260add8790b3_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "menuCat": "Details", "order": "44", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "menuCat": "Details", "order": "45", "role": "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i330867f88a774fb08f247e81d478866e_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "menuCat": "Details", "order": "46", "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)", "menuCat": "Details", "order": "47", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails", "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "48", "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i6f4032436bb84e00a3478c08a4a4bac8_I20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "menuCat": "Details", "order": "49", "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Inventories - Schedule of Inventories (Details)", "menuCat": "Details", "order": "50", "role": "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails", "shortName": "Inventories - Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Inventories - Narrative (Details)", "menuCat": "Details", "order": "51", "role": "http://www.merck.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331", "decimals": "-8", "lang": "en-US", "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Contingencies (Details)", "menuCat": "Details", "order": "52", "role": "http://www.merck.com/role/ContingenciesDetails", "shortName": "Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Equity (Details)", "menuCat": "Details", "order": "53", "role": "http://www.merck.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i48e93ba87cab4afc961e66db38e74311_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)", "menuCat": "Details", "order": "54", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i48e93ba87cab4afc961e66db38e74311_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanSettlementsPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)", "menuCat": "Details", "order": "55", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanSettlementsPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "menuCat": "Details", "order": "56", "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Other (Income) Expense, Net - Narrative (Details)", "menuCat": "Details", "order": "57", "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "shortName": "Other (Income) Expense, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Taxes on Income (Details)", "menuCat": "Details", "order": "58", "role": "http://www.merck.com/role/TaxesonIncomeDetails", "shortName": "Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)", "menuCat": "Details", "order": "59", "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Earnings Per Share - Narrative (Details)", "menuCat": "Details", "order": "60", "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails", "shortName": "Earnings Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Other Comprehensive Income (Loss) (Details)", "menuCat": "Details", "order": "61", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails", "shortName": "Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Segment Reporting - Narrative (Details)", "menuCat": "Details", "order": "62", "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Segment Reporting - Sales from Products (Details)", "menuCat": "Details", "order": "63", "role": "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails", "shortName": "Segment Reporting - Sales from Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)", "menuCat": "Details", "order": "64", "role": "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "shortName": "Segment Reporting - Consolidated Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)", "menuCat": "Details", "order": "65", "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://www.merck.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Spin-Off of Organon & Co.", "menuCat": "Notes", "order": "9", "role": "http://www.merck.com/role/SpinOffofOrganonCo", "shortName": "Spin-Off of Organon & Co.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20230331.htm", "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 134, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_CO": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COLOMBIA", "terseLabel": "COLOMBIA" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S.", "verboseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mrk_A0.500Notesdue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.500% Notes due 2024 [Member]", "label": "0.500% Notes due 2024 [Member]", "terseLabel": "0.500% Notes due 2024" } } }, "localname": "A0.500Notesdue2024Member", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.375Notesdue2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.375% Notes due 2036 [Member]", "label": "1.375% Notes due 2036 [Member]", "terseLabel": "1.375% Notes due 2036" } } }, "localname": "A1.375Notesdue2036Member", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.875Notesdue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.875% Notes due 2026 [Member]", "label": "1.875% Notes due 2026 [Member]", "terseLabel": "1.875% Notes due 2026" } } }, "localname": "A1.875Notesdue2026Member", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A2.500Notesdue2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.500% Notes due 2034 [Member]", "label": "2.500% Notes due 2034 [Member]", "terseLabel": "2.500% Notes due 2034" } } }, "localname": "A2.500Notesdue2034Member", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_AcceleratedDepreciationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Depreciation [Member]", "label": "Accelerated Depreciation [Member]", "terseLabel": "Accelerated Depreciation" } } }, "localname": "AcceleratedDepreciationMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.", "label": "Acquisitions Research Collaborations And License Agreements [Text Block]", "terseLabel": "Acquisitions, Research Collaborations and License Agreements" } } }, "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "mrk_AdempasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adempas", "label": "Adempas [Member]", "terseLabel": "Adempas" } } }, "localname": "AdempasMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueAdempasVerquvoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Adempas/Verquvo", "label": "Alliance revenue - Adempas/Verquvo [Member]", "terseLabel": "Alliance revenue - Adempas/Verquvo" } } }, "localname": "AllianceRevenueAdempasVerquvoMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueKoselugoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Koselugo", "label": "Alliance revenue - Koselugo [Member]", "terseLabel": "Alliance revenue - Koselugo" } } }, "localname": "AllianceRevenueKoselugoMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueReblozylMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance Revenue - Reblozyl", "label": "Alliance Revenue - Reblozyl [Member]", "terseLabel": "Alliance Revenue - Reblozyl" } } }, "localname": "AllianceRevenueReblozylMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AlliancerevenueLynparzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Lynparza [Member]", "label": "Alliance revenue - Lynparza [Member]", "terseLabel": "Alliance revenue - Lynparza" } } }, "localname": "AlliancerevenueLynparzaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AnimalHealthsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Animal Health segment [Member]", "label": "Animal Health segment [Member]", "terseLabel": "Animal Health", "verboseLabel": "Animal Health segment" } } }, "localname": "AnimalHealthsegmentMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "terseLabel": "Net assets acquired" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AssetAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition.", "label": "Asset Acquisition Share Price", "terseLabel": "Asset acquisition, share price (in dollars per share)" } } }, "localname": "AssetAcquisitionSharePrice", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "perShareItemType" }, "mrk_AstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_BayerAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayer AG [Member]", "label": "Bayer AG [Member]", "terseLabel": "Bayer AG" } } }, "localname": "BayerAGMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_BelsomraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Belsomra [Member]", "label": "Belsomra [Member]", "terseLabel": "Belsomra" } } }, "localname": "BelsomraMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BridionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bridion [Member].", "label": "Bridion [Member]", "terseLabel": "Bridion" } } }, "localname": "BridionMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol Myers Squibb", "label": "Bristol Myers Squibb [Member]", "terseLabel": "Bristol Myers Squibb" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Preferred Stock Investment In Counterparty", "label": "Collaborative Arrangement, Preferred Stock Investment In Counterparty", "terseLabel": "Preferred stock investment in counterparty" } } }, "localname": "CollaborativeArrangementPreferredStockInvestmentInCounterparty", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementProfitSharing": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Profit Sharing", "label": "Collaborative Arrangement, Profit Sharing", "terseLabel": "Alliance revenue - profit sharing" } } }, "localname": "CollaborativeArrangementProfitSharing", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Regulatory Milestone Payments Accrued", "label": "Collaborative Arrangement, Regulatory Milestone Payments Accrued", "terseLabel": "Regulatory milestone payments accrued" } } }, "localname": "CollaborativeArrangementRegulatoryMilestonePaymentsAccrued", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments", "terseLabel": "Eligible future contingent development-related payments (up to)" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments", "terseLabel": "Regulatory milestones payments" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments", "terseLabel": "Sales milestone payments" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementSalesNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Sales, Net", "label": "Collaborative Arrangement, Sales, Net", "terseLabel": "Net sales by Merck" } } }, "localname": "CollaborativeArrangementSalesNet", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements [Abstract]", "label": "Collaborative Arrangements [Abstract]", "terseLabel": "Collaborative Arrangements [Abstract]" } } }, "localname": "CollaborativeArrangementsAbstract", "nsuri": "http://www.merck.com/20230331", "xbrltype": "stringItemType" }, "mrk_CompanionAnimalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Companion Animals [Member]", "label": "Companion Animals [Member]", "terseLabel": "Companion Animals" } } }, "localname": "CompanionAnimalsMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Complaint Against The Johns Hopkins University", "label": "Complaint Against The Johns Hopkins University [Member]", "terseLabel": "Complaint Against The Johns Hopkins University" } } }, "localname": "ComplaintAgainstTheJohnsHopkinsUniversityMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_ContingentProceedsCollaborativeArrangement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents proceeds that may be received in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.", "label": "Contingent Proceeds Collaborative Arrangement", "terseLabel": "Contingent proceeds collaborative arrangement" } } }, "localname": "ContingentProceedsCollaborativeArrangement", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CostsExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.", "label": "Costs Expenses And Other", "totalLabel": "Total Costs, Expenses and Other" } } }, "localname": "CostsExpensesAndOther", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "mrk_DebtSecuritiesandEquitySecuritiesFVNI": { "auth_ref": [], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities and Equity Securities, FV-NI", "label": "Debt Securities and Equity Securities, FV-NI", "totalLabel": "Total debt and publicly traded equity securities, fair value" } } }, "localname": "DebtSecuritiesandEquitySecuritiesFVNI", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes and Other Assets, Current", "label": "Deferred Income Taxes and Other Assets, Current [Member]", "terseLabel": "Other current assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsCurrentMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes And Other Assets, Noncurrent", "label": "Deferred Income Taxes And Other Assets, Noncurrent [Member]", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "mrk_DificidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dificid", "label": "Dificid [Member]", "terseLabel": "Dificid" } } }, "localname": "DificidMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_EisaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eisai [Member]", "label": "Eisai [Member]", "terseLabel": "Eisai" } } }, "localname": "EisaiMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimate of cumulative pre tax costs that will be noncash.", "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash", "terseLabel": "Estimate of cumulative pre tax costs that will be noncash" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).", "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays", "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EurodominatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro-dominated Notes [Member]", "label": "Euro-dominated Notes [Member]", "terseLabel": "Euro-denominated notes" } } }, "localname": "EurodominatedNotesMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other", "negatedTerseLabel": "Other" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_GardasilGardasil9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gardasil/Gardasil 9 [Member].", "label": "Gardasil/Gardasil 9 [Member]", "terseLabel": "Gardasil/Gardasil 9" } } }, "localname": "GardasilGardasil9Member", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ImagoBioSciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Imago Bio Sciences, Inc.", "label": "Imago Bio Sciences, Inc. [Member]", "terseLabel": "Imago Bio Sciences, Inc." } } }, "localname": "ImagoBioSciencesIncMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_IncreaseDecreaseInHedgeRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Hedge Revenue", "label": "Increase (Decrease) In Hedge Revenue", "terseLabel": "Increase (Decrease) In Hedge Revenue" } } }, "localname": "IncreaseDecreaseInHedgeRevenue", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_InternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "Int\u2019l" } } }, "localname": "InternationalMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoriesProducedinPreparationforProductLaunchesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventories Produced in Preparation for Product Launches [Member]", "label": "Inventories Produced in Preparation for Product Launches [Member]", "terseLabel": "Inventories Produced in Preparation for Product Launches" } } }, "localname": "InventoriesProducedinPreparationforProductLaunchesMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryNetAndInventoryNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of current and noncurrent inventories.", "label": "Inventory Net And Inventory Noncurrent", "totalLabel": "Total current and noncurrent inventories" } } }, "localname": "InventoryNetAndInventoryNoncurrent", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory Not Expected to be Sold Within One Year [Member]", "label": "Inventory Not Expected to be Sold Within One Year [Member]", "terseLabel": "Inventories Not Expected to be Sold Within One Year" } } }, "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory [Table]", "label": "Inventory [Table]", "terseLabel": "Inventory [Table]" } } }, "localname": "InventoryTable", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_IsentressIsentressHDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Isentress/Isentress HD [Member].", "label": "Isentress/Isentress HD [Member]", "terseLabel": "Isentress/Isentress HD" } } }, "localname": "IsentressIsentressHDMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanumetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Janumet [Member].", "label": "Janumet [Member]", "terseLabel": "Janumet" } } }, "localname": "JanumetMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanuviaAndJanumetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Januvia and Janumet", "label": "Januvia and Janumet [Member]", "terseLabel": "Januvia and Janumet" } } }, "localname": "JanuviaAndJanumetMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_JanuviaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Januvia [Member] .", "label": "Januvia [Member]", "terseLabel": "Januvia" } } }, "localname": "JanuviaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_KeytrudaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Keytruda [Member]", "label": "Keytruda [Member]", "terseLabel": "Keytruda" } } }, "localname": "KeytrudaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LagevrioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lagevrio", "label": "Lagevrio [Member]", "terseLabel": "Lagevrio" } } }, "localname": "LagevrioMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LegalDefenseCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Defense Costs [Member]", "label": "Legal Defense Costs [Member]", "terseLabel": "Legal Defense Costs" } } }, "localname": "LegalDefenseCostsMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_LenvimaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lenvima [Member]", "label": "Lenvima [Member]", "terseLabel": "Alliance revenue - Lenvima", "verboseLabel": "Lenvima" } } }, "localname": "LenvimaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LivestockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Livestock [Member]", "label": "Livestock [Member]", "terseLabel": "Livestock" } } }, "localname": "LivestockMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of States In Which Plaintiffs Reside", "label": "Loss Contingency, Number Of States In Which Plaintiffs Reside", "terseLabel": "Loss Contingency, number of states in which plaintiffs reside" } } }, "localname": "LossContingencyNumberOfStatesInWhichPlaintiffsReside", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "mrk_LossContingencyTrialPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Trial Period", "label": "Loss Contingency, Trial Period", "terseLabel": "Loss contingency, trial period" } } }, "localname": "LossContingencyTrialPeriod", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "durationItemType" }, "mrk_LynparzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lynparza [Member]", "label": "Lynparza [Member]", "terseLabel": "Lynparza" } } }, "localname": "LynparzaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ManufacturingAndSupplyAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing and supply agreements", "label": "Manufacturing and supply agreements [Member]", "terseLabel": "Manufacturing and supply agreements" } } }, "localname": "ManufacturingAndSupplyAgreementsMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "mrk_MilestonePaymentsMadetoCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments Made to Collaborative Partner", "label": "Milestone Payments Made to Collaborative Partner", "terseLabel": "Capitalized milestone payment" } } }, "localname": "MilestonePaymentsMadetoCollaborativePartner", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_MilestonePaymentsSalesBased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments Sales-Based", "label": "Milestone Payments Sales-Based", "terseLabel": "Sales-based milestone payments" } } }, "localname": "MilestonePaymentsSalesBased", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_NoxafilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noxafil [Member].", "label": "Noxafil [Member]", "terseLabel": "Noxafil" } } }, "localname": "NoxafilMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.", "label": "Offsetting Assets And Liabilities [Table Text Block]", "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis" } } }, "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "mrk_OrganonCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organon & Co.", "label": "Organon & Co. [Member]", "terseLabel": "Organon & Co." } } }, "localname": "OrganonCoMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherNonoperatingIncomeExpenseOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other nonoperating income and expense items not separately disclosed.", "label": "Other Nonoperating Income Expense, Other", "negatedLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpenseOther", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "mrk_OtherPharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other pharmaceutical.", "label": "Other Pharmaceutical [Member]", "terseLabel": "Other pharmaceutical" } } }, "localname": "OtherPharmaceuticalMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PharmaceuticalsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical segment.", "label": "Pharmaceutical segment [Member]", "terseLabel": "Pharmaceutical", "verboseLabel": "Pharmaceutical segment" } } }, "localname": "PharmaceuticalsegmentMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_Pneumovax23Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pneumovax 23[Member].", "label": "Pneumovax 23 [Member]", "terseLabel": "Pneumovax 23" } } }, "localname": "Pneumovax23Member", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PotentialFutureMilestonePaymentsRegulatory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Future Milestone Payments Regulatory", "label": "Potential Future Milestone Payments Regulatory", "terseLabel": "Potential future regulatory milestone payments" } } }, "localname": "PotentialFutureMilestonePaymentsRegulatory", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PotentialFutureMilestonePaymentsSalesBased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Future Milestone Payments Sales-Based", "label": "Potential Future Milestone Payments Sales-Based", "terseLabel": "Potential future sales-based milestone payments" } } }, "localname": "PotentialFutureMilestonePaymentsSalesBased", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PrevymisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prevymis [Member]", "label": "Prevymis [Member]", "terseLabel": "Prevymis" } } }, "localname": "PrevymisMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PrimaxinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primaxin [Member].", "label": "Primaxin [Member]", "terseLabel": "Primaxin" } } }, "localname": "PrimaxinMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProQuadMMRIIVarivaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ProQuad/M-M-R II/Varivax [Member].", "label": "ProQuad MMR II Varivax [Member]", "terseLabel": "ProQuad/M-M-R II/Varivax" } } }, "localname": "ProQuadMMRIIVarivaxMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProbableContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Probable Contingent Payments Collaborative Arrangement", "label": "Probable Contingent Payments Collaborative Arrangement", "terseLabel": "Probable contingent payments" } } }, "localname": "ProbableContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PrometheusBiosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prometheus Biosciences, Inc.", "label": "Prometheus Biosciences, Inc. [Member]", "terseLabel": "Prometheus Biosciences, Inc." } } }, "localname": "PrometheusBiosciencesIncMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_RecognizedAsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recognized as.", "label": "Recognized As [Abstract]", "terseLabel": "Recognized as:" } } }, "localname": "RecognizedAsAbstract", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "stringItemType" }, "mrk_RegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory Milestones [Member]", "label": "Regulatory Milestones [Member]", "terseLabel": "Regulatory Milestones" } } }, "localname": "RegulatoryMilestonesMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_RemicadeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remicade [Member].", "label": "Remicade [Member]", "terseLabel": "Remicade" } } }, "localname": "RemicadeMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.", "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity", "terseLabel": "Non-cash activity" } } }, "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RidgebackBiotherapeuticsLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ridgeback Biotherapeutics LP", "label": "Ridgeback Biotherapeutics LP [Member]", "terseLabel": "Ridgeback Biotherapeutics LP" } } }, "localname": "RidgebackBiotherapeuticsLPMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "mrk_RotaTeqAntitrustLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RotaTeq Antitrust Litigation", "label": "RotaTeq Antitrust Litigation [Member]", "terseLabel": "RotaTeq Antitrust Litigation" } } }, "localname": "RotaTeqAntitrustLitigationMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_RotateqMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RotaTeq [Member]", "label": "Rotateq [Member]", "terseLabel": "RotaTeq" } } }, "localname": "RotateqMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RoyaltyRateDeductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Rate, Deduction, Percentage", "label": "Royalty Rate, Deduction, Percentage", "terseLabel": "Royalty rate, deduction" } } }, "localname": "RoyaltyRateDeductionPercentage", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "pureItemType" }, "mrk_RoyaltyRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Rate, Percentage", "label": "Royalty Rate, Percentage", "terseLabel": "Royalty rate" } } }, "localname": "RoyaltyRatePercentage", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_SalesBasedMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales-Based Milestones [Member]", "label": "Sales-Based Milestones [Member]", "terseLabel": "Sales-Based Milestones" } } }, "localname": "SalesBasedMilestonesMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SalesDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales Discounts", "label": "Sales Discounts", "terseLabel": "Sales discounts" } } }, "localname": "SalesDiscounts", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SanofiPasteurMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanofi Pasteur [Member]", "label": "Sanofi Pasteur [Member]", "terseLabel": "Sanofi Pasteur" } } }, "localname": "SanofiPasteurMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "mrk_SegmentReportingUnallocatedOtherExpensesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other net expenses not allocated to segments.", "label": "Segment Reporting Unallocated Other Expenses Net", "negatedLabel": "Other unallocated, net" } } }, "localname": "SegmentReportingUnallocatedOtherExpensesNet", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.", "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]", "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd." } } }, "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_SimponiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Simponi [Member].", "label": "Simponi [Member]", "terseLabel": "Simponi" } } }, "localname": "SimponiMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_StockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Stockholders Equity [Table]", "label": "Stockholders Equity [Line Items]", "terseLabel": "Stockholders Equity [Line Items]" } } }, "localname": "StockholdersEquityLineItems", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "mrk_StockholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders Equity [Table]", "label": "Stockholders Equity [Table]", "terseLabel": "Stockholders Equity [Table]" } } }, "localname": "StockholdersEquityTable", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "mrk_TaxBenefitResultingFromAcquisitionCharge": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Benefit Resulting From Acquisition Charge", "label": "Tax Benefit Resulting From Acquisition Charge", "terseLabel": "Tax benefit resulting from acquisition charge" } } }, "localname": "TaxBenefitResultingFromAcquisitionCharge", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_TransitionServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition services agreement", "label": "Transition services agreement [Member]", "terseLabel": "Transition services agreement" } } }, "localname": "TransitionServicesAgreementMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "mrk_VaqtaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vaqta [Member]", "label": "Vaqta [Member]", "terseLabel": "Vaqta" } } }, "localname": "VaqtaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_VaxneuvanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vaxneuvance", "label": "Vaxneuvance [Member]", "terseLabel": "Vaxneuvance" } } }, "localname": "VaxneuvanceMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_VerquvoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Verquvo", "label": "Verquvo [Member]", "terseLabel": "Verquvo" } } }, "localname": "VerquvoMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_WeliregMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Welireg", "label": "Welireg [Member]", "terseLabel": "Welireg" } } }, "localname": "WeliregMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZerbaxaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zerbaxa [Member]", "label": "Zerbaxa [Member]", "terseLabel": "Zerbaxa" } } }, "localname": "ZerbaxaMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZetiaantitrustlitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zetia antitrust litigation [Member]", "label": "Zetia antitrust litigation [Member]", "terseLabel": "Zetia antitrust litigation" } } }, "localname": "ZetiaantitrustlitigationMember", "nsuri": "http://www.merck.com/20230331", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific (other than China and Japan)" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r263", "r309", "r321", "r322", "r323", "r324", "r325", "r327", "r331", "r397", "r398", "r399", "r400", "r402", "r403", "r405", "r407", "r408", "r776", "r777" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r263", "r309", "r321", "r322", "r323", "r324", "r325", "r327", "r331", "r397", "r398", "r399", "r400", "r402", "r403", "r405", "r407", "r408", "r776", "r777" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r261", "r262", "r410", "r415", "r677", "r680" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "stringItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r392", "r393", "r394", "r395", "r506", "r621", "r637", "r670", "r671", "r694", "r707", "r716", "r778", "r802", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r392", "r393", "r394", "r395", "r506", "r621", "r637", "r670", "r671", "r694", "r707", "r716", "r778", "r802", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r333", "r622", "r695", "r714", "r773", "r774", "r779", "r810" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r333", "r622", "r695", "r714", "r773", "r774", "r779", "r810" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r392", "r393", "r394", "r395", "r454", "r506", "r510", "r511", "r512", "r597", "r621", "r637", "r670", "r671", "r694", "r707", "r716", "r768", "r778", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r392", "r393", "r394", "r395", "r454", "r506", "r510", "r511", "r512", "r597", "r621", "r637", "r670", "r671", "r694", "r707", "r716", "r768", "r778", "r803", "r804", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r261", "r262", "r410", "r415", "r679", "r680" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r507", "r756" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r282", "r507", "r727", "r756" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r334", "r335", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r696", "r715", "r779" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r334", "r335", "r659", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r696", "r715", "r779" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r282", "r507", "r727", "r728", "r756" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29", "r713" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r339", "r340" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableSale": { "auth_ref": [ "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease from sale of accounts receivable.", "label": "Accounts Receivable, Sale", "terseLabel": "Factored accounts receivable" } } }, "localname": "AccountsReceivableSale", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r17", "r185", "r197" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r43", "r49", "r151", "r738", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r103", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r238", "r246", "r547", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r238", "r247", "r248", "r547", "r681", "r738" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r46", "r48", "r49", "r228", "r631", "r642", "r643" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r246", "r247", "r578", "r579", "r580", "r581", "r582", "r584" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r45", "r49", "r151", "r587", "r638", "r639", "r738", "r739", "r740", "r753", "r754", "r755" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r42", "r49", "r151", "r247", "r248", "r579", "r580", "r581", "r582", "r584", "r738" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r21" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Other paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r513", "r514", "r515", "r753", "r754", "r755", "r795" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Other Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r73", "r101" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "negatedLabel": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r229", "r341", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r73", "r97", "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r785" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r708", "r786", "r787", "r788" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration transferred, asset acquisition" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r708", "r786", "r787", "r788" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Asset acquisition costs" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r785" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": { "auth_ref": [ "r785" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.", "label": "Asset Acquisition, Price of Acquisition, Expected", "terseLabel": "Asset acquisition, price of acquisition, expected" } } }, "localname": "AssetAcquisitionPriceOfAcquisitionExpected", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r184", "r196", "r220", "r258", "r317", "r323", "r329", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r543", "r548", "r572", "r713", "r776", "r777", "r800" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r214", "r231", "r258", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r543", "r548", "r572", "r713", "r776", "r777", "r800" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r176" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r92" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt securities, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r93" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Debt securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r343", "r359" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Debt securities, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r91", "r342", "r359", "r625" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Debt securities, fair value", "verboseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r161", "r164" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r537", "r746" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Changes in estimated fair value" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r141", "r142", "r536" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Fair value, ending balance", "periodStartLabel": "Fair value, beginning balance", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r141", "r143" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input, discount rate" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r75", "r216", "r673" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r75", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March\u00a031, 2023 and 2022, respectively, included in Other current assets)", "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r180" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r730" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivatives designated as hedging instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Hedged items" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r224", "r225", "r226", "r258", "r286", "r287", "r294", "r296", "r303", "r304", "r350", "r397", "r400", "r401", "r402", "r408", "r409", "r413", "r414", "r417", "r421", "r428", "r572", "r672", "r726", "r749", "r757" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r538", "r539", "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r789" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r115", "r389", "r390", "r660", "r775" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared on common stock (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r753", "r754", "r795" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock ($0.50\u00a0par value)", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Common stock, ending balance (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r713" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r243", "r245", "r252", "r627", "r633" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income Attributable to Merck\u00a0& Co., Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r63", "r251", "r626", "r632" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r697", "r699", "r811" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r85", "r322", "r323", "r324", "r325", "r331", "r760" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment", "verboseLabel": "Corporate, Non-Segment" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r58", "r622" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, Expenses and Other" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r222" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r411", "r571", "r692", "r693" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of loans payable and long-term debt, including current portion" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-Term and Short-Term, Combined Amount", "terseLabel": "Debt, carrying amount" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r73", "r136", "r523", "r528", "r529", "r751" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r516", "r517" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred Income Taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r431", "r470", "r495", "r699", "r700" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Net (gain) loss amortization" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r431", "r471", "r496", "r699", "r700" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of unrecognized prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement": { "auth_ref": [ "r780" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement", "negatedTerseLabel": "Increase to pension liabilities due to remeasurement" } } }, "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r431", "r469", "r494", "r699", "r700" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r431", "r436", "r468", "r493", "r699", "r700" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r466", "r491", "r699", "r700" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r432", "r473", "r498" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 7.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedLabel": "Curtailments" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r432", "r473", "r498" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r434", "r467", "r492", "r699", "r700" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "terseLabel": "Partial settlement charge" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r73", "r102" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedLabel": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r40", "r41" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, asset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r39", "r41", "r233" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative asset.", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r232", "r235", "r571", "r680" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "netLabel": "Gross amounts recognized in the consolidated balance sheet, asset", "terseLabel": "Derivative assets", "verboseLabel": "Fair Value of Derivative, Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageRemainingMaturity1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Average Remaining Maturity", "terseLabel": "Maximum average period of maturities of contracts in years (less than)" } } }, "localname": "DerivativeAverageRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r41", "r171", "r234", "r678" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "negatedLabel": "Cash collateral received, asset", "terseLabel": "Cash collateral received from counterparties" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "auth_ref": [ "r41", "r171", "r234", "r678" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "negatedLabel": "Cash collateral received, liability" } } }, "localname": "DerivativeCollateralRightToReclaimCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimSecurities": { "auth_ref": [ "r41", "r234", "r678" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset", "terseLabel": "Cash collateral advanced to counterparties" } } }, "localname": "DerivativeCollateralRightToReclaimSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r792" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedTerseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r162", "r163", "r167", "r169", "r680" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r159", "r162", "r167", "r169", "r173", "r175", "r555" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "negatedLabel": "Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r166", "r793" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r232", "r235", "r571", "r680" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "netLabel": "Gross amounts recognized in the consolidated balance sheet, liability", "terseLabel": "Derivative liabilities", "verboseLabel": "Fair Value of Derivative, Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r40", "r41" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, liability" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r39", "r41", "r233" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative liability.", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Total swap notional amount", "verboseLabel": "U.S Dollar Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r155", "r157", "r158", "r159", "r160", "r165", "r167", "r170", "r172", "r175", "r558" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "terseLabel": "Period of continuing involvement after disposal" } } }, "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]", "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r12", "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Spin-Off of Organon & Co." } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCo" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r782", "r783", "r784" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r227", "r399", "r400", "r401", "r407", "r408", "r409", "r589", "r675", "r752" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from related parties, current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r29", "r399", "r400", "r401", "r407", "r408", "r409", "r589", "r752" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related parties, current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East and Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r253", "r274", "r275", "r276", "r277", "r278", "r283", "r286", "r294", "r295", "r296", "r300", "r561", "r562", "r628", "r634", "r683" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic Earnings Per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r253", "r274", "r275", "r276", "r277", "r278", "r286", "r294", "r295", "r296", "r300", "r561", "r562", "r628", "r634", "r683" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r297", "r298", "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r577" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r119", "r210", "r246", "r247", "r248", "r269", "r270", "r271", "r273", "r279", "r281", "r302", "r351", "r429", "r513", "r514", "r515", "r524", "r525", "r560", "r578", "r579", "r580", "r581", "r582", "r584", "r587", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFundsMember": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.", "label": "Equity Funds [Member]", "terseLabel": "Equity Funds" } } }, "localname": "EquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity securities, noncurrent" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r221", "r570", "r676" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 2.0, "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Publicly traded equity securities, fair value", "verboseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r764" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Loss (income) from investments in equity securities, net", "negatedTerseLabel": "(Income) loss from investments in equity securities, net" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r635", "r764" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized net (gains) losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r94", "r194", "r717", "r718", "r719" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investments without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized losses on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized gains on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r563", "r564", "r568" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r411", "r457", "r458", "r459", "r460", "r461", "r462", "r564", "r594", "r595", "r596", "r692", "r693", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r563", "r564", "r565", "r566", "r569" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r411", "r457", "r462", "r564", "r594", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r411", "r457", "r462", "r564", "r595", "r692", "r693", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r411", "r457", "r458", "r459", "r460", "r461", "r462", "r564", "r596", "r692", "r693", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r177", "r179" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r411", "r457", "r458", "r459", "r460", "r461", "r462", "r594", "r595", "r596", "r692", "r693", "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r567", "r569" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r161", "r165", "r173" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r344", "r345", "r354", "r355", "r356", "r357", "r358", "r360", "r361", "r362", "r412", "r426", "r558", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r686", "r761", "r762", "r763", "r812", "r813", "r814", "r815", "r816", "r817", "r818" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r100", "r623" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r573", "r574", "r575", "r576" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Exchange losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r680", "r697", "r712" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeFutureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange).", "label": "Foreign Exchange Future [Member]", "terseLabel": "Foreign Exchange Future" } } }, "localname": "ForeignExchangeFutureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).", "label": "Foreign Exchange Option [Member]", "terseLabel": "Currency options" } } }, "localname": "ForeignExchangeOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r781", "r811" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign government bonds" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r782", "r783", "r784" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r770" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Loss related to litigation settlement", "terseLabel": "Charge for Zetia antitrust litigation settlements" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r218", "r364", "r624", "r687", "r713", "r766", "r767" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r159", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r145", "r147" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Net Income (Loss) Attributable to Noncontrolling Interests" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r53", "r182", "r191", "r205", "r317", "r322", "r328", "r331", "r629", "r685" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Profits", "totalLabel": "Income Before Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r147", "r258", "r272", "r317", "r322", "r328", "r331", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r562", "r572", "r685", "r776" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r6", "r7", "r8", "r9", "r10", "r11", "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r374", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r259", "r520", "r521", "r522", "r526", "r530", "r532", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r260", "r280", "r281", "r315", "r518", "r527", "r531", "r636" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r72" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Net changes in assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r96", "r99" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other Intangibles, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r181", "r193", "r249", "r311", "r586" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r747" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r680", "r697", "r711" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r711" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r732" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r736" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total (approximates current cost)" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r735" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r230", "r674", "r713" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note\u00a07)" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r731" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventories classified in Other assets", "verboseLabel": "Other Assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/InventoriesNarrativeDetails", "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "auth_ref": [ "r736" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials", "terseLabel": "Raw materials and work in process" } } }, "localname": "InventoryWorkInProcessAndRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r60", "r310" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r258", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r544", "r548", "r549", "r572", "r684", "r776", "r800", "r801" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r187", "r201", "r713", "r750", "r765", "r796" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32", "r215", "r258", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r544", "r548", "r549", "r572", "r713", "r776", "r800", "r801" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "verboseLabel": "Payables included in Accrued and other liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r176" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r14", "r15", "r16", "r18", "r19", "r258", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r544", "r548", "r549", "r572", "r776", "r800", "r801" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Payables included in Other Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r34", "r770" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Legal defense costs reserve" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r770" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r770" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r223" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r116", "r117", "r391", "r392", "r393", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [ "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss contingency, claims settled" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Loss contingency, new claims filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [ "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "terseLabel": "Loss contingency, number of patents allegedly infringed" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss contingency, pending claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r38", "r186", "r200", "r258", "r350", "r397", "r400", "r401", "r402", "r408", "r409", "r572" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling Interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r256" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Used in Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r256" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r71", "r74" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r55", "r74", "r192", "r204", "r213", "r241", "r244", "r248", "r258", "r272", "r274", "r275", "r276", "r277", "r280", "r281", "r292", "r317", "r322", "r328", "r331", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r562", "r572", "r685", "r776" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income Attributable to Merck\u00a0& Co., Inc.", "totalLabel": "Net Income Attributable to Merck & Co., Inc.", "verboseLabel": "Net income attributable to Merck\u00a0& Co., Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r149", "r153", "r241", "r244", "r280", "r281", "r740" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r274", "r275", "r276", "r277", "r283", "r284", "r293", "r296", "r317", "r322", "r328", "r331", "r685" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income attributable to Merck & Co., Inc., basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r285", "r288", "r289", "r290", "r291", "r293", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income attributable to Merck & Co., Inc., diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "auth_ref": [ "r431" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost" } } }, "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r145", "r429", "r753", "r754", "r755" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non- controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "verboseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r156", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "verboseLabel": "Number of interest rate swaps held (in interest rate swaps)" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r49" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r49", "r51" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r688", "r689", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "terseLabel": "Separation Costs" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r321", "r322", "r323", "r324", "r325", "r331" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "verboseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r78", "r79", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r219" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r44", "r46", "r147", "r150" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Benefit plan net (loss) gain and prior service (cost) credit, net of amortization" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r147", "r148", "r150" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r47", "r246" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "negatedTerseLabel": "Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r237" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "verboseLabel": "Net unrealized (loss) gain on derivatives, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r236", "r237", "r551", "r552", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r237", "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Increase in Sales as a result of AOCL reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r51", "r119", "r242", "r245", "r251", "r578", "r583", "r584", "r626", "r632", "r738", "r739" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive (Loss) Income Net of Taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r147", "r148", "r150", "r242", "r245" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r161", "r173" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r124", "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInventorySupplies": { "auth_ref": [ "r733" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.", "label": "Other Inventory, Supplies, Gross", "terseLabel": "Supplies" } } }, "localname": "OtherInventorySupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r31", "r713" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 5.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r126", "r430", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r481", "r484", "r487", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503", "r504", "r505", "r699", "r700", "r701", "r702", "r703" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefit Plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [ "r688", "r689", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r741", "r742" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r378", "r745" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "(Payments) receipts, net" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid to stockholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "auth_ref": [ "r742" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of Imago BioSciences, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r90" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of securities and other investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r254", "r786", "r787", "r788" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r770" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r454", "r456", "r462", "r480", "r482", "r483", "r484", "r485", "r486", "r501", "r502", "r503", "r509", "r699" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Pension and Other Postretirement Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r125", "r430", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r481", "r484", "r487", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503", "r504", "r508", "r699", "r700", "r704", "r705", "r706" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r729" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromCollaborators": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from collaborators during the current period.", "label": "Proceeds from Collaborators", "terseLabel": "Proceeds from Collaborators" } } }, "localname": "ProceedsFromCollaborators", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r743", "r744" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r65" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales of securities and other investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Revenue related to the sale of the marketing rights" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r66", "r133" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r213", "r241", "r244", "r255", "r258", "r272", "r280", "r281", "r317", "r322", "r328", "r331", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r542", "r545", "r546", "r562", "r572", "r629", "r685", "r709", "r710", "r740", "r776" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r104", "r203", "r630", "r713" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r734" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [ "r734" ], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r202", "r206", "r713" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "verboseLabel": "Receivables included in Other current assets" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r49" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedLabel": "Reclassification adjustments, pretax" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r49", "r51" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTotalLabel": "Reclassification adjustments, net of taxes" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r47", "r240", "r246" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Tax" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r82", "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Segment Profits to Income before Taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartiesAmountInCostOfSales": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.", "label": "Related Parties Amount in Cost of Sales", "terseLabel": "Related party amount in cost of sales" } } }, "localname": "RelatedPartiesAmountInCostOfSales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r209", "r588", "r589", "r799" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r68" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Payments on debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r98" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Charge for the acquisition of Imago BioSciences, Inc." } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r135", "r208", "r808" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 3.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r75", "r76", "r183", "r198", "r216" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r730", "r748" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r376", "r378", "r381", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r377", "r380", "r384", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Cumulative costs since program inception" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r377", "r380", "r384", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected restructuring and related cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r377", "r380", "r384", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Total pretax restructuring costs", "verboseLabel": "Expenses" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r73", "r382", "r384", "r769" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 4.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r111", "r114" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r377", "r378", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r378", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring reserve, ending balance", "periodStartLabel": "Restructuring reserve, beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r120", "r199", "r641", "r643", "r713" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r210", "r269", "r270", "r271", "r273", "r279", "r281", "r351", "r513", "r514", "r515", "r524", "r525", "r560", "r638", "r640" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r481", "r484", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r782", "r783", "r784" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r481", "r484", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r782", "r783", "r784" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r125", "r126", "r430", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r481", "r484", "r487", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503", "r504", "r505", "r508", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r125", "r126", "r430", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r481", "r484", "r487", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r503", "r504", "r505", "r508", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r56", "r207", "r399", "r400", "r401", "r407", "r408", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r250", "r258", "r308", "r309", "r321", "r326", "r327", "r333", "r334", "r337", "r350", "r397", "r398", "r400", "r401", "r402", "r404", "r406", "r408", "r409", "r572", "r629", "r776" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Sales", "totalLabel": "Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyIncomeNonoperating": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Income, Nonoperating", "terseLabel": "Royalties" } } }, "localname": "RoyaltyIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r49", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in AOCI by Component" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Information on Investments in Debt and Equity Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r137", "r138", "r535" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r789" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r789" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Collaboration Arrangements" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r128", "r129", "r130", "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r162", "r167", "r555" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Location and Amount of Pretax Gains and Losses of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r758" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Calculations of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Sales from Products" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r26", "r27", "r28" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Net Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r794" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income" } } }, "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r166", "r793" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r377", "r378", "r379", "r380", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r109", "r110", "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r108", "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r57", "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Consolidated Sales by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r52", "r88" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r80", "r81", "r83", "r95" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r305", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r337", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r380", "r386", "r687", "r810" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r305", "r306", "r307", "r317", "r320", "r325", "r329", "r330", "r331", "r332", "r333", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r72" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r188", "r189", "r195", "r737" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r212", "r305", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r337", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r380", "r386", "r687", "r810" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r224", "r225", "r226", "r258", "r286", "r287", "r294", "r296", "r303", "r304", "r350", "r397", "r400", "r401", "r402", "r408", "r409", "r413", "r414", "r417", "r421", "r428", "r572", "r672", "r726", "r749", "r757" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r35", "r119", "r210", "r246", "r247", "r248", "r269", "r270", "r271", "r273", "r279", "r281", "r302", "r351", "r429", "r513", "r514", "r515", "r524", "r525", "r560", "r578", "r579", "r580", "r581", "r582", "r584", "r587", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r23", "r24", "r89", "r713", "r750", "r765", "r796" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Merck\u00a0& Co., Inc. stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Merck\u00a0& Co., Inc. Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.", "label": "Stockholders' Equity before Treasury Stock", "totalLabel": "Stockholders' equity before deduction for treasury stock" } } }, "localname": "StockholdersEquityBeforeTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r145", "r146", "r152", "r210", "r211", "r247", "r269", "r270", "r271", "r273", "r279", "r351", "r429", "r513", "r514", "r515", "r524", "r525", "r560", "r578", "r579", "r584", "r587", "r639", "r640", "r750", "r765", "r796" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/EquityDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r123", "r257", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r429", "r559" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Share-based compensation plans and other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r585", "r590" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r585", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r585", "r590" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r190", "r221", "r676" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "totalLabel": "Investments" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r344", "r345", "r412", "r426", "r558", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r761", "r762", "r763", "r812", "r813", "r814", "r815", "r816", "r817", "r818" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Treasury stock, ending balance (in shares)", "periodStartLabel": "Treasury stock, beginning balance (in shares)", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r37", "r121", "r122" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "terseLabel": "Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r20", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury stock shares purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r119", "r120", "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury stock shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r789" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r377", "r378", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r682", "r697", "r809" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government and agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r264", "r265", "r266", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r264", "r265", "r266", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r758" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Common shares issuable (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r285", "r296" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average common shares outstanding assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r283", "r296" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(ii)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r721": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r722": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r723": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r724": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r725": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 84 0001628280-23-015990-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-015990-xbrl.zip M4$L#!!0 ( /(\I596LE]OP < $XA > 97AH:6)I=#,Q,2UR=6QE M,3-A>#$T83$U9'@N:'1MY5IK<]NX%?W>7X&5IUEG1D]+LAW9\8QC>V!3,JEX5CL9'<2<$JJXHI^RRDO6.M5CWJ2I<+HZ:I8T?=HS[[K,V=FO'0 M[Y3+Y,52SGDG/)]W_"+GD1:+BW.A9DR)MPTU&':[0W["NSSI#V0DWL1]<7HB M3^+H>-@]%N*?/2C9P? PQ[I%)M\VCWA&$.7GO6CQ3TV+D36P$:QFF]MJO#GK'W;/-SS%+^4PR(V=*SL$/+E66_5QQ ZAE"[27&@[2!?M! MFYSUNJV_,)VP]]+$=TLQ_=,S,$B[R<9%C'6&;UZ(TXYV.NT=MW 5G)(OV%VA MYYD44]D,OJL])C04*32(%^MP53!>+%A5.%-)V $J]JP,5W*6X\DHGK&$QV@R M3.<@"J?#N(T!A8REM=PL:$C.[R3679-IT2:@#);,/*5C#1H0*P,*Q[ "TZ&) MD(;-4Q6GS%;TL9H_ET;60LB 7-D,7$]I8ZY<"@-M*6.O(,DMH9H6,'.&:8)% MBW4WO" T])^/!LD25<#?%+J5?YN H:CVZSUJR+!!N.4]/$]SBH!F8CAFC.; MB+^B35DB!(0>0E66K>!11\8^61H(%+Z::-*(*L, 8$(C<'XYZ_6)N4U9DNFY M70+&R*FR#J6(8YP:@][0LKD6=[M49D/;%Q3ZP<[03Q[YZ=7!Z5'OY,S6P:US M"6T -X@YZ%LK&F;85 MYA&C&)V%N)5&QU*@V;)#A$E(Q#W$XN8^3GDQE>P2F_6VRC"BU^>MWO!0!BUZ M0Q&>PJ.BZJ((>"'YC';T&HQ"6$F7O1=*'BV48"&R\RFX,()RT+/3;PS4[+^*8[.F+>I4H!CH8G6FA#]UV"JR2BAN M%!F@0H[R9%F0I,I2WO"[QOHDXZD$QQHHA/.&GU2B)%%QE7%B0)CEE5CE'\P( MV6P]">-;)&D@2 KSI7@V*?V1,!;MB;&]-_H&U/:GB+T1!Y3.E" @<8OS+G$A MMP AE2F$+F[$,M+ GN*1RI1;4([:MBSAWH/"QSM ]M'0M3+'4^Y];5!9F1)X MLSZGQK$VPBO@"YZI+) J,\ ./;(D/-,0%',!6L"]*L%Z+QI<\4YPW&&B;2E=NMP3Z\RA]&2RK0 MDE\N;UFT+/W\]I#!$]#'0X$6>*EP$+NY)GAZ,V)T *H+!=^S%1;/8!C*43J. M*T-Q64L(6Z3FVCJTTPL4R+(Q!-5'7':X8TH"@&'O/QE=*XYB6?JS&QWKBNI! MK]=!JY3;A^Q)K.$!*86G4^^/FNH6.*'=R:P^R#T9W_S-+OI5(/QV(3?\_:MP M_^I#+ ';7&UG8I=UT*QV-H7]&0ETHTQZT(ZC5'+:V(>Z, M-+(B]0L%_;R00T +5&6)"O&7"K;E?I _5PKJ>^Q71>R/?*__3XOM2QR7J211 M *=/>@4$RN)L-7YYJ'HG4M^1PDDE 0^A?ABQK^?61Z=GP6&NCX-)[\M#, % M)EKY0 [@5.70)B"Z*-2:88L9I'";)4C=G"5-Z8FWJTO&5Y\AMI=#5\B$24& MVZV)D$A/$@BJ?]551[\9>%P5,YW-))%YP:?U&SM3\XK,RTPO)'KGJ0Y,PA]A M"UCX73)=^[?1]U=R_S5>+X/=A,UPO?6/V#/>R)YCP'-7K)J?+T7"7 M)&H9$?:R-"U8E/'2RM'RRQDR5)GQQ4@57B\_Z>SQBK3"C#(=JI5Z%;]@ MZ*YOU ;#]G%O0)=JSN"_6"YU_7U;QXG-OC?MPS[TM23T_; M_:/!7F([7N.@-?QB2UZ\;?0;RPDU,8V.RGO6>^QLXJH-U^CR?[\M_'7FNX7? M%+NHZ0G*:J_\D0U^=3 V_G/I[=MC\S<,\!=LK;Q1=?4VXCV'<8R_Q**+0U] MIM_"]OE*KKO]^.[F=N+==?GW\5_I^OLJY0H)O&BRJU3)A-W/+02V?O]>ZO#K@U%XVS>3&S?R*U][]NFNIO (#J_< M[BF[+K1W7N_7G^&7!OXW#Q?_ 5!+ P04 " #R/*564"LR;\4' "I( M'@ &5X:&EB:70S,3(M5::6_C.!+]OK^" MXV![TH!O.XG;20=(.VF,@?0Q@6<;^VE!BY3%C2QJ2,J.]]?O*U(^$MO=SLSL M'-D 4221+-;Q^*HHYN*[ZT^#T3\_W[#$35/V^:=WM\,!J]0:C2^=0:-Q/;IF M/XP^W+)NO=EB(\,SJYS2&4\;C9N/%59)G,O[C<9\/J_/.W5M)HW178-$=1NI MUE;6A1.5RPMZ@ZODXO)O%]_5:NQ:1\549HY%1G(G!2NLRB;LBY#VGM5J9:^! MSA=&31+'VLUVAWW1YE[->&AWRJ7R+QI^DHNQ%HO+"Z%F3(FW%27; MLMDZZT8]WCOM]GK=WAGO1*<=\:8;Q[$XC?[5@I(-= ]CK%ND\FUEJK):(FG^ M?K==/SO)W?E<"9?T6\WFWRN^Z^5%K#.'^0S&A]L@9EL8-Q/(&VOG]+3?:D.8 MDP^NQE,UR?K>RDJ0MAP1Z52;_E'3_YQ32RWF4Y4N^M^/U%1:]E'.V9V>\NS[ MJD5D:E8:%8>.5OU'0DU,XA_GI160DZI,+JUJM/#*IU?L= M3-H=HV&5#;C1U,!NE8N26,E45%DD#:G)7,+=JZ.3WOG+,+=5?W74.FV>;U^' M+.$SR8R<*3D';[A$6?9SP0WPER[P/M?&,9VQ]]I,6:M9^Y'IF'V0)KI?BNGT MSL$L]2H;9A'F.7GS0IS6WNNT=]S"57#*=,'N,SU/I9C(:O!=Z3&AH4BF0C.(IBWF$5X;I*=C#Z=!OJT,F(VDM-POJ M,N7W$O-NR+1X)Z ,IDP]U6,.ZA I VI'MPS#H8F0ALT3%27,%G19CY]+(TLA M9,!4V10Y@-+)7+D$!MI<1EY!DIM#-2U@Y@S#!!LO-MWP@M#0>3X:)(M5!G]3 MZ-;^K0(*Z(YFL]&NLA@+C%,Q@/LH+01D(H8;SJPB_HH698X0$'H(56FZAD<9 M&?MD:B!0^"JC2CV*%!V "8W ^>FLUR?B-F%QJN=V"1@C)\HZE"B.<7H9](:6 MU8VXVZ4R6]J^H-!W]X9^],A/KXYZ[=;9N2V#6^826C@ZCA4>C^UK[\0AXT;Z M<,']:IQ*(6VYT) 5>6W:, M, F)N(=8W#Q$"<\FDEUAL=X5*7JT.KS6.CF608O6B0A/X5%1R9$%O)!\1BMZ M T8AK*3+P1/%CR:*,1'9^11"6*F6RCC XT\,(?YZ'X2NI86^ M\*2GX6^'N4H9(N*%/7P(4?58(F3E3('\=6$@ ,MXIJPG!_22F9=#U<^:5C:I MRPR4[+^.8[6D+6I4H!CH8E%?";\;L<78*J&X462 "CG*DV5&D@I+><.O M&NN3C*<2;'>@$/8A?E".DD1%16H7=,2[CTH?+P#9!]UW2AS/.4^E ;EAT%U\V,IX5?Y>1Y&<GGEX<,GH ^ M'@HTP4N%@]C/-<'3VQ&C#5!9*/B6G;!X!L-0CM)15!B*RT9"V"%UJJW#>_JJ M EDV@J!RB\N.]PR) 3"L_2>]2\51+$N_=Z-M75:L]'H=M$JX765/8@T/2"D\ MG7I_E%2WP [M7J;E1NY)_^JO=M$O N&?%W(GOWT5[C]]B"5@J^OE3.RR"9KU MRJ:P/R.!;I5)*^TX2B6GC5WE+/\"(J?8_3LIO\*=8XVL2.U"03\OY!C0 E59 MHD+\I8)MN1[DSX6"^A[[11;Y+=_K_]-B^PK;92I)%(! >P_:Q41*(FQEOED5 MO7/)[RF!A)+ IQ!?S/CO,\NM\[/ 4-:G8>>W@P&XP$ K5P2P%SAE"80AB#XJ ME6K(8A8IS!93Q ZN\L:4Q+OS(\.+SU#[J^$K)*+88+E5$1+I20)!]9^ZRNA7 M X^K;*;3F20RS_BD_&)G2EZ1TSS5"XG6>:(#D_!'V (6?I-,5_]U]/T'N?\: MKO0DL^W_#WP1;DZJX1SJ6P8ZG?=//)"7,.1L]3 MONBKS.OE!YT_=A:=/Z9[0R90S^!7+BK=]\<)K;A-0Y:PR\VY]G;2J>R'% NY'X[ M?V"MQ["AM;WE&IW__C#R9X+O%GM M'U=H:CTS5_9[%='77"$O^XZIWIDZH&A M;I+%E:^ZIUQ0M-S0E_G/-VQI[#-]%Q;2'^2^P=7=I]OAQQMV.QP-?G@_O+F] MIA/EFP<9%;0S9/] '<@^8]>G*$U5V2!1,F;O5^3[*52*VWYN>#+9055/SK5S M'0[V^^&#V4QNG72OG>X)J;D>PL?P?.'V#]DZ**Y\X]B\O(9#?/_O!)?_!5!+ M P04 " #R/*56*0E,7&0$ !@#P '@ &5X:&EB:70S,C$MU76V_;-A1^WZ\XM;%< %L72TYLV3'0VBX6H+DT<1?L M:: ERN(BB2I%Q?%^_0Y)**W\SDD,DOA M_-.[#\=3:'5M^\J;VO9L,8-?%BWY:0M:B91%8-OK M]=I:>Q87*WMQ82M5OIUR7E(KDE%K,E9?\$E)-/EI_*;;A1D/JXSF$D)!B:01 M5"7+5W 5T?(:NMV::\J+C6"K1$+/Z7EPQ<4UNR&&+IE,Z:31,[;-^]C61L9+ M'FTFXXC= (N.6BST_.&!UQNZ-"0^[??)M3*6=Q.J[ =^SSKL%W*T9I%, M=Q?FYIULDXYKE$>P+ES5^C9DN9I+>R M2U*VR@/M4LN(-N20IUP$;4?_1HK2C4G&TDVPNV 9+>&4KN&"9R3?[928AFY) M!8L-8\G^I(@)X>G7=0T9]:0LIXT+;D^!GM\F;,DD>#W+A;]#?N@Y$2MT7O(B M<)7;#\"'&&TJOCOZPR?17])0E=].VSUP1J[7=YYWX9\">4J%9#$+B0(./(9I MPF@,\UL:5I+=4#B+D4K%MB??&._AJ^K#A/9_+*_$\D2U_5&5F/"-Z1F61UA\ M@7=0_*B&/Z]$61&T*SFX _AD75I3"[8:J0,RH5 A7%&B%SB1>5V76+(G5(37 MAG>G[0U&.)BM#ASGH05[2FRG/>CUG-&49P7)-_K-'>UW(*&"+C<0FA9 GV1" MI#94L^Z6\+$B KLSW< %+;B0@%WRGHL,7*?[$6(N-/]GPP44 49P0D28&#R> MVS'+X2$0HZG! 7&5HOH03:8*Q)K)1"L5]'/%!%7[HU1N/@K*'MD'-._V]Z)] M158BR%()7(&H9GX;)B1?47@;2D5VAYX/)(_NG60YPL],XX>8*,)47%FNB;6W M,6'*]T+04L'H*#))4T QS#=)$619(*[2)"AF.@ZV-:KYOVC<5]7,Q:O),N4-@)++K!2NEC$*2E*&C1_1A$KBY1L I;K M4M1"HUK]DDO),VWA1I5$2-+:BC9HR/6*'0XLU^VK+2MQM4-A]]"O))K^M[S'# M7YZ%^L0VPZ;::?=Q@)V0C6GSOAD?CPYO+\?I:WW^$>[NM/W#4:F?J&Z)R.#$ M@AFY8>6=OU^1YF>KZ)ZU'@OZW%B@OSQE$32._IM"=THR4RGJ9+]05POS]C!L M__$07)R]FU\L=,6\_?7X4@5BFN"V0L4=S MQ^5FZ\VP=:I[XB;U NW1/&PN:@4W-]5 T)0H=%M7M_N$Z:WDW(N0)6:MDMLB M+]SVZJ>Y>^I;\.0O4$L#!!0 ( /(\I5;N:"198P0 * . > 97AH M:6)I=#,R,BUS96-T:6]N,3,U,&-E#.^',W^N)I +)<)7'W\;7HV@EK3MF^\D6V/9V-X-SN?0MMR7)@)DN9, M,IZ2Q+8G%S6HQ5)FOFVO5BMKY5E<+.S9M:UV$\YQ:H0QKPX'Z#SXI"8>_ M#-XTFS#F0;&DJ81 4")I"$7.T@7W'!QR^Z( MD4LF$SJL_ QL\SZP=9#!G(?KX2!D=\#"DQH[[A$O:G>/>G/':W=IFX0N)=U> MV"$HZ=#6GRZ"M%'=V.1RG="3VI*ES9BJ^'Z[9?4ZF>RO6"ACWW6<7VM:=3B( M>"HQGD![\].XV7(FZ;ULDH0M4E]3JAG32ASPA N_[NB_OI(T([)DR=K?G[$E MS>&"KN":+TFZW\@Q#G750D9_20LI14%MZ5 3^YC-F<2 MO);5@G]"WF1.Q +)2Y[YKJ*] 3[ TZ;BNZ/O/8O^ PU4^>W5W:[3=[V.LYO" M?P7RB K)(A80!1QX!*.8T0A.64K2@)$$+B.44O$"$Y:&R,+WNEE5.<\4W;]B M9,[LKR)'V.O^=_;SH\O_JA!Y03"NY. >P4?K@S6R8*NL&B!C"@7"%3FRP/[$ MRRQA L^I"&Z-[E[=.^ICF[(:<)8&%APHL[WZ4:OE]$=\F9%TK=_<_F$#8BKH M? V!*0CD)&,B=:!2=3^']P416*O)&JYIQH4$K)E3+I;@.LWW$'&A]3\9+: ( M,(1S(H+8X/'@2X/V_JJ[O>D^975C,4KR3RAE<&<"ZR4)A9Q0K*<^M6/?LCR M+"%KGZ6Z%+51OW0_YU+RI8YPITHB($D910G9H[$:R?#*G Y MCBP]CFP9;LLZCN5UNSO%CN7NE'W1K>5U=EM^J]>V8QT?>5_EUM8'(2J%\I*W MVKJSH"&F(,Z75^8!O)DF7GYI%[+^F<0WJNW>_U< M/V%$!%<:,&4RB+$=)^$#YUV7SHY">=W059 M4ETK:O#/U*YMWC;/[/_,?_3V^G)Z=C&!Z=EL].[T;#(=JY.8W.,(E.R.PN^X M'L 53AZF=IS&KC5ON\AL/15>L<$^OWM]J^Q)!ZT^=#)NOO1\01.B"&Y]^CSF M5\\QY]&$S#')A=PV>>%KJ7R:;S?]%3G\&U!+ P04 " #R/*56*BMPET$( M P"T)"8 $ &UR:RTR,#(S,#,S,2YH=&WLO6N7'$6N+OS]_ I>WJ^GAK@H M(A2L&HV-K_^*/OB&QXP4-V569W@9=?_)\O_O[_+1;_]\L'=SZY M==1.#G5U_,G-M=*QRB<_+X^???*]Z.:G3_KZZ/"3[X_6/RU?T&)Q^IF;1\]? MK9=/GQU_$ER([[VY_KS[TGT->>')^04PT8+ Y85+T!22*[6'__WT\Y;9M]1T M4<". ."\J"GSHCH-$,4'9/W?\GEL]E^/)9G1R\^LS<^LZ\;/CT_&'O MO3[XYY]_?GWLWF;:Z,7A[>AD=;Q^]>$?=?[F.S]L.&#Y M6U]GM3FF57M]@9>_^D(_Q].C?:WUL]-WW]RS_W1>']^Z:6]_$WE/'.=?(W]V M]N;%H8?K=[_"H:[;3W]K1X?#3XLNOKG?F_7QZR,[;?CTC/;BN_=@L_S0+[(+ M^\_^[]T[#]LS/:3%>W?B/]^# 5\7IS[9+)X2/?_U=SA_XWV0??B._1;"@ENX ML/!G)_G\@%9/__&IKA;?/?S4D*XD7_S]4(_ID^&T"_WWR?+%/SZ]>;0Z-OU= M/'KUW'Y-.WOVCT^/]>7Q9Z=?_K,O_M?_^E]_/UX>'^@7=J\7%W?U[Y^=O?;W MS\[.S$?RZHN_R_+%)YOC5P?ZCT]EN7E^0*\^7QVMU*Z_?/GY<*"NSQXN171U M^M#>OV?Q ^S\^75:L:&J:? L %'W-/F*DAA4\29$?;IU^%6^6 MXHVD5W0X7%J7G]\PLR2#:?KJ@)Y^^LG9;;+3OCS^O"]?JBPZ'0RZLA1[4>*_ M7O&MHQ=WPH,7C^/=$_GQ]HLG7]B7X?C'X?$O]WYY'.^% M?[J[X3'^_>_7D\)^_//;H[H0GKQY_W_*]7W[Z^UU\MGQS>=G=OW0WW']WX^7%XWOO^=GS\BWW7KQ_[^[>>V6L_P=U' M/YU_YE]VK;1Z\NCHY>-'-\+=K[_YYXOS=EUX/[7 MW[C[CYZ^O/\O_.7.H]O'=Q^ZE_;O+W-#AXKK;^R5S:SB']/Q.X# M(G9- JK=Z<:)%^9[>4$4\R+%:&]TY8CRZ1>#&'8FX6_M_$(52OGFR M7K]CJ&^OY):%#^^Z:;%7%H=VV6<+H1D$OPN"^ $0>'8Q,[")P57SU(//M@AI M(:H>E5FZ-Q#X\%G\0UK>[8. F;36"*U5"I0"QDZ&+/0^__#-P&5]>"/VGLU M?(E3EKMC&-Q_6 _;X5>K^S_>'L0V7 >>_/A-O/_HP8]VO!W[U4_WO_[JI\?? MWUL^^?ZNN_?+P<&=^.#9X\.7!_O+HP<'=6U\^N_OU M@Z4]?O;DUE/[#D\.'G__Y,>+S]BU3IZ$[_)C.\_C[V_#8[ONW4?_?7#OZ^]^ MOOOU[9^??#T\MFO>LM][^*]G3P[O]7LW3R%P"H6[O]P.=Q\]_:%)C]65N&B% M# >AQP6A/2T.4VA!T&7Z](O?"DS^_UO:U=16OEE9<*6/Z*5N;JSD_O$S79^* MKLV/H MW/] CM%[#B61?=-04@E=.AL-2XU8NO'] M0$5*MLO,AF>$Z&D.B_K<%U@9%N":&]:S>=$#AR:2-<3?B\JV@QYJWN6<7##$ M0@\12PCVV.=60^\ZKVWL$CEWWRR5'M]]=/?EO1]OPP\N:U=R#&2--/2[ ,+&HXLNB* EDK,9"?H\*75(\3^;18C9VW9H9 M)0I(I72Q+RL-&'*:O=O8L&1QEP?1(5U=+)A7; N+@'#!H*T396.V?C=8BI0@ M]&8Q&B; 5%BHYIPU9Q:7LLY1VL[Q],VOG1PJ9!6+T$H4LTV=PX)BU05A1?89 M -1=?H3?H9,X"^PI!F/94#E)&Q;,G,^Q](\B1S-VKAH[%)%[4&>.+!AV6,N" M4I$%F* LX X]7P5VU-@98B1"B]"4.V8LN<9:6@(72I[MSLZQ\]W[?BS^X+J/ M *4NB'TPFB4 M\,&$F3O'10^5%A!:'BJ(9)%J[=[4';S\7B7L'X#/9^_VNJT' J6KIIL/=.@- M_9*?;TX;# U@GYSV3WY^_.JY 6>S/'Q^,'0;GK[V;#W@[^UFO+^]W(B=X;-W M3W%V^3?7//\*FZ.3]>FSTW[/S\\Q?0:G/U/8?W$B/>W=N'BVE.%Y7^KZD],O MI!_LE[WYS?^\VX/P_H>_N'CIW;,_/^W]N7BV.:;U\=! <-J0M+ OY_S%Y]Z\ M]_IKREN'QD7T;RYQ]L[%\XN+?/;.C?K@??,QF3GRG9DMEC8^'1$:YL#!Q22R MB_MV_O/UZ6!5SIZ*7>SE\X-E6Q[?U4.V2\CR<# M0VOWA7%Z;8EN'M!F<[\_ M/#YJ/]UXN=Q\^L7%(3>/#@^/5J=OG)WG[Y]]\/2O;]WK;S$-84+)P=P,*RLD MR1/_[?XMG[&O=3/W"M1]:6SD4AQ MD3B9K>V-O1%*IW0>5T-T(^".9Z,\CL_O "RB>WVB\W<^[@Z ML,:(IG+8L$/B3*"F;=V$PUECA%-M"Q?:%L9(\R'+%_8;WC[TWEEP?K3^D^+ZU>>'%V_IZNAPN?K0:3\64N^49U!X9!0-NY STT#@&\+ZE95&MV8^@GZ&9"C4Y\HI)ZEZOSZ7^6FIVN4-YH_SY9GF55W["R;]='AWK\3$\V7RZ/-FUY MFBS[9M5^AYM]/"D\X8W^^\2^[NT7]M3XV6C@YM'=XYE6Z@:8'2_WUBO:?7T-*_Q_D+ P0'QT?JL MG.O-48^&R934!@WX?GG\[-OAESPZ^D]'7SX4P\=#,2P";@&*7$5%"OCD(H3B M,6IK.4BOH2>'%_5Q,P+W%('O,JZW0?570M$VAΰ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end

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᰻+GF'.4\:U=6B-=C70UTA6UW"CSC@&L>8 Z1X0UEB?% MO9*44:MQC73K@71SB3W[9:H#O-YBG<%)HAD-BB>> =XYF50D46,;4R3?$>#KV.7S@7]![7L" MLX?A_\@+! M/:FL,.!E)?@AO>!&48D]#[96V/50V+E0DDI*P8(J$;8)(ZZ<1LZF1#K;'KHK'"9&*9R*EAL,1*HT6P%"8]&7"%!4ZUQJZ'QL[7TQ)! M&ZQA325%_1(7D76PQ K&L$\4]-F$%9ZOKZ,>ZW?EJRT;'HO4]ASM"/%K;'6N M+F.[7]<.GRZ,0F4 U0\B),>#DX;E0XB,>4*II^0[FEIUJ./9@'[P^WRH@Z?D M5-[#T^#C(NX3!W=)412IT4$JSYUP=27BUZK.R9GH"+A/X#GS0+1)7$5&O?2) M$%O5-:WML!^NMG.A#A%=]G0Q8HP[!'@LD+'8(:(#)]X[+)+?VEW_LJ:UPBZ9 M)NWR_$IC9$B<)V$#]B33/W#-A37?,399K[^K4.2Y$ A+3 1/8-75.4W:"HR< M4A:%2'TRTE/):R: 5ZO.7"3E58C2,LM,_E@5>]KK#5W3E ]H M)"Q,,. S:1L(C2K%H)SW3'['@VHU9#\>LA>PIY$8HG!<9ON*(ZZ)1D90BKSP M,'G"4(_9*LA;ZLVF-=-8P9344:<0@ M.8\1R<@H G^8(QU!L:VA0I6,+[%.SWJMZLQEY(DIZFD27&IN!%>4)FA4,HZG M>@%>$[6=S_:@7'GK/.(RQRRMU4AKXY"1 J:1N!"X@P6XSO9X;1JKJ&(Z%KD! MG+-H;&2)"V(MUM&X4.\RK(G&SD4Y$C?&43!;1,R$P^#?(&VY0"IP'\"JRJDZ M6[N"K;W&KE_X8%.N?&:1HA>J?[[*E[[28Y8_??US$EPTGE#FO<]G,34."F"- M4N&5YZ$NK;$6J]""2D+"!H>5(\A;+<#=BPJ9Z"42@0>?>"28RQ6R[JYI_?,: M:6NDW1"DQ<8Q0QA8^%Z#BFKCO;,DQ\<-%='7I3W6!&GG FM>>TP$&/B:6;#W M&?QF8O0HZD ]#8+@S%-)38VT-=+62+L&2*NQ4L19(:D+/&*CB1",,2F,-\3X MVJ9=$Z2=BX42G@^1.XXBCV#3IH21QHR 3:N(C$KAI'/^)JV1MD;:&FG7 &F3 M84Q;;+77B0LG+8_.^.0(*P62!XL;_=<+;X_JI3/M^V =N:5V4;BX&"#WM-^.6Z"8('KZDZ"=T%X0#! M*7_/EXV')6MR>57:KL[T+F@VC%.(_=B%H M3>;(EHM%#\86&C=L:J]Q;K^6PEXT.IL2S?:@&*?.53$!T&&X'%:0L_/A4Z^B M+^8Z]V\ 2I-[7TSW-CPT3T,:]//GL.@T>X6V0:.][9TW4JMS72IS;Y 2#%\E M&7E"QA,Q>H'K=+XTOMK6(()&[\>N_])H]HJ+NZ'LTQUB\IA9+::JF-H\*!.3 M67PQU;?M0DJ;?M"RW9%BA#G-:+0ZWE;X4XRKR[*8!_?2WDR-+0B'#1D,RJ=T M8VI!EQO^W+;/8NYA;]#JYR>F;N<2_CR#-_<[@%\PNYU,$)3U##[H[6PH"!4L M1X5,?FWV;S+36.;R+<8JFZ7P@6\-0I:J/$$-Z^";3CMKS/808FX:O?-!'X7. M=3G&Y;@,YZ8 BJEE ,2C;[\USFRS76(3S'!O?K +T^>@9:B$+-^YS \M1'-&8+*% M4 EF\?5J1&BW( "[4S0K2>!T1V7N5>A>,8J_%N,">C^F7,V^S\2-E;&*Q[=8 M!RO*H'_W+7?WH22P>DFA1PU"&FAF B9^GG>'S;BR9S!Y8'9\039!*W^UK6M[ MT]OZUW3?H&,S8[G\,%13^7+C4+X\9! O1.Y76"9B-U^UM9OEN)<1\?=.%JHL MO/!;X7L4"O)'LVW;H"RMQN<^?)#5 31@T+8#4,081BR%+S:EC3=#6!^_?')* M9]2K=(VQ\-'X0,%1=USZH*G)I3F5,E(9JOG6:*T(;W-6-B>1BP#?$L^X8]@( MZV,2$1SZ?,0CC0($E:'?>#Z?^G0,X+,_!VNY%0_35#0@UR+I?HV_W1S=7,%W M.0QP!*_]#9;!+YL9!6C%__YT<_)/N'*4R_V+?7*X!][Y^[_/3_8^P'4GK9/W M[_CA^X_0YG!Q?/L!'Q\=7!YT53 >,?%Q2K7_H(G\$ M2VGJM,#F*VS5DJ][<)G=B]NLYO U6#S=LVIU!;.O79AUY3J0;^G,&+&5@S!< M9/.ZG"J3NE]PP%YV"@[8..: +9?%B@B6_?H8>TG"/[L)S(?+\$RNP&#\$S^XM8SNG_[Y\7A/^]N M#O?@_HM/7_;W]L7!^[^_G!R=7QX?'=^<['UJ[1^=X=F-YL.]X]O]RWUQ?/2! M@XM*#]Y_O-Z__8+AG:W#]R?G!Q=_?CEX_]>WP[U/:7]!?0'OI$_L+$(5\H!8'DPPA=&N7JQ5G3ZY;SDY-C%;#V6/);J&_Q(%B>$HX8\PQ)W(Y MN\B"XI+XY\'9JRZ^\&(P-T]T:[&+RBBDL<6(LXB1==0@*R*-7%)!#*MYO6NH MJZ%NJF@%#I81;2WEB@L*XV$SDTFR]-ZIS56 @D@W:(NTAR82R%!"8>*UB#5(A;NX(\NVK'2\'9ZZRT M^:Y,0:S+:\X82D%[!@X@-\QPXHB66L+_2&#>!F;3PJR*^IS%"\/.@BH-2B1P MV0%L8N(:_,+,2.!Y0D99F#DLI-%V:Y>O/S-47=UK24H@:V54& P +,"YH89J M"2L#J*VW+DA9:^QZ:.S\:?^HA9#"(]!;EZM[<:3!KD.<6&4-B8Y&N1%<;K7& M+GF6,=?B X^781HY!XLP">88QX9Y 3._.'.QUM@7U]BY0 47,@4B-&+8$010 M&Y +UJ#H?,YE)319MK7+1*VQKTQCGY1K7&OLBVOLG#/NHB,BT8@\211Q0R@R M3A)0X&!XWD<1*FWMFG6J>?LZ^3W?_,?>%,<:?LGGW&+S*I]B:L>?@M_SS8_T MOX?C_D>G.P4Z-;0L RTW"QQNKPSACJ+@G,K,81%9%@%II!2$2(&-*O)-YJ!E M+KEV2CZ]]MW;6Z1.KT-HYISL?2S/6^&P!@*L=HT0:U!4EH9V &:2" MZYKO;Z/T=YGE=>6N=[V\KD91YWSMD*(%D(U("B,1%P" +X.!9PTK+J$^2@6 MLE74R^OFJN?*_>Q:/5>CGG..==36:&HTTBZ'PJSB"/XT2# ?9,1:!F.V=M5\ MSLX/4<_7N85]T&FCHOS,L#9'O9?]?7SIR^Z7A;DR']H^E]"*>['\%R8DS\?; M:CIJ(WX%X'/P^[SK'?+9&XDYBCY8Q!W'R"J#$2=@OU.L*;AH-0'=1JGU,E;" M"KSP'O02?GNV@M>*O(PBSWGCE&#I-38H1"X0ER8B&ZU$P;A(;3(1?B[< G^\ M%5&K[[JI[PI\\%I]?X3ZSOGHSD2EO=)(!@RKK^(<68!EI 45VL8890(???[ M9:V]FZN]*W#1:^W]$=H[Y\(#U!(X 2+KP#%)9(A(4@ 6\HQ$N/6+L/K MH;X_E AQV2,R:U'48D&9L,8*"PF*'2V>5&QH06',//J([9 %]<-RJ<^RB.(; M,EN*L":6J(DEGIW:96#Y(MH0[Q.G6ACJ6:1)"_ M=>"\.$NU;$97?9;J"4O4 M@IH>2F!+B%>("1P1%P)7FT!.:264(YRRG&.QXK-4ZT8>4?/TU'"Z(7 *+CPS MGF@7J>-8*>NI2E2!R^]E-$D^#T[K>/HJ8'8^#)?W0SR)*"GXP0%5D2'!(:PY M"TYS9=/JXNDUU-906T/M"J V.AXI=H$[RSA8JMK2Q"QC1GD)^0\UP"I-"3P.*3.!JK M\K7 Z2-(#^^E.*K:@#(H%;KR (4&,JNBT. [X@EA87IW6)CN<'Y?6'@Q%\V# MW#(S;"7PL0O:B&"8XDQ%IPD+D2E!.]YV&6D^GW$,URYC)UC.2];P>. MLA%,V!C!:8Z<5V'NN;E=\,G*(OE/X PHYFM2QMA.Q<*R<)2>.KH/C]91089W M:9OMO/=19$-V!OV6O2GI^#+1H*_8Z%QLM#(K2^NF8 YKQ?RYNRF)"S,I6?APOM.P*+:GX//[GXP Z//EW ]7#M'U\.W__QY?B?@^;)/_OXX+;5FN-I M.OJ+'[X_N-R_/;_W#7UY)(=F+,"G:H_X[A+$/7VQ'UTX927V8D_AUPU;9O,GVH/:NH ML)KPD2^H<%.G"S=D]M>2$+11\+!>=K[&\7 T,V,&F-"SWV6A@7^B[6:@[VU/ M\:["?K?V>BT:^Q/1@2(U<3E-F$AO-M4X()*,ATF[V\)!?$P+ B#WEA)ZZ= MDHW>3B-+5<==E,2YY=1FKE7+H)(/FK:%UOE*T:EI2PZ@/9JM'X? MCM:GW._]4;\?TR^V?N(\"4WG,+\PK>!9-7OG,0REMW%>XG"FPV[93/8,W\;^ M_,2#]+7A\V8[,U\7'U5W#B6IX/F$W_N9^=@6M+S]QM=.=FD*=M\,A"6/])QL MSF#:I'J,X TN&O1*P_5A]=E0^)E2^B'LS$S4B#.QV2OY%,/ EUSE&;-+R+]9 M9K#@7MMO7'<&K9 1*\]>?MI?.Y]W&B%S( XG8#R!$_-5X#^\J>!:GIM8&,7. M)2PA!0UW)F'>GN"C+_R/0;>SW?C3P@A'6'EN*G[MW\^;Q=_P%+C=-0$/.X ] MYTT8"[@/NCX:INU)^"M9S_-(Q8:=Q.^,;+EUT/+6Y4)GTN7;@; MW\J=N;G*WCX,3[L#9D W=Q>D[S[G0D7I/9.*8^=X4,0JPP+W8!\JQ[E>?"QD MVKD8VVEOH6&@\Y^&KN6^S1&]_@V9VH0&^?:_AD'WNM,-O=C^Z9R.C_3@[#0Y M<#E\(,APYA /B2)M@T=16*%5U)%*N[7;O^Z 6-ONG*>0Y:IJPS95/"CHQ';>;<#UM$0?D"@>TW M$I!+& LP-SLI@25;6#J%X00#!. QQ,+"XIJRID<+S9#;W7>Z93P-GKQ=F;FQ M:$)NRA!,)VW6QB)+OEE8T_VF;UZ5X- %>*^BZL.&94QKYPNRVI:<[X,N-"Z/ M OCDT)L1SEP-X/575:-@"*]M-Q3:G..V53O'-_L2?JL;=A8$7S9F69OQ4V N M -XGG(?1&!2 VS]GHV8%U9[18]J<:G=O\<&LC+%$-<+&:G;QJ#%M>3GY_[") MD[\'L?F2-N]AV3B0]VX\AZ$I73CX._X UO5U&(_?/[QXQW_9!JD:TF0#HER? MQV)6LO!->M;9SLJ>:2&SH!/9."E\PLK6F40E@!!8'E*CURE-([ HXA#RIJ[< M:8#;,_&:WMA@F7[;R-RKUJ'RN8,V+$ MZ&MH%,9^H8F=C/BY)Z6"WZ$GH!MK M,.%OP1*[')1>=*D,OT\IP_] 9WY.57A[^/O__/+R7<^+'\A("Z"^F9J%G(") ML@;C\3D;."\_'H &Y3HTM. F[)"A)=3L%6IUULZ*6&IT_[PSM;;VX$%-6)BR M"K8[_0>5&YR;1K%]7ZR^H,+@&?F1"3IO^6W?!P5KJ/<_:#8GC(/2U,PC7VX= ME:YTX4*[#IB/DS.4XRZ=-IKX:!94LU%>SF45WH6U9!RG*]]POQ7TN0__%#&= M3BJO_SU+Q1^Y6=-F<>C G&8A*AB>2P6=E+24Y:]KR_6LV^B!9S$H-[6S69L# MH!L=G)GU#A8-^"A45EBL8U.T8?NE#)0N06_@P.-IVNY-5HLBKR([9)=P\5EV M: K/K C'%$HW\G9@;;WLP./SC8NC_3N-_?LOF(IVP,OMV#_I5.:'K0S@0=M7 MVP7C2[+9<08SVI[L0RF*E^"2@D,4B.X. M8XIS CCT<&$R>H.\ABP6J *Z9B9O(O2[(/8(0AJ[_LN4ZSS(E]^6*%(XQB.A M'T->CJ 5H8$[%01>%F!Q;(%N9JP'@H8YW(A'@4N)MI4A/H6-&J\HU;@ M]$S\%+RQY-;P^4WT]&=6;#-D-C:#IT4TK]_"@L M-G@J0Z;83NOF%G:_E)'9XK?^:#>TAI89: %_"98I&/K6S?;4QLQ,T&1N'LYC MZVH:5V9N&858ROV.\2JR&&ULOPS!YRS!.[931ZO5]%['=OX[7O7'H<]^:?44 M?^4U!@V;'YJ@-?D95>PSF]3CCT:R-;E?' 9Q^.#>.2Q1"#3TLHQHCGHW$>LK MK?)QP/_<9I.[C+^#,!9Q][*[&1WBU3#R"M9K[^%= ;YV/"YWY*X8Z-P M9I][ E9&^3.]T0[W.%6GN3B+8_&ZM'!-JC!B_OUVO@7EPY\7A)M#RR(Z6&Z: M-&S(TUJT(-OF:V)L_X @['R+=:"K@_[=M]RMC[XP#E]2^U"#T ::&:B)G^?=<8;^640.I/8+L@E:^:MM M7=N;WM:_IOL&'9L9R^6'X8'4HM6/0_GRD#6L$(U?P7V(W3)=_Z!3Y%IT[H+C M<7;I")A[C3>#M@6O +[_ >'8-Z,TU-GZ,W?GMCZ8JSJ3V\J<$5X3J0('@X40 MQZ2S7'M#D@O4L;6=ZJW=,EJ=#:(U"43DJ/W+2TE.1VP-MSH+T]>"5=[ICLX: M%'' @>OU<_BZ,'1'W[2:_SO(XC^19#D.*4W',F!E!?\8-,C';K_< NZ6"_'0 ML!YY_].[MGE!7YRD.HY:C/,4QAMEI=.^T"T:GJ?WBZ;=6 MKNSL+:,5N(S7KXG@_(A%=7IV1T-26E'#C?(BC;K=S&+S\- 6@8DO/GV:JEY;= MSVRJ_S&7AYC#D3!3A=U>AB479J4O2-MS_2E)&N4_@__9!. 9P&#Z(I:0XWQH M,O#=+A;DPNEV,;:G+?+M47QHA /%IPNVPY:PV*7BF$"]WJ(PTU@[ $E@U=ZCG.Y[S^NQ!M :M>)@.8O_# M2*;^NY"W#^V)I(4B.CB5LO"A"!3FO(6C'!O[N0^%O3OE06EL;4"Y9CKB(I?W MT9HC&AD1@JN(;9P]Y+4Y*'HT'=E?= AD0<)^&1CX215YM)]P]^I:JE !E+WS MSG6[/-CRZV-6VG+^RZCTR*LOSLL7>9Q7O?CK\)=_AV;OJF5O?FVVBU86-_V[ M>E85"EA0$[00M_+KRATV9D<+ECWBJD1L]>+*6=XIG.69T__E=^!6&W7WUWB' MW/G=?8\E=(=)\Z3'WO^=8/0'-W9!G9?A-,)Z$-?FRHT:U!_?6$K5JY* !PI& M/UC?W8RK&$U5 UEIE>CA*[Y3T%(]M!P44<2WEWDC/J/^?[JQ;[\UWKP'L_N7 M(O&S\6G*2U^4'_IAU/;TB7P2X'[GE6^'C>81^?=&'.R M7_\BE)O_BO#)3R_59S; M>L0(WBE FR ].?RSDC[>J6FO9Z#H#P*S'P*0KV?::OE^U?+]3&*BU1(/K6"Z M]!,7KH/8;XSC]*.Z5I^&A\_/FU>]QVC"L\;K,5JR\2]8/QUXK2.]^2]8/UE9 M$1=[68(;_R!LO!<)Y_;U1TD0SR'.^R%%QQ_7X<<7'5_4KQ>M&_ZX#BU1-YS9 M$(D5A+B N<3"8B52X Z+Z&7T=GD^S.$.^'W[VO-[XCGREK_Y+>9DAD^CX^.^ M6'W?ML.1_;8V=U2'_0@_>[^/]O3-\N/>1G%Q\@OO?\>-__F@>P]./ M;S_R@]N3RP/Z1W.N#OG1,8;OK^$^?K#W]^5!WDD_.C\__N=/Z/'?%P=[9^S@ M\IC!WPN)Y[VSUB0-XDQB0-PQ@:QD'B7&/4W)$\, Y^;IJC>>P6/GBG*-=>*1RXU#BIRIR07GO.D"J2B0Z2B#U,=U #UHP%JCLF+8QM,9 IY MHS4 %&?(!".1=81T)%AH:QI[ ?OX\,)V%T1)<:R1=&DG%+)(:'S7E+")"542<4HVT2@H) M302LH-H%XFM3KT:IM33U").21<1B^=IM:@2 S 4W !&2$9L@0SY2VSD=A%\%3;>=]O*^=.NK#- M"5V^6W@ZZ,YM&[K:L5FXG*P)_"YC)')ADO5<@OG ::3&\DQR);@,-#"GZI#@ MIB+QYP4A0:]5(%8C#QXV@BD6R*@DD* Q,\_I%%G:VA7TA9@)UY#+]<'=JI\( M198QXIQ)&EQ,$XUQ/%JBC:@M!WISH34FB$JPH"'I%0;?U4=D M++4H4096LXJ8*+>U6YS>I?^N[:8:5I;SOL!NXA),)D"5O*WIC%24!66%UXY2 M]N-C7S6LK,03FXN)22X5T5*@F">7AY!0+KB%<"0N<>L(EO3UX,KZF54+2.M_ M3DKZ-^27.]FQ?S1M>Z[ U[#5R5AREF2U+&V6 MZ]]/E"F;KPXY20>].1RH'X;$KY]R?:'71X!Z:6^*.E+3!+>]:WLU4:P+EMAA M@;F).EWMT "\ZW:NBX)@XS)-O;)L>!ZD4>'841?O4;IS%=G[8]OCJX96-_(RJ(MY$ M59B)*F033*"9J&Y4FS^7H,XUNG8:']K5(^ZR6X9#P>IJ%49Z$> MU[/N_7=LA?G:U>W!Y:AV=664X,TT2IY1Q?JC.+C]"]ZUSP^//MZ>AA 9N*8> MX6 5XHXRY)25B!.'>512<@9.2X)!G;,L1J6/>WW;+31I)*I94M^"?+4*05J5 M[# FO3&$*Y\]ZT@,"5IZP@*U2I#@*]GA#->R\WUE1QSLO:6G#-P0[!-'%F.* M.-,6&6,#$CIZG5*,6+B"(75>=++15#'/+):B[9),IZ"-L1GGRHOMJ#3#?RT3 MDL'4I* \"';BX(Q;J1.GX)!3&\%7=XM!9]YE&DO)0=6@LM;!M.\#HH)"IR@4 MG)^TZ0[0JK"&G8*[JH.A#K!&Y2Q.K %KF$:,1LF=XB(PNY1/;$0R@1AOE1;P M.*JUQ5QPE1<8(A5># CUO*YX7GG0G D7P2T-&'%%)-*$>F0MJ)>#R7!>;>T2 MC.=PX YOM2H3\(,*,XZEX<.XMN:']JB.W&$:%?/^3^5(_6&;W;]S!=N?N28C MM.54@!@HPB62@A+$HP6AX%PC$:UDPG@CE=[GKR>"H#9J2L[6[AV MY:]#!NVQD_B<,EB/RH> YW0[UW.Y$1L^NG_M?-ZIAK+@V/U_KONOW6'XY;XQ M73 6/U%9REHHUT,H-W2->ORF\1.K=JZBKM^&",O;3%_\$HKV2L;K?RJ.YYM: MC&HQ^H%BM Z5+>$A*\XS71+9)S:\&WM3 >)AA'>Y(SGP2CFS\D4V_* MJ6:H^0V=-T.([5\W+7V@/"MQN2]._OGC_/#]AV\'1^]N3HX^M?;W?CO??_^I M";^?G^R=01M.6L?_G%S,GI4XAN<<__..'\-[]X_^;!V\_^MZ__V[ZY/W^7=X MYQ[T]_+O\Y/+@\6%+/,)8JP8\LH:Q&EBR&KX4V$MJ*=!8VGK(5_ID$=KL=), M(\(CSDF "FEG!#+.<>99T"GI(4E1X>J,%7WZGT<6;GFTJK^F(DZ/[_1F'W(3 M7+M@M;8\1>Z"<"E9"R(E%.<\V+!\HF8IJ_?26GXSJ^4"6^H-YHA[(A&W M!H"5:HU8HEI9;U7(9]!6539NF>7\)6K*/]"",Y(@BWCL$3K".NRA_]Y8BDLTL\_15$OTLLLTG2NZ@Y)V"8KD"4D(IZ8 M!>\GU]^QF)@DD[(5=*<)$TM E\Q(1ZT0L8EBX*B5 3L#-=JX];PIR85K??FY,KW M:S>BU_7^X%/5?:*0^,'>7V"UGYV:D(0/P2,I'4'<,H9TI 99HH/BSGM,3#WD M*QWRQ+P&/Q9<(ZXMXE%PY(AQ2.E$I"4$ULLPW)(]Z+3]H-O-E:*&B97-^, 6 M[4C3'U&IL$H^D17L(M=:N69:R:EP3N::/,ES*XAA MS$LG0TX>^/_9^]:F-HYM[;^BHO9;Y52Y25]6WYQ35#FVD^U3&]A.2%S.%ZJO M(!LDCB1LXU__KAZ)J\!&0H@1]#G9-EBCF9[N?IYU[;6L?=M\_6G+[LNA6BU1'O+9X$6KV+$ D55)SO+F$W*.+OH>NT5M&T! M+;>0I12<&> H2(/G4F<1;;:E XB3U2_=%MQVK^"69^8S2X90&:!XJCRQ!L&; M)'>X7Z.V0K81M_.>(VJW$_:W_@!_[772UW%A]<4<%&KW.UI(D"- MLJ@QE6K#NN3 7%"!<*-T3P&::#TH*M3OL@I=Y"$=(KP*%@Y*L")3SP3GF6F M+EKF5#AU/)]ZG=TMS@3=2J6X;1_WU5,I5(B4FV"IR@:GF/M,?>8V"2>[YR11J65.-#AA2^%K6% 4^P$2<^ZD MY:\8).^44577YO'2Y1/J"O!@KNA33J6":B8C$+3%2HQ(".*L"(1ZD8 !2!'R MV@8\Y]=T#Z[(76WD9N<"5\J4>!$D#SZ[5,Z=&@$Y4L7F3\>OH)P%E--I]Q*" M+XTGJ6E2]F0@AD9&2E\=:91GB>NU#"&<"4B >TML1F .*8X4XRQ8'W1= QOD_WX.!.=%^QM7HEWKJ[/>='< MG79]&J:M%IH3;U Y@D@M07*61#(5!:*:@JYISHN=9IXXG$M"^)R!L(%9P M3CA+I74ISGJ6LU2>>NJ!ZV2R\SJHY#EHQ;R2(0@N5:+>YBR8 M4 P\H4 =[G/*B)E"VK[75OE#KE M9$Z,<#6IN?H\;P_HDVF?IV""NYP4B3X9 EY;8EAD1'%6SE1S M XG7*5_HE%L;4>()()D)34 ;5A*2T&#D ?"U0#B.4_XRA,%Q::#5BYW^I03G M@X66U5BQ:';--&COVLQ25H-Z$#Y:2%(!VF3&Y. LA8"J17 <:EF-)3(4G0J$ M 2WY69Y$IQP!%S+QV4HB:&]B4KP MJ(A3HFFJHM$N2Y(DR@"$$@R"7-L0SP':E !4D5NUG15CLN9,]MAY?8V)3TL8)B5%H]8E4\[I*T\,K@\)%#3E M68D,Q:=%%]6-J@+S\0*SJCOW"-RIPL\:M5-J#4'C!(%K@B6&RTBBI]GPQ"DN MY=H&?ZYLFZ!;$YX?RSM7M^B<:-Z^IN\K8XE+:CR1RN620F.(0VY&*1R:!&)Z8R,=8C?]) B976D\P]#S&JQ$6H=9UK&L*JK,TLW3YB%M0[ M[HT7$"&9F$%E*;1-,N$*5P?T$HEIR@%M++.\5(YUJ(T3T"(0ST(FY20B%2%Y M)I&8:H)Z166MZWR?P)SN")JD-5HRXAQ#)0VX(QZX))DIR;FG0=*XML'N?FZ_ M0K,J,T][;6:AS<2UU#S'[#. #,['+)WB3D>M*.?5O[Q,*VO*OVQ]MC2D2$PN MS9.#*D?R;2+:\:RH3#EE7[M45%A6;>:^D7G5@4Q]TEIG5&>D8P124,33I$C. MT@:5T@M=ITNU+94Z"R:KG.S6=3;G@F'* R6VU=\(S'$*US+M3R-\MALZGR-QX- MSN20P[+W:(U2FXD%+XFP)HA I="E@BB':HU6*JM4=C]45JW1N?EL.HZJ9E(J&96;<>9^=0>N M%U+GS_V41IU7[JCL]7N9G;9,T'UE1LSR_C?F==4)KA-<)[A.<)W@.L'+G. G MF 1Y/Y5>5WA"ZDGP.4W-S4F67YZ_/[T[+V[1=^QZO)[RBZ_P*A2 MDG(9#60NC.8%EPO^K-,RK%G&,F7CE.P*A K$N29"DDE-(G MAKMR=G91M8IJ^*)R60NY[$XU+>N>KGNZA7OZ0>5S#??%:?$>_P5J-/.1,DAE48/9E&-'BJ7 M52YK(9=5DZ3NZ<>VIQ]4/E>3Y![]BCMO3T,)WS9W/GS=?KDK18@Y.UKZ]^5Q M(,& 0ALE*\A6@8JE*:=Y+N'.=?G:GB?8^FAVK9->PX8SX'WS0MCP'5[_[F27 M4:LR=X$DF06!E!.QD6FBDXN@C%64UT+I"Y[S (Q!3(KPJ W.N0G$-,>#(87L MG)).L=-0[=_VKLV#LF6M M(WHGUMRZRII@.62?,[(F1_7 &4V\L)IPIX.@40J:S-J&NO,IK0K-ED%3.BXL M%5YI(2$)X50.S!FEE0-O#2L>%T%O%8UI[UK\Z!<^CTW=.74^8W&FINYOE>N[J9 M5P74;Z=/IY@$*D67B191$#1O.''")N*,-9XI "B9;G7.%SGG3AB?>:)$)XYS M[I,F3NI(4#$5FF>>59GSER$,CDNMB%[L]"^=#CI8:&?.:T#?9E7C3ED@>@7OUY */U% 5/&'<2@+.H6Z1 M$R,!;32MC'*:CHM;2[NH HH5NU7A>:)K,P.O9L@NTF2B$QPR!^ME#,+93)D2 M.L^1?ED5GCO89#LOKZ971D^E*-H."CT@("40FZ(E27JKK+9)>;>V(19VXJM" M\_%"LZH\]PG=J:_5RS MGZM;>C&8_NMJ)J[8I9D) &V)\PP1#ZO=.O='_6:@W>L4"WS4IH;UK,X,&F*AE MQ@CG3#20?#;*:&6%U4$"Y5I5;_0RF>G<&_T.-;R7)[O"9ZW1_B)"B)*NSA.: M9K9XHZ.@P''Q.*_IZA66-27ZOI'9O8+,Z#7GI4^/X"$2L$80EQ@CY8BQ*^4F M4O:EVMV=XT05FU6=>=IK,P-O>BJUI]I0SSR*QV@X!&^$I"Y$Z1V_HZ^Y)E@N MQ@ []T'3S6]OOFSN[2JD3:EH)-9R3\#)0#P+E A0C(&T7 ;6Q@3+"MMVPK:F M1M\31:[P3-N<+0FF.*R$BDW#0D(YU9'&()E3;43NPGLLM-Q->X<^'HM^ M\U;TV+A+%9BG5Q+J,=6#\LY%%XWV2F0P ";&+(6B4E"%QINMU1F67IWA-/DR M<>$T%R3QD FJ?D",Y9Q0"5$&*A*3)9S)[[T#;JL*VRV^JEWEK\I?U6>_H&() M5S/(C301DJ4DL9*3(9,E5CE!8@Q,<*5U\,4S>/=J"97$*HE5$JNI9TNM"#,A MN6BULUPKDFT,!+BUQ"5-B>'>VIACL)RN;7#ZG!M3>:[RW)/E. M@9J,:GPS','5[A1/,#Z][)EI??QZH1/R*&3=8F=DM66A#"*4/AHF2@?66T/Q M3RYMEEPC>^8:_UZ*F'LW'?]VWL=D01)O7"1@/"VA(UO*I2G'HU"RM%#'I5I0 M'M7"&',9N9-W'^RM;8'*GY4_E\F?U24R/XE.Q=\3 _Q_04LE3T5 2$6\I9Y8 MAS2*[$HE"TBB9E$G>(CE*HSR1#'1:E?JD2F+'"64$\%(2I_5OZL_/EH^+,: M^W?PF$[G/R29H\N1$>.C)> -TBCCC##@8(--1C./-$JKS[32:*71QT.CU=R_ M3YJ=RK\PB3+P.1 %01&@TA-K$NJML73M >] ^>)5?:[,XS#XF_R,GT?.'R3\ M.W8_;YR^UM;Q(>[",/Z][/)N[]@U[_D_>-GI:QVZP5ZWUXQ.7>:QC\?#43>? MC/^IVXNIAP"3#9RSX]'-7[GY'0(..@T60S;V1V3#R[A(AXD.N3PM M%__<'YP.X\CM)>('R7TB+N,H7[B#+^YDN/;SY7?#%[LRE[-/PV0IES31D50V0PR"Z<#5UK8G&300I@9E_HFU"YE MPEX..[U^64KG^Y_3\\YH/^$2'^+C3SJ#LB?BL-/%18UG4G+8P7ES'>37X;#C MW;"+%_0FW[MVD_SJ#G"3I,Z?^RF-UCL[%YZP[X:=0S=$1'5Z:813O-=Q>X,T MV4A?NJ/]SC AI^(&Z^=F'/ELQW5[.'NCXV890Q'8:7#D!L4&ZCP;IM2YC[W7 MW.9%=X3K%VXQN3@-A=7&N!J65W@U2(B,SA_=X:?E8\.G@_Z7G]8[_W-)Z%S6 MJJRQ)D 3C"KF##"!6.!N:CC[NLFB,(H(^?1E+%"=3CX]&([Y^%X(<<^ MO9>]>,$XW2FB;P>?]>M!/WQ:3.17MP\[P MV'],853$ 7YGF*:0.QB4 O5C["*PN[E<=]+YD@;EZ?B-7J&#ACWP.V/N>-YQ MI\/$436#:32I I9^LYDZ_N0BOD^:)H[!#?>+V8H*2L,.I]7Q8^\R&=P% M.BG?:U0:O"J,<3@\/CKJ#T;X42]]3<,7T_K8#2K3!5*7-Z@QUXJ:'RXDJK'- M:IUI6(U"VKSIT3"]./WAE]@='AVXDQ?=7@/TYDN_3$8U4 MJ";6K@.313N9) Y/'CQ17-8;Q>6*>CW^3,&Z ';CQW3]YL^^=UN]S@V?ZZ[? M_TP*N?"QJG5&Y[OK\L>Z2O-:QGJ[N_X@Y?T!L[#U(E+4[6W>9,PX#_\NFVX0 M]CN"/>\4S> 6:?<_+%VY4J__.H5TZ%'D3&: 7YJ!%=BHMU=NF_=]]J^B]^/] M#XIV\--MCEG>-F_[QS->IYG^R""YX/--2M]$BMM$= M#[O-/!LM.,_V>^-R<4UT8MAX9_9Z^.UXZG\)9_Z7<-'_XB?^EV'QO\SI,?_Q M=#W"^-HM7GJU0VCUV-9WHV-;^_B$@A>$\>8(2:&*,!EY3WH M*I]5/EM1/JM)]NV@,C:EFDF?8Z2!Y$@9 0B!F!P\\=IEZH+W-LA[R+&O5%:I MK%)95[WQV?S=F&Z M[MF,7L,T%].UB)T.LB\?C)<=@Q?R-"89%"5.\YU3V)X38-YZZ9 MZS8WG'OV\,ZTK?YHG%3U7UR&9WBF'3-9"T5X MD*6Y!I3F&L82"%Q[0V-RV:QM,)@N.C\5\YR'8NZYG.F=VD-6M,[A+SJIB%TL M8J>\2;AJ(8)PA#&K"5@MB0?*B18^@Z=92YXJ8A\;8N_)(U+1NEBT3CE,)'.L M+!9A-G@"FAOBO$R$9654%#F+(E\YIQ6M%:U5OBX?L5,N@>"3DII9@JOC$+&V M<0E8$K0#H7P(S(@6(7;>3*!V)_N\NG+"89!"0A3$GX_Z:,G'N:SO%6OW_K#Z M_*NSN=_V. '-(8Z=_A]I=#SHE<6I-#,#S9R5U+Q ,R+R9&F2A')ED&8 B-.V M' +'50K4L5S.P[#I0,KM66:!S=WG))>Y]((5PVE+8/I'&5)!:#APW<,Q1"^6 M<,C=KRF2;VG0K]"=#;I3%KBFSLDH@"BA,D*W-*0U0(EVWG*:E(N!EL,M!C6\ M7Q84.*@@;HVP7;QR7X7M8A$[984+ "&-0A%+%2=@(.!/7I.40@2@*DN?UC:N M:713A6W%Z6VE;<7H+!B=LKNIU-ZJR A5,1)0PA&C0FG=H:(&024-Q:\]'8E_ M$(S.&V>?NP;3-0D"+;/9M]+H- H_9V>PN\_*H\B06OBDM)#('SZUX#?7'?SM M#H[3V)WZ3MO]4=_CA-*=OJ;31+)UJ3 RWD*R65';)4#L\B! M/Z<=(RIG[2F-1*M/-.30D70LA+[-!ZM_'. MV<2U\G/EYZ4FDU2.;@5'3WG F =-)6=$*M $,L\$;6I)$LU):NV0JU5Q7B^X M@IAZ<*D>+*>D*U# 2 9F*%Z0I%TD1AA#J$&#*@@IT&Q"DM;3 MF68K2M*76P!,%?L_*U)^#^693^'Q9]A/\?@ H7 .E+>(AL%Q64GW[7Q6Y_V_:="D5/3"$Z_CO+D+0? 8+&H44>'>%2^=AK*;3XZP-V5FFKH%XO*X[WQW9MCAMU>)R-A=SX7QN[T!^-JS[D, M [?N7GG>N#5%OS?<[QZ5LLVW*M.\].+** +7Z5@,SEI=6=IU;F[^>-[*NK". M3'$O58#K6.M8G_I8+;WU7:\QU4Y9!V5_JE<^QBMO603ZYIJNMRH8W9:ZK3O[ M@Y0ZFWC=_K#S!M68V#DK$7Z+\K=+F>JG66][%:K^WK*&_&6+[LIKSMZ+[%MDQ4W8NMV(OMTR_KE4M5(F>O<39K_O+9WF\< M6P^H?%[3Z+/SRAV-&YOU.E_VNZC7O\DYA5'CV2L!E\[?I_Z[YBSS;\5_=Z.G M;C(QI,Q"<5$^K*[][Q3WTK#C!JGS1],$\\*!ZW$WT:L;R=[3KF@+)_[I#M)4 M4OM"S^CG3[VG5L2WF][MT7X:=)YU>Z%_F'[JI*]'I?S>\Z9/X@(; MA<*ZE'-!XIJFT&45"%\'N*8"HANF<0/A9^QJ&]Y5VCIM =]X=^#6.!JD?=P8 MI2_G>*MTGI5HRFV< >V3KJV0V)<#PS-HQ'/?L16I++?;=_.FLK0M5>5V;SM# MJLI<8?COY:S\D3ZGWG$I9WRQ8D'O^)#$?M.;O;]C6Z_W]S6^?OFS__N$+CH_]\_ZWC_^4\/S'_[VVU"?GSH*)@6@%F8!G MB7A<1<*B"5(SR,$V.8'/P2PX+;!M:7_WDM97N>XQY3O'I/3)6"(%2P2)3Q"3E2$R6 _.TLQMZ<##Y-WKC;>-ZJI65WGP@=UQ ME?V6&Y38/*WXM;/Y=>OC&]B5P+(0:-C2E"(!X)EXG23)PV(R/LUNV@6WA4\&U)6TS#46?@1JDS_.*.&ANBZ(WSY?#^ MP#%7[U'OL:+W:!]AU2M;:9:,!8"]1@!<+--#8/V:RC#+-UF: RRQTQVEPYL9 M?R6ZHMSN?2>MIFIGJ;HV=6WNQ_%LE&^L>&/SC^QQ-_5;DB-ZJSN=8)5 M-)T'32(!%31P83@3-S @3@BXES6M3OQ6"]RSQ=N35V;ZN_8OFP#-0F>C_JE4\CQ_SMX1$*HU(Z]=;-CAXH M[[;>H]ZC1?=H'T?5*]OK\=;K6JY&#O=O_0'^VNNDKZ$Q)VL&=[U'O<=*$%:] M5H[H6&LC\H.U]346J:4%V;NC9U;>K:U+6YMZ1RX6)B3C+F(P5% MI:-:Y@B>RA14"NY^BK:5?E.EW5234'X:>_TU932I_TCAP V'W=P=-ZM_V8L[ M[FN-O,Y2Q&CGY6C[:A&C0+WFWCBB\0<"EBOB0_1$P9P2TA!: X&C(8$RM"H2WU2!3( 9+W04F05T_>-ZOVR]W M=98\:RH)ESD04#D18Q'DC@-3P3 6-"L-4^Y Q>(F3-07+# MU!)OT*7>D3<.EDS0[G^[0 M>ZR"3,@N,DY$P+*!-QEGKB3-;:,NIU$&CP+ZJ/8L5D"_VM=6WJ MVCSMM5E17_B4QRR/TJ#ZS&87BU-^\"2Y"AD<00O"EBYU0*QAF:3(11")!UK. M%%ZGJ\[;>"@>N7*L/_C#8.> M)\NW-$N^Z/:=9]U&H?^ID\;MDY]W>FFTPMGS*V;F5>]:79NZ-O?L^134*)V- M02,9LJ.U]A,AG M#K=7G"X2("Y)ZGSTP0&O.&T_3JNN4]>FNO+K ME0MQY4]ZXXXW$>Z\'[1Y?US.GJ9/=_NUKVM?U[ZN?5W[55O[)3NK:\F*UGG.WDVGZ@+DX!T-1-"4"-@HB/LDL=3(X\%>- K>;20/*Y)!C: D'*0&3*0$ &3QR/C/@@ MN%7 F39ZQ>FC?0ZQ>N4].!A_'CE_D$[]0C?Y^*[TBOQX/!QU\\EEKY]=E,\/ MUJ6Q93#] MY\,Z#_FEY.9)CEBG6VI;(/T?X5KV[JV\Q7?'])WLM?4KGL8Q VX='^*#PNGY M[\FO5PY\&VMR%)(%#N $LXH)(UPP%IB+.EZK?%\6E'^&_12/#])V;D9XH77H M5G_T^JQYZ,OA= >N/T?X2?/3=OZMVW.]@)/TWS1H^N_U0D+A>?[/DWWVG_Y8 ML.X4#.W@B_QZT ^?5E.L'J1__W'RS_MXY#FHS1T4G;]O'6Y^0W'Z,HF00G- M4+GF@2$?)50^CG#%<-K3Y:#"H1O@DI""6/5CNH&%A1CLK7;\SG[J-%39\:GT M9SD:]#]W8QIVNKUQA\:B' [2GAL4UNS@[NN,T8&CFVRL#@KT%$;#@M@+GOE. MKS_Z<6/;%Y=A=?V\C>=D/,Q3S6*L0.#<'+BC87IQ^L,OIQ*AVVM>MOG2+Y-[ M3=2-:]K_-DLP_OB7+]TXVB]Z\CH=UW:8!*LF3YY\O-Y\=$7?&7\F^;H!?>/' M=)W=^-GW;LO-NM1FKMM^_S,I;G[HO(-5ZT*J%1JKO>U=5T<%NCG&.L/ABD5> M:M>NH'>"1S9++#>DHC<\O 5]'IL]E\:=_P[2R'WM/"OVZD^=8K%V_K@4M!W; MMY>LI159J\+#*[E0._N#E#J;>-W^L/,&I6SL;+I!V.\(]OP6)^F6 L2';.$V M8\S_V;_*/L;['Y2R:U.&_])V\(W;*"J=I!6[7S^I)!,#%7.Q?LU;L<;IYKJ[=UYL:J0N?,?N^\AYZD2<59IFX:^/3[9BU?]WE0,(, M<<*EO= ,X?9,!0HB3Y/T":BAWDENK+3,2ZD37!\NN%6X_5P7NZ!O_3" WWG^@_^QL?ME^ M'?/6*_KM/Y,0^^:W-WQS9V]71:H]-X& 89P T4,2XYD<#P')[R-=&V#B<=7 M8+82T\H3D_+*V\2]!:I+,R0;0Q!2.D=3E#K>H2!@):8E$Q.[2DP"M&4A /'9 M^M(41Q!+,R-*R<@-Y1"47MO@=^Z)\P3/#Z[N>;?6F&6K;.[PNY@[=\B6:Z.0HVQ?4[JX>#%AISICE8$ 0V1M)$\LR@X!LDG%6 M\J(O,J=%O$-IG(9;$<)PJ199Y12,!U7%$/ M -2$]<>>L+ZSGX;I0H;K!?OD:("<-L G=P[QO?>::MV-#5/R:)NDV<_NX#B5 M;+%!.DQN>#Q(L9,G!D\X'@Q2+YS@O7O]P^XX.GZ(&V3D!B<=-QPF?(3KQU7;W?ZX\R4-Y/7BJAWC9-A=_J_IIVRSW)"XL$7&I\@P)?Y M.GK1.SXDL3\BDR&NNJ8V][&2[9V]D^UWNSG&'+F,A"7.">ARR-+G1+)0 ;RS M65LTRO3T4LOMW+KW?* 2,WSI4_/A@S M!JI)E[;'4YX@Q"6"JYN1,HL0SU=]X(W&-E'NUCM_G&*\%/^?Z(1CM+M!NCB_ M,8W2 /&*EWI4(<2,$;A+(C%\KD2<">.-_ M_.#GC1MUS